Solubilizing promoieties, taxanes comprising solubilizing promoieties and methods of use

Sol-moiety drug conjugates with enhanced solubilizing promoieties address the solubility and bioavailability challenges of therapeutics, ensuring effective drug absorption and therapeutic efficacy through controlled enzymatic conversion and release.

WO2026241642A2PCT designated stage Publication Date: 2026-11-19SALACIA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028373
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing therapeutics with poor aqueous solubility and oral bioavailability face challenges in achieving sufficient drug exposure and therapeutic efficacy due to the use of complex and costly formulation strategies that do not accurately reflect human bioavailability.

Method used

Development of sol-moiety drug conjugates with enhanced solubilizing promoieties that maintain solubility and stability throughout the gastrointestinal tract, allowing controlled enzymatic conversion and release of the parent drug, thereby improving oral bioavailability.

Benefits of technology

The sol-moiety drug conjugates enhance aqueous solubility and oral bioavailability, ensuring effective drug absorption and reducing potential toxicity concerns while maintaining therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028373_19112026_PF_FP_ABST
    Figure US2026028373_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Dings having a solubilizing promoiety with enhanced aqueous solubility and enhanced oral bioavailability compared to that of the parent drug are disclosed. Following oral administration the sol- moiety can be cleaved from the sol-moiety drug conjugate to release the drug in the gastrointestinal tract. Reactive solubilizing promoieties and methods of synthesizing the reactive promoieties, methods of synthesizing sol-moiety drug conjugate, and methods of using the sol-moiety drug conjugate to treat diseases are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

SOLUBILIZING PROMOIETIES, TAXANES COMPRISING SOLUBILIZING PROMOIETIES AND METHODS OF USE

[0001] This application claims the benefit under 35 U. S. C. § 119(e) of U. S. Provisional Application No.63 / 806,876 filed on May 16, 2025, which is incorporated by reference in its entirety.RELATED APPLICATIONS

[0002] This application is related to PCT International Application No. PCT / US2024 / 056391 filed on November 18, 2024, which published as PCT Publication No. WO 2025 / 106974 Al, on May 22, 2025.FIELD

[0003] The field relates to taxanes having a solubilizing promoiety with enhanced aqueous solubility and enhanced oral bioavailability compared to that of the parent taxane. The sol-moiety can be cleaved from the sol-moiety taxane conjugate to release the taxane in the gastrointestinal tract. Reactive solubilizing promoieties and methods of synthesizing the reactive promoieties, methods of synthesizing the solubilized taxanes, and methods of using the solubilized taxanes to treat diseases are also disclosed.BACKGROUND

[0004] High solubility throughout the varying pH levels of the gastrointestinal tract is essential for therapeutics to be readily absorbed into the bloodstream. However, many small molecule therapeutics tend to be lipophilic and poorly soluble in water. In preclinical settings, dimethyl sulfoxide (DMSO)- or polyethylene glycol (PEG)-based formulations are often used for rodent pharmacokinetic (PK) or pharmacodynamic (PD) studies. However, the data generated may not reflect the oral bioavailability or dose proportionality in human patients. To address these issues, sophisticated formulation strategies including particle size reduction, surfactants, co-solvents, amorphous solid dispersions, and lipid nanoparticles have been used to improve drug dissolution and bioavailability. However, such approaches are often time consuming, expensive, and may not provide sufficient drug exposure to achieve therapeutic efficacy in a clinical setting.SUMMARY

[0005] According to the present invention a sol-moiety drug conjugate has the structure of Formula (1):or a pharmaceutically acceptable salt thereof, whereinat least one of R1, R3, and R5is -O-P(O)(OH)2;at least one of the other of R1, R2, R3, R4, and R5is independently selected from - P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; each of the other of R1, R2, R3, R4, and Rsis independently selected from hydrogen, halo, methyl, and methoxy;R6is a cleavable linker; andD’ is derived from a taxane,wherein R6is bonded to an oxygen atom of the taxane.

[0006] According to the present invention pharmaceutical compositions comprise a sol-moiety drug conjugate or a pharmaceutically acceptable salt thereof according to the present invention and a pharmaceutically acceptable excipient.

[0007] According to the present invention kits comprise a sol-moiety drug conjugate or a pharmaceutically acceptable salt thereof according to the present invention

[0008] According to the present invention methods of treating cancer in a padent comprise administering to a patient in need of such treatment a therapeutically effective amount of a sol-moiety drug conjugate or a pharmaceutically acceptable salt thereof according to the present invention or a pharmaceutical composition according to the present invention.

[0009] According to the present invention a protected sol-moiety intermediate has the structure of Formula (2):or a salt thereof, wherein,at least one of R1a, R3a, and R5ais -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R5ais independently selected from -O-P(O)(OR9)2, - P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2, -C(O)(-OR10), -CH2C(O)(-OR10), and - CH(C(O)(-OR10))2;each of the other of Rla, R2a, R3a, R4a, and R’ais independently selected from hydrogen, halo, methyl, and methoxy;R7is selected from -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2-C(CH3)2)-, and -C(CH3)2- CII2—; andeach R9and R10is independently selected from C1-4 alkyl, benzyl, phenyl, 2- (trimethylsilyl)ethyl, and -C(CH3)3.

[0010] According to the present invention reactive sol-moiety precursor has the structure of Formula (3):or a salt thereof, wherein,at least one of Rla, R3a, and R5ais -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R5ais independently selected from -O-P(O)(OR9)2, - P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2, -C(O)(-OR'°), -CH2C(O)(-OR10), and - CH(C(O)(-OR10))2;each of the other of Rla, R2a, R3a, R4a, and R3ais independently selected from hydrogen, halo, methyl, and methoxy;R7is selected from -(CR2)P- where p is selected from 1 and 2, and each R is independently selected from hydrogen and methyl;R8is selected from a moiety reactive with a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, an NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group; and each R9and R10is independently selected from C1-4 alkyl, benzyl, phenyl, 2- (trimethylsilyl)ethyl, and -C(CH3)2.[Oil] According to the present invention methods of synthesizing a sol-moiety drug conjugate according to the present invention comprise reacting a therapeutic agent comprising a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group with a reactive sol-moiety compound, in the presence of a base to provide a protected intermediate; and treatingthe protected intermediate (a) with TMSBr in CH2Cl2or (b) with hydrogen gas in the presence of Pd / C in ethanol; to provide the compound of Formula (1).BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Those skilled in the art will understand that the drawings described herein are for illustration purposes only. The drawings are not intended to limit the scope of the present disclosure.

[0013] FIGS. 1 A- IB show a schematic of the sol-moiety concept.

[0014] FIGS. 2A-2C show examples of methods for synthesizing protected sol-moieties, reactive sol-moieties, and sol-moiety drug conjugates provided by the present disclosure.

[0015] FIGS. 3A-3K shows examples of sol-moiety drug conjugates.

[0016] FIGS. 4A-4J shows examples of reactive sol-moiety precursors.

[0017] FIGS. 5A-5B shows examples of drug derivatives.

[0018] FIGS. 6A-6. T shows the chemical structures of sol-moiety paclitaxel conjugates, sol-moiety docetaxel conjugates, sol-moiety cabazitaxel conjugates, and sol-moiety tesetaxel conjugates

[0019] FIG. 7 shows the results of a sol-moiety paclitaxel efficacy study using a pancreatic BxPC-3 xenograft mouse model.DETAILED DESCRIPTIONDefinitions

[0020] For purposes of the following detailed description, it is to be understood that embodiments provided by the present disclosure may assume various alternative variations and step sequences, except where expressly specified to the contrary. Moreover, other than in any operating examples, or where otherwise indicated, all numbers expressing, for example, quantities of ingredients used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0021] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard variation found in their respective testing measurements.

[0022] Also, it should be understood that any numerical range recited herein is intended to include all sub-ranges. For example, a range of “1 to 10” is intended to include all sub-ranges between (andincluding) the recited minimum value of 1 and the recited maximum value of 10, that is, having a minimum value equal to or greater than 1 and a maximum value of equal to or less than 10. A sub-range can include, for example, a range from 1 to 5, from 2 to 7, or from 7 to 10.

[0023] “Compounds provided by the present disclosure” include, for example, sol-moiety precursors, protected sol-moiety precursors, reactive sol-moieties, and sol-moiety drug conjugates.

[0024] “Compounds” including derivatives and moieties disclosed herein include any specific compounds within the disclosed formula. Compounds may be identified either by chemical structure and / or by chemical name. Compounds are named using the ChemDraw® Professional 25.0.2.14 (Revvity Signals Software, Inc.) nomenclature program. The compounds described herein may comprise one or more stereogenic centers and / or double bonds and therefore may exist as stereoisomers such as double-bond isomers (i.e., geometric isomers), enantiomers, diastereomers, or atropisomers.Accordingly, any chemical structures within the scope of the specification depicted, in whole or in part, with a relative configuration encompass all possible enantiomers and stereoisomers of the illustrated compounds including the stereoisomerically pure form (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures may be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled in the art.

[0025] Compounds including derivatives and moieties disclosed herein include optical isomers of compounds and moieties, racemates thereof, and other mixtures thereof. In such embodiments, the single enantiomers or diastereomers may be obtained by asymmetric synthesis or by resolution of the racemates. Resolution of the racemates may be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high-pressure liquid chromatography (HPLC) column with chiral stationary phases. In addition, compounds include (Z)- and (E)-forms (or cis- and trans-forms) of compounds with double bonds either as single geometric isomers or mixtures thereof.

[0026] Compounds including derivatives and moieties may also exist in several tautomeric forms including the enol form, the keto form, and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated compounds. Compounds may exist in unsolvated forms as well as solvated forms, including hydrated forms. Certain compounds may exist in multiple crystalline, co-crystalline, or amorphous forms. Compounds include pharmaceutically acceptable salts thereof, or pharmaceutically acceptable solvates of the free acid form of any of the foregoing, as well as crystalline forms of any of the foregoing.

[0027] “Patient” refers to a mammal, for example, a human.

[0028] “Pharmaceutically acceptable” refers to approved or approvable by a regulatory agency of the Federal or a state government or listed in the U. S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.

[0029] “Pharmaceutically acceptable vehicle” refers to a pharmaceutically acceptable diluent, a pharmaceulical ly acceptable adjuvant, a pharmaceutically acceptable excipient, a pharmaceutically acceptable carrier, or a combination of any of the foregoing with which a compound provided by the present disclosure may be administered to a patient and which does not destroy the pharmacological activity thereof and which is non-toxic when administered in doses sufficient to provide a therapeutically effective amount of the compound.

[0030] “Pharmaceutically acceptable salt” refers to a salt of a compound, which possesses the desired pharmacological activity of the parent compound. Such salts include acid addition salts, formed with inorganic acids and one or more protonable functional groups such as primary, secondary, or tertiary amines within the parent compound. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. A salt can be formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3 -phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like. A salt can be formed when one or more acidic protons present in the parent compound are replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion, or combinations thereof; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, and A-methylglucamine. A pharmaceutically acceptable salt can be the hydrochloride salt. A pharmaceutically acceptable salt can be a sodium salt. A pharmaceutically acceptable salt can be selected from a sodium salt, a calcium salt, a magnesium salt, a tromethamine salt, a N-methyl D-glucamine, and a lysine salt. In compounds having two or more ionizable groups, a pharmaceutically acceptable salt can comprise one or more counterions, such as a bis-salt, for example, a dihydrochloride salt.

[0031] The term “pharmaceutically acceptable salt” includes hydrates and other solvates, as well as salts in crystalline or non-crystalline form. Where a particular pharmaceutically acceptable salt is disclosed, it is understood that the particular salt (e.g., a hydrochloride salt) is an example of a salt, and that other salts may be formed using techniques known to one of skill in the art. Additionally, one skilled in the artwould be able to convert the pharmaceutically acceptable salt to the corresponding compound, free base and / or free acid, using techniques generally known in the art.

[0032] A “salt” can be a pharmaceutically acceptable salt.

[0033] “Pharmaceutical composition” refers to a compound of Formula (1) and at least one pharmaceutically acceptable vehicle. A pharmaceutically acceptable vehicle refers to a diluent, excipient or carrier with which a compound is administered to a patient. Pharmaceutically acceptable vehicles are known in the art. A pharmaceutical composition can be administered to a patient.

[0034] “Disease” refers to a disease, disorder, condition, or symptom of any of the foregoing.

[0035] “Preventing” or “prevention” refers to a reduction in risk of acquiring a disease or disorder (z.e., causing at least one of the clinical symptoms of the disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease). In some embodiments, “preventing” or “prevention” refers to reducing symptoms of the disease by administering a compound provided by the present disclosure in a preventative fashion. The application of a drug for preventing or prevention of a disease of disorder is known as prophylaxis. Compounds provided by the present disclosure can provide superior prophylaxis because of lower long-term side effects over long time periods.

[0036] “Curing” a disease refers to climinaling a disease or disorder or eliminating a symptom of a disease or disorder.

[0037] “Treating” or “treatment” of a disease or disorder refers to inhibiting the disease or disorder or one or more clinical symptoms of the disease or disorder, arresting the development of the disease or disorder or one or more clinical symptoms of the disease or disorder, relieving the disease or disorder or one or more clinical symptoms of the disease or disorder, causing the regression of the disease or disorder or one or more clinical symptoms of the disease or disorder, reducing the severity of one or more clinical symptom of the disease or disorder, delaying the onset of one or more clinical symptoms of the disease or disorder, mitigating one or more clinical symptoms of the disease or disorder and / or stabilizing the disease or disorder or one or more clinical symptoms of the disease or disorder. “Treating” or “treatment” of a disease or disorder includes producing a clinically beneficial effect without curing the underlying disease or disorder.

[0038] “Therapeutically effective amount” refers to the amount of a compound such as pharmaceutically active ingredient that, when administered to a patient for treating a disease, or at least one of the clinical symptoms of a disease, is sufficient to affect such treatment of the disease or symptom thereof. A “therapeutically effective amount” may vary depending, for example, on the compound, the disease and / or symptoms of the disease, the severity of the disease and / or symptoms of the disease or disorder, the age, weight, and / or health of the patient to be treated, and the judgment of the prescribing physician.A therapeutically effective amount in any given instance may be ascertained by those skilled in the art or capable of determination by routine experimentation.

[0039] “Therapeutically effective dose” refers to a dose that provides effective treatment of a disease or disorder in a patient. A therapeutically effective dose may vary from compound to compound, and from patient to padent, and may depend upon factors such as the condition of the patient and the route of delivery. A therapeutically effective dose may be determined in accordance with routine pharmacological procedures known to those skilled in the art.

[0040] A dashthat is not between two letters or symbols is used to indicate a point of attachment for a moiety or substituent. For example, -CONFF is attached through the carbon atom.

[0041] “Alkyl” refers to a saturated or unsaturated, branched, or straight-chain, monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene, or alkyne. Examples of alkyl groups include methyl; ethyls such as ethanyl, ethenyl, and ethynyl; propyls such as propan-l-yl, propan-2-yl, prop-l-en-l-yl, prop-l-en-2-yl, prop-2-en-l-yl (allyl), prop-l-yn-l-yl, prop-2-yn-l-yl, etc.; butyls such as butan-l-yl, butan-2-yl, 2-methyl-propan-l-yl, 2-methyl-propan-2-yl, but-l-en-l-yl, but-l-en-2-yl, 2-methyl-prop-l-en-l-yl, but-2-en-l-yl,but-2-en-2-yl, buta-l,3-dien-l-yl, buta-l,3-dien-2-yl, but-l-yn-l-yl, but-l-yn-3-yl, and but-3-yn-l-yl.The term “alkyl” is specifically intended to include groups having any degree or level of saturation, such as groups having exclusively carbon-carbon single bonds, groups having one or more carbon-carbon double bonds, groups having one or more carbon-carbon triple bonds, and groups having combinations of carbon-carbon single, double, and triple bonds. Where a specific level of saturation is intended, the terms alkanyl, alkenyl, and alkynyl are used. An alkyl group can be C1-6 alkyl, C1.5 alkyl, C1-4 alkyl, C1-3 alkyl, ethyl, or methyl.

[0042] “Alkoxy” refers to a radical -OR where R is alkyl as defined herein. Examples of alkoxy groups include methoxy, ethoxy, propoxy, and butoxy. An alkoxy group can be Ci-6 alkoxy, C1-5 alkoxy, in CM alkoxy, CM alkoxy, CM alkoxy, ethoxy or methoxy.

[0043] “Cleavable linker” refers to a group that is capable of being cleaved from a parent compound such as a drug in the gastrointestinal tract. For example, a cleavable linker can be cleaved by alkaline phosphatases located on the apical membrane of epithelial cells of the intestine.

[0044] “Derived from” in the context of a drug means that a compound derived from a drug is lacking one or more atoms. For example, a drug can have the structure X-H and a compound derived from a drug can have the structure X-, where the hydrogen atom is absent and X- can be bonded to a sol-moiety provided by the present disclosure.

[0045] “Y-” as in a compound Y-X refers to the point of attachment of X- to a sol-moiety provided by the present disclosure.

[0046] “-OMs” refers to -O-mesylate, “-Ots” refers to -O-tosylate, and “-OTf” refers to -O-triflate.

[0047] “Phosphonate group” refers to phosphinic acid group (-P(O)(OH)2 and deprotonated analogs such as a -P(O)(O)2 group and a -P(0)(0H)(0 ) group.

[0048] “Phosphate” group refers to the moiety -O-P-(O)(OII)2 and deprotonated analogs thereof.

[0049] “Phosphonomethyl group” refers to the moiety -CH2-P(O)(OH)2 and deprotonated analogs thereof.

[0050] “Drug” refers to any substance or combination of substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or other conditions in humans or animals or intended to affect the structure or any function of the body of humans or animals.

[0051] Reference is now made in detail to certain embodiments of compounds, compositions, and methods. The disclosed embodiments are not intended to be limiting of the claims. On the contrary, the claims are intended to cover all alternatives, modifications, and equivalents.

[0052] To overcome the limitations of current solubilizing prodrug technology, a solubilizing promoiety (sol-moiety) approach is disclosed where solubility and stability a sol-moiety drug conjugate is maintained throughout the physiologically encountered pH levels of the gastrointestinal tract. In compounds provided by the present disclosure one or more sol-moieties is bonded to a drug. Using a combination of sol-moieties the rate of enzymatic conversion in the intestine from the sol-moiety drug conjugate to the parent drug can be titrated so that the rate of gastrointestinal absorption of a drug is greater than the rate of precipitation of the released drug.

[0053] FIGS. 1A-1B show a schematic diagram of the sol-moiety concept. As shown in FIG. 1 A, a sol-moiety can consist of a benzyl scaffold substituted with a phosphate group in either the ortho or paraposition, and either a carboxylate or phosphonate group bonded to another position of the phenyl ring. As shown in FIG. IB, following oral administration, drug liberation can occur by hydrolysis of the phosphate ester group by alkaline phosphatases located on the apical membrane of epithelial cells of the intestine, followed by a 1,4- or 1,6-elimination reaction. The addition of a carboxylate group or phosphonate group enhances the ionic character of the parent drug, ensuring solubility of the sol-moiety drug conjugate through the varying physiological pH levels encountered in the gastrointestinal tract. Following drug release, the ionic character of the quinone methide or its hydrolyzed benzyl alcohol derivative (sol-moiety by-product) can have poor membrane permeability, thereby reducing potential toxicity concerns. The design allows for control of the rate of enzymatic conversion by intestinal alkaline phosphatases with substituents that can alter the steric and / or electronic environment surrounding the phosphate group. A sol-moiety can be bonded to a drug directly or through various linkers such as a linker comprising a formyl group, a carbonyl group, an ester group, or a gem-dimethyl group, to enable an elimination reaction to occur following hydrolysis of the phosphate, carboxylate and / or phosphonate groups.

[0054] Compounds provided by the present disclosure include sol-moiety drug conjugates comprising a solubilizing promoiety bonded to a drug. The solubilizing promoiety, also referred to as a sol-moiety, enhances the aqueous solubility and the oral bioavailability of the parent drug in the gastrointestinal tract.

[0055] Compounds provided by the present disclosure include sol-moiety drug conjugates. A sol-moiety drug conjugate can have the structure of Formula (1):where the moiety -D’ represents a derivative of drug D and the sol-moiety has the structure of Formula (la):In a sol-moiety drug conjugate of Formula (1) the cleavable linker -R6- of the sol-moiety can be bonded to an oxygen atom or to a nitrogen atom of the drug. For example, a drug can comprise a hydroxyl group and the sol-moiety can be bonded to the drug derivative D’ through the oxygen atom of the hydroxyl group and have the general structure (D-O)-(sol-moiety).

[0056] As shown in FIGS. 1A-1B a sol-moiety bonded to a drug can be enzymatically cleaved, for example via 1,4- or 1,6-elimination, by alkaline phosphatases located on the apical side of the epithelial cells facing the gut lumen. The drug can cross the cell membrane and the released sol-moiety by-product can be hydrolyzed to its corresponding alcohol derivative in the gastrointestinal tract.

[0057] A sol-moiety drug conjugate provided by the present disclosure can have the structure of Formula (1):or a pharmaceutically acceptable salt thereof, whereinat least one of R1, R3, and R5can be -O-P(O)(OH)2;at least one of the other of R1, R2, R3, R4, and R5can independently be selected from - P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; each of the other of R1, R2, R3, R4, and R5can independently be selected from hydrogen, halo, methyl, and methoxy;R6is a cleavable linker; andD’ is derived from a drug comprising a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, and imide group, or a urea group, wherein R6is bonded to an oxygen atom of the hydroxyl group, or to a nitrogen atom of the primary amine group, the secondary amine group, the tertiary amine group, the NH- heterocycle, the sulfonamide group, the sulfamide group, the sulfonimine group, the amide group, the imide group, or the urea group.

[0058] In a compound of Formula (1), R1can be -O-P(O)(OH)2.

[0059] In a compound of Formula (1), R3can be -O-P(O)(OH)2.

[0060] In a compound of Formula (1), R5can be -O-P(O)(OH)2.

[0061] In a compound of Formula (1), each of R1and R3can be -O-P(O)(OH)2.

[0062] In a compound of Formula (1), each of R1and R5can be -O-P(O)(OH)2.

[0063] In a compound of Formula (1), each of R3and R5can be -O-P(O)(OH)2.

[0064] In a compound of Formula (1), each of R1, R3, and R5can be -O-P(O)(OH)2.

[0065] In acompound of Formula (1), one of the other of R1, R2, R3, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0066] In a compound of Formula (1), one of the other of R1, R2, R3, R4, and R3can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0067] In a compound of Formula (1), one of the other of R1, R2, R3, R4, and R3can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0068] In a compound of Formula (1), one of the other of R1, R2, R3, R4, and R5can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0069] In a compound of Formula (1), one of the other of R1, R2, R3, R4, and R5can be -P(O)(OH)2.

[0070] In a compound of Formula (1), one of the other of R1, R2, R3, R4, and R3can be -CH2- P(O)(OH)2.

[0071] In a compound of Formula (1), one of the other of R1, R2, R3, R4, and R5can be -CH2CO2H.

[0072] In a compound of Formula (1), two of the other of R1, R2, R3, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0073] In a compound of Formula (1), two of the other of R1, R2, R3, R4, and R3can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0074] In a compound of Formula (1), two of the other of R1, R2, R3, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0075] In a compound of Formula (1), two of the other of R1, R2, R3, R4, and R5can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0076] In a compound of Formula (1), two of the other of R1, R2, R3, R4, and R3can be -P(O)(OH)2.

[0077] In a compound of Formula (1), two of the other of R1, R2, R3, R4, and R5can be -CH2-P(O)(OH)2.

[0078] In a compound of Formula (1), two of the other of R1, R2, R3, R4, and R5can be -CH2CO2H.

[0079] In a compound of Formula (1), three of the other of R1, R2, R3, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0080] In a compound of Formula (1), three of the other of R1, R2, R3, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0081] In a compound of Formula (1), three of the other of R1, R2, R3, R4, and R5can independently be selected from -P(O)(OH)2, -CH(-P(O)(OH)2)2, and -CH2CO2H.

[0082] In acompound of Formula (1), three of the other of R1, R2, R3, R4, and Rscan independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0083] In a compound of Formula (1), three of the other of R1, R2, R3, R4, and R5can be -P(O)(OH)2.

[0084] In a compound of Formula (1), three of the other of R1, R2, R3, R4, and R5can be -CH2-P(O)(OH)2.

[0085] In a compound of Formula (1), three of die other of R1, R2, R3, R4, and R5can be -CH2CO2H.

[0086] In a compound of Formula (1), one of the other of R1, R2, R3, R4, and R3can be selected from halo, methyl, and methoxy; and each of the other of R1, R2, R3, R4, and R5can be hydrogen.

[0087] In a compound of Formula (1), one of the other of R1, R2, R3, R4, and R5can be halo; and each of the other of R1, R2, R3, R4, and R5can be hydrogen.

[0088] In a compound of Formula (1), one of the other of R1, R2, R3, R4, and R5can be methyl; and each of the other of R1, R2, R3, R4, and R5can be hydrogen.

[0089] In a compound of Formula (1), one of the other of R1, R2, R3, R4, and R3can be methoxy; and each of the other of R1, R2, R3, R4, and R5can be hydrogen.

[0090] In a compound of Formula (1), two of the other of R1, R2, R3, R4, and R5can independently be selected from halo, methyl, and methoxy; and each of the other of R1, R2, R3, R4, and R5can be hydrogen.

[0091] In acompound of Formula (1), each of the other of R1, R2, R3, R4, and R5can be hydrogen.

[0092] In a compound of Formula (1), at least one of R1, R2, R3, R4, and R5can independently be halo, wherein halo can be fluoro.

[0093] In a compound of Formula (1),R1can be -O-P(O)(OH)2;one of R2, R3, R4, and R5can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(- P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R3, R4, and R5can independently be selected from hydrogen, halo, methyl, and methoxy.

[0094] In a compound of Formula (1) where R1is -O-P(O)(OH)2; one of R2, R3, R4, and R3can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0095] In a compound of Formula (1) where R1is -O-P(O)(OH)2; one of R2, R3, R4, and R3can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0096] In a compound of Formula (1) where R1is -O-P(O)(OH)2; one of R2, R3, R4, and R3can be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0097] In a compound of Formula (1) where R1is -O-P(O)(OH)2; one of R2, R3, R4, and R3can be selected from halo, methyl, and methoxy.

[0098] In a compound of Formula (1) where R1is -O-P(O)(OH)2; each of the other of R2, R3, R4, and R5can be hydrogen.

[0099] In a compound of Formula (1),R3can be -O-P(O)(OH)2;one of R1, R2, R4, and R5can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(- P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R4, and R3can independently be selected from hydrogen, halo, methyl, and methoxy.

[0100] In a compound of Formula (1) where R3is -O-P(O)(OH)2; one of R1, R2, R4, and R3can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0101] In a compound of Formula (1) where R3is -O-P(O)(OH)2; one of R1, R2, R4, and R3can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0102] In a compound of Formula (1) where R3is -O-P(O)(OH)2; one of R1, R2, R4, and R3can be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0103] In a compound of Formula (1) where R3is -O-P(O)(OH)2; one of R1, R2, R4, and R3can be selected from halo, methyl, and methoxy.

[0104] In a compound of Formula (1) where R3is -O-P(O)(OH)2; each of the other of R1, R2, R4, and Rscan be hydrogen.

[0105] In a compound of Formula (1),R5can be -O-P(O)(OH)2;at least one of R1, R2, R3, and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R3, and R4can independently be selected from hydrogen, halo, methyl, and methoxy.

[0106] In a compound of Formula (1) where R5is -O-P(O)(OH)2; one of R1, R2, R3, and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0107] In a compound of Formula (1) where R5is -O-P(O)(OH)2; one of R1, R2, R3, and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0108] In a compound of Formula (1) where R5is -O-P(O)(OH)2; one of R1, R2, R3, and R4can be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0109] In a compound of Formula (1) where R5is -O-P(O)(OH)2; one of R1, R2, R3, and R4can be selected from halo, methyl, and methoxy.

[0110] In a compound of Formula (1) where R5is -O-P(O)(OH)2; each of the other of R1, R2, R3, and R4can be hydrogen.

[0111] In a compound of Formula (1),each of R1and R3can be -O-P(O)(OH)2.one of R2, R4, and R5can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R4, and R5can independently be selected from hydrogen, halo, methyl, and methoxy.

[0112] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2;one of R2, R4, and R5can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0113] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2;one of R2, R4, and R5can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0114] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2:one of R2, R4, and R5can be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0115] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2;one of R2, R4, and R5can be selected from halo, methyl, and methoxy.

[0116] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2;each of the other of R2, R4, and R5can be hydrogen.

[0117] In a compound of Formula (1),each of R1and Rscan be -O-P(O)(OH)2;one of R2, R3, and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, - CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R3, and R4can independently be selected from hydrogen, halo, methyl, and methoxy.

[0118] In a compound of Formula (1) where each of R1and R5is -O-P(O)(OH)2:one of R2, R3, and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0119] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2;one of R2, R3, and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0120] In a compound of Formula (1) where each of R1and R5is -O-P(O)(OH)2;one of R2, R3, and R4can be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0121] In a compound of Formula (1) where each of R1and R5is -O-P(O)(OH)2:one of R2, R3, and R4can be selected from halo, methyl, and methoxy.

[0122] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2;each of the other of R2, R3, and R4can be hydrogen.

[0123] In a compound of Formula (1),each of R3and R5can be -O-P(O)(OH)2;one of R1, R2, and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, - CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, and R5can independently be selected from hydrogen, halo, methyl, and methoxy.

[0124] In a compound of Formula (1) where each of R3and R5is -O-P(O)(OH)2:one of R1, R2, and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0125] In a compound of Formula (1) where each of R3and R5is -O-P(O)(OH)2;one of R1, R2, and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0126] In a compound of Formula (1) where each of R3and R5is -O-P(O)(OH)2;one of R1, R2, and R4can be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0127] In a compound of Formula (1) where each of R3and R5is -O-P(O)(OH)2:one of R1, R2, and R4can be selected from halo, methyl, and methoxy.

[0128] In a compound of Formula (1) where each of R3and R5is -O-P(O)(OH)2;each of the other of R1, R2, and R4can be hydrogen.

[0129] In a compound of Formula (1),each of R1, R3, and R5can be -O-P(O)(OH)2;one of R2and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2and R4can be selected from hydrogen, halo, methyl, and methoxy.

[0130] In a compound of Formula (1) where each of R1, R3, and R5is -O-P(O)(OH)2; one of R2and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0131] In a compound of Formula (1) where each of R1, R3, and R5is -O-P(O)(OH)2; one of R2and R4can be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0132] In a compound of Formula (1) where each of R1, R3, and R5is -O-P(O)(OH)2; one of R2and R4can be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0133] In a compound of Formula (1) where each of R1, R3, and R5is -O-P(O)(OH)2; one of R2and R4can be selected from halo, methyl, and methoxy.

[0134] In a compound of Formula (1) where each of R1, R3, and R5is -O-P(O)(OH)2; the other of R2and R4can be hydrogen.

[0135] In a compound of Formula (1),R1can be -O-P(O)(OH)2;two of R2, R3, R4, and R3can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R3, R4, and R5can independently be selected from hydrogen, halo, methyl, and methoxy.

[0136] In a compound of Formula (1) where R1is -O-P(O)(OH)2; two of R2, R3, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0137] In a compound of Formula (1) where R1is -O-P(O)(OH)2; two of R2, R3, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0138] In a compound of Formula (1) where R1is -O-P(O)(OH)2; two of R2, R3, R4, and R5can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0139] In a compound of Formula (1) where R1is -O-P(O)(OH)2; one of R2, R3, R4, and R3can be selected from halo, methyl, and methoxy.

[0140] In a compound of Formula (1) where R1is -O-P(O)(OH)2; each of the other of R2, R3, R4, and Rscan be hydrogen.

[0141] In a compound of Formula (1),R3can be -O-P(O)(OH)2;two of R1, R2, R4, and R3can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, - CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R4, and Rscan independently be selected from hydrogen, halo, methyl, and methoxy.

[0142] In a compound of Formula (1) where R3is -O-P(O)(OH)2; two of R1, R2, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0143] In a compound of Formula (1) where R3is -O-P(O)(OH)2; two of R1, R2, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0144] In a compound of Formula (1) where R3is -O-P(O)(OH)2; two of R1, R2, R4, and R5can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0145] In a compound of Formula (1) where R3is -O-P(O)(OH)2; one of the other of R1, R2, R4, and R3can be selected from halo, methyl, and methoxy.

[0146] In a compound of Formula (1) where R3is -O-P(O)(OH)2; each of the other of R1, R2, R4, and R5can be hydrogen.

[0147] In a compound of Formula (1),R5can be -O-P(O)(OH)2;two of R1, R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R3, and R4can independently be selected from hydrogen, halo, methyl, and methoxy.

[0148] In a compound of Formula (1) where R3is -O-P(O)(OH)2; two of R1, R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0149] In a compound of Formula (1) where R5is -O-P(O)(OH)2; two of R1, R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0150] In a compound of Formula (1) where R3is -O-P(O)(OH)2; two of R1, R2, R3, and R4can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0151] In a compound of Formula (1) where R5is -O-P(O)(OH)2; one of the other of R1, R2, R3, and R4can be selected from halo, methyl, and methoxy.

[0152] In a compound of Formula (1) where R5is -O-P(O)(OH)2; each of the other of R1, R2, R3, and R4can be hydrogen.

[0153] In a compound of Formula (1),each of R1and R3can be -O-P(O)(OH)2;two of R2, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2, R4, and R5can be selected from hydrogen, halo, methyl, and methoxy.

[0154] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2:two of R2, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0155] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2;two of R2, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0156] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2:two of R2, R4, and Rscan independently be elected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0157] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2;one of the other of R2, R4, and R5can be selected from halo, methyl, and methoxy.

[0158] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2;the other of R2, R4, and R5can be hydrogen.

[0159] In a compound of Formula (1),each of R1and R5can be -O-P(O)(OH)2.two of R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2, R3, and R4can be selected from hydrogen, halo, methyl, and methoxy.

[0160] In a compound of Formula (1) where each of R1and R5is -O-P(O)(OH)2:two of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0161] In a compound of Formula (1) where each of R1and R3is -O-P(O)(OH)2;two of R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0162] In a compound of Formula (1) where each of R1and R5is -O-P(O)(OH)2:two of R2, R3, and R4can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0163] In a compound of Formula (1) where each of R1and R5is -O-P(O)(OH)2;the other of R2, R3, and R4can be selected from halo, methyl, and methoxy.

[0164] In a compound of Formula (1) where each of R1and R5is -O-P(O)(OH)2; the other of R2, R3, and R4can be hydrogen.

[0165] In a compound of Formula (1),each of R3and Rscan be -O-P(O)(OH)2;two of R1, R2, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R1, R2, and R4can be selected from hydrogen, halo, methyl, and methoxy.

[0166] In a compound of Formula (1) where each of R3and R5is -O-P(O)(OH)2: two of R1, R2, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0167] In a compound of Formula (1) where each of R3and R5is -O-P(O)(OH)2;two of R1, R2, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0168] In a compound of Formula (1) where each of R3and R5is -O-P(O)(OH)2;two of R1, R2, and R4can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0169] In a compound of Formula (1) where each of R3and R5is -O-P(O)(OH)2:the other of R1, R2, and R4can be selected from halo, methyl, and methoxy.

[0170] In a compound of Formula (1) where each of R3and R3is -O-P(O)(OH)2;the other of R1, R2, and R4can be hydrogen.

[0171] In a compound of Formula (1),each of R1, R3, and R5can be -O-P(O)(OH)2; andtwo of R2and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0172] In a compound of Formula (1) where each of R1, R3, and R5is -O-P(O)(OH)2; two of R2and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0173] In a compound of Formula (1) where each of R1, R3, and R5is -O-P(O)(OH)2; two of R2and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0174] In a compound of Formula (1) where each of R1, R3, and R5is -O-P(O)(OH)2; two of R2and R4can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0175] In a compound of Formula (1),R1can be -O-P(O)(OH)2;three of R2, R3, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2, R3, R4, and R5can be selected from hydrogen, halo, methyl, and methoxy.

[0176] In a compound of Formula (1) where R1is -O-P(O)(OH)2; three of R2, R3, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0177] In a compound of Formula (1) where R1is -O-P(O)(OH)2; three of R2, R3, R4, and R3can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0178] In a compound of Formula (1) where R1is -O-P(O)(OH)2; three of R2, R3, R4, and R5can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0179] In a compound of Formula (1) where R1is -O-P(O)(OH)2; the other of R2, R3, R4, and Rscan be selected from halo, methyl, and methoxy.

[0180] In a compound of Formula (1) where R1is -O-P(O)(OH)2; the other of R2, R3, R4, and R3can be hydrogen.

[0181] In a compound of Formula (1),R3can be -O-P(O)(OH)2;three of R1, R2, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R1, R2, R4, and R5can be selected from hydrogen, halo, methyl, and methoxy.

[0182] In a compound of Formula (1) where R3is -O-P(O)(OH)2; three of R1, R2, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0183] In a compound of Formula (1) where R3is -O-P(O)(OH)2; three of R1, R2, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0184] In a compound of Formula (1) where R3is -O-P(O)(OH)2; three of R1, R2, R4, and R5can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0185] In a compound of Formula (1) where R3is -O-P(O)(OH)2; the other of R1, R2, R4, and R5can be selected from halo, methyl, and methoxy.

[0186] In a compound of Formula (1) where R3is -O-P(O)(OH)2; the other of R1, R2, R4, and Rscan be hydrogen.

[0187] In a compound of Formula (1),R5can be -O-P(O)(OH)2;three of R1, R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R1, R2, R3, and R4can be selected from hydrogen, halo, methyl, and methoxy.

[0188] In a compound of Formula (1) where R5is -O-P(O)(OH)2; three of R1, R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CII(CO2II)2.

[0189] In a compound of Formula (1) where R5is -O-P(O)(OH)2; of R1, R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0190] In a compound of Formula (1) where R3is -O-P(O)(OH)2; three of R1, R2, R3, and R4can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0191] In a compound of Formula (1) where R5is -O-P(O)(OH)2; the other of R1, R2, R3, and R4can be selected from halo, methyl, and methoxy.

[0192] In a compound of Formula (1) where R5is -O-P(O)(OH)2; the other of R1, R2, R3, and R4can be hydrogen.

[0193] In a compound of Formula (1),R1and R3can be -O-P(O)(OH)2;andeach of R2, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0194] In a compound of Formula ( 1 ) where R1and R3is -O-P(O)(OH)2:each of R2, R4, and R5can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0195] In a compound of Formula (1) where R1and R3is -O-P(O)(OH)2;each of R2, R4, and R3can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0196] In a compound of Formula (1) where R1and R3is -O-P(O)(OH)2:each of R2, R4, and R5can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0197] In a compound of Formula (1),R1and R5can be -O-P(O)(OH)2, andeach of R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0198] In a compound of Formula (1) where R1and R5is -O-P(O)(OH)2:each of R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0199] In a compound of Formula (1) where R1and R3is -O-P(O)(OH)2;each of R2, R3, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0200] In a compound of Formula (1) where R1and R5is -O-P(O)(OH)2:each of R2, R3, and R4can independently be selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0201] In a compound of Formula (1),R3and R5can be -O-P(O)(OH)2;andeach of R1, R2, and R4can independently be selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OII)2)2, -CO2II, -CII2CO2II, and -CII(CO2II)2.

[0202] In a compound of Formula (1) where R3and R5can be -O-P(O)(OH)2;each of R1, R2, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0203] In a compound of Formula (1) where R3and R5can be -O-P(O)(OH)2;each of R1, R2, and R4is independently selected from -P(O)(OH)2, CH2 P(O)(OH)2, and -CH2CO2H.

[0204] In a compound of Formula ( 1 ) where R3and R5can be -O-P(O)(OH)2;each of R1, R2, and R4is independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0205] In a conjugate of Formula (1) or a sol-moiety of Formula (la), a cleavable linker R6can be selected from -(CR2)P-, -(CR2)P-O-(CR2)P- -(CR2)P-C(O)-, and -(CR2)P-O-C(O)-, where each p is independently selected from 1 and 2, and each R is independently selected from hydrogen and methyl.

[0206] In a conjugate of Formula (1) or a sol-moiety of Formula (la), p can be 1.

[0207] In a conjugate of Formula (1) or a sol-moiety of Formula (la), p can be 2.

[0208] In a conjugate of Formula (1) or a sol-moiety of Formula (la), each R in the cleavable linker R6, can be hydrogen.

[0209] In a conjugate of Formula (1) or a sol-moiety of Formula (la), a cleavable linker R6can be selected from -CH2-O-C(O)- and -C(CH3)2-CH2-C(O)-.

[0210] In a conjugate of Formula (1) or a sol-moiety of Formula (la), a cleavable linker R6can be selected from -CH2-O- and -CH(-CH3)-O-.

[0211] A sol-moiety can have the structure of Formula ( 1 a)wherein,at least one of R1, R3, and R3can be -O-P(O)(OH)2;at least one of the other of R1, R2, R3, R4, and R5can independently be selected from - P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2;each of the other of R1, R2, R3, R4, and R5can independently be selected from hydrogen, halo, methyl, and methoxy; andR6is a cleavable linker.

[0212] In a sol-moiety of Formula (la), each of R1, R2, R3, R4, and R5can be selected from any of the combinations as disclosed for a sol-moiety drug conjugate of Formula (1).

[0213] In a sol-moiety of Formula (la), a cleavable linker R6can be selected from -(CR2)P-, -(CR2)P-O-(CR2)P-, -(CR2)P-C(O)-, and -(CR2)P-O-C(O)-, where each p is independently selected from 1 and 2, and each R is independently selected from hydrogen and methyl.

[0214] In a cleavable linker R6, p can be 1.

[0215] In a cleavable linker R6, p can be 2.

[0216] In a cleavable linker R6, each R can be hydrogen.

[0217] In a sol-moiety of Formula (la), a cleavable linker R6can be selected from -CH2-O-C(O)- and -C(CH3)2-CH2-C(O)-.

[0218] In a sol-moiety of Formula (la), a cleavable linker R6can be selected from -CH2-O-, -CH(-CH3) O, and CH2CH2C(O).

[0219] A sol-moiety of Formula (la) can have a structure consistent with Formula (3 A) where R is selected from hydrogen, methyl and methoxy.

[0220] A sol-moiety of Formula (la) can have a structure consistent with Formula (3B) where R is hydrogen.

[0221] A sol-moiety of Formula (la) can a structure consistent with Formula (3D) where R is hydrogen.

[0222] A sol-moiety of Formula (la) can have a structure consistent with (3E) where R is selected from hydrogen, fluoro and methyl.

[0223] A sol-moiety of Formula (la) can have a structure consistent with Formula (3 J), (3K), (3L), (3M), or (3AAA).

[0224] A sol-moiety of Formula (la) can have a structure consistent with Formula (3KK), where R is selected from hydrogen and methyl.

[0225] A sol-moiety of Formula (la) can have a structure consistent with (3RR), where each R is independently selected from hydrogen and methyl.

[0226] A sol-moiety of Formula (la) can have a structure consistent with Formula (3ZZ) where R is selected from hydrogen, fluoro and methyl.

[0227] A sol-moiety of Formula (la) can have a structure consistent with any one of Formula (3A)-(3AAA), where Z represents the point of bonding to an oxygen atom or a nitrogen atom of a drug such as paclitaxel, docetaxel, cabazitaxel, or tesetaxel.

[0228] A compound of provided by the present disclosure comprises a sol-moiety bonded to a drug D or D’-H. A drug can comprise any drug capable of being bonded to the cleavable linker -R6- of the sol-moiety. For example, a drug can be bonded to the cleavable linker -R6- via an oxygen atom or a nitrogen atom of a drug D’-II. A suitable drug can comprise, for example, a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, and imide group, or a urea group. In a compound of Formula (1), the linker -R6- of the sol-moiety can be bonded to an oxygen atom or to a nitrogen atom of a derivative D’- of corresponding drug D’-H.

[0229] A drug can be a taxane such as paclitaxel, docetaxel, or cabazitaxel.

[0230] A derivative of a drug can be a taxane such as paclitaxel, docetaxel, or cabazitaxel having the structures listed in FIGS. 5A-5B, where Y shows the point at which a sol-moiety is bonded to the drug.

[0231] A paclitaxel, docetaxel, cabazitaxel, or tesetaxel derivative of Formula (41), (80), (81), (168), (169), or (223), can be bonded to a sol-moiety consistent with the structure of any one of Formula (3A)-(3 AAA) as shown in FIGS. 3A-3K.

[0232] In a sol-moiety drug conjugate provided by the present disclosure the drug can be paclitaxel and the sol-moiety paclitaxel conjugate can have the structure of any one of Formula (168-3 A) to Formula (168-3AAA).

[0233] In a sol-moiety drug conjugate provided by the present disclosure the drug can be paclitaxel and the sol-moiety paclitaxel conjugate can have the structure of any one of Formula (169-3 A) to Formula (169-3AAA).

[0234] In a sol-moiety drug conjugate provided by the present disclosure the drug can be docetaxel and the sol-moiety docetaxel conjugate can have the structure of any one of Formula (80-3 A) to Formula (80-3AAA).

[0235] In a sol-moiety drug conjugate provided by the present disclosure the drug can be docetaxel and the sol-moiety docetaxel conjugate can have the structure of any one of Formula (81-3 A) to Formula (81-3AAA).

[0236] In a sol-moiety drug conjugate provided by the present disclosure the drug can be cabazitaxel and the sol-moiety cabazitaxel conjugate can have the structure of any one of Formula (41-3 A) to Formula(41-3 AAA).

[0237] In a sol-moiety drug conjugate provided by the present disclosure the drug can be tesetaxel and the sol-moiety tesetaxel conjugate can have the structure of any one of Formula (223-3 A) to Formula (223-3AAA).

[0238] A compound of Formula (1) can be the free base.

[0239] A compound of Formula (1) can be a pharmaceutically acceptable salt.

[0240] A compound of Formula (1) can be selected from a sodium salt, a calcium salt, a magnesium tromethamine salt, a N-methyl D-glutamine salt, and a lysine salt.

[0241] In a compound of Formula (1) or a pharmaceutically acceptable salt thereof, the drug can be effective for treating cancer.

[0242] The cancer can be a solid tumor or meiastalic cancer.

[0243] For a compound of Formula (1) or a pharmaceutically acceptable salt thereof wherein the drug is paclitaxel, the compound can be used to treat breast cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, prostate cancer (castration-resistant)

[0244] For a compound of Formula ( 1) or a pharmaceutically acceptable salt thereof wherein the drug is paclitaxel, the compound can be used to treat bladder cancer (urothelial carcinoma), cervical cancer, endometrial cancer, esophageal cancer, kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma), melanoma, ovarian cancer, pancreatic cancer, small cell lung cancer (SCLC), soft tissue sarcoma (including angiosarcoma and leiomyosarcoma), testicular cancer (refractory germ cell tumors), or thyroid cancer (anaplastic and differentiated).

[0245] For a compound of Formula ( 1) or a pharmaceutically acceptable salt thereof wherein the drug is paclitaxel, the compound can be used to treat bladder cancer, breast cancer, colorectal cancer, fallopian tube cancer, gastric cancer, head and neck cancer, liver cancer, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, prostate cancer, or urothelial cancer.

[0246] For a compound of Formula (1) or a pharmaceutically acceptable salt thereof wherein the drug is docetaxel, the compound can be used to treat breast cancer (locally advanced or metastatic, and early-stage adjuvant), castration-resistant metastatic prostate cancer, gastric adenocarcinoma (including gastroesophageal junction adenocarcinoma), head and neck squamous cell carcinoma (SCCHN), or non-small cell lung cancer (NSCLC)

[0247] For a compound of Formula (1) or a pharmaceutically acceptable salt thereof wherein the drug is docetaxel, the compound can be used to treat bladder cancer (urothelial carcinoma), cervical cancer, endometrial cancer, esophageal cancer, kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma), melanoma, ovarian cancer, pancreatic cancer, small cell lung cancer (SCLC), soft tissue sarcoma (including angiosarcoma and leiomyosarcoma), testicular cancer (refractory germ cell tumors), or thyroid cancer (anaplastic and differentiated).

[0248] For a compound of Formula (1) or a pharmaceutically acceptable salt thereof wherein the drug is docetaxel, the compound can be used to treat adrenocortical carcinoma, bladder cancer, breast cancer,esophageal adenocarcinoma, gastric cancer, leukemia, non-small cell lung cancer, prostate cancer, sarcoma, squamous cell carcinoma of the head and neck, squamous cell lung cancer, or stomach cancer.

[0249] For a compound of Formula (1) or a pharmaceutically acceptable salt thereof wherein the drug is cabazitaxel, the compound can be used to treat castration-resistant metastatic prostate cancer.

[0250] For a compound of Formula ( 1) or a pharmaceutically acceptable salt thereof wherein the drug is cabazitaxel, the compound can be used to treat bladder cancer (urothelial carcinoma), breast cancer (including docetaxel-resistant), gastric cancer, head and neck squamous cell carcinoma, liver cancer (hepatocellular carcinoma), non-small cell lung cancer (NSCLC), ovarian cancer, renal cell carcinoma, or small cell lung cancer (SCLC)

[0251] For a compound of Formula ( 1) or a pharmaceutically acceptable salt thereof wherein the drug is cabazitaxel, the compound can be used to treat adrenocortical carcinoma, brain cancer, breast cancer, esophageal cancer, gastric cancer, glioblastoma, liposarcoma, lung cancer, ovarian cancer, penile neoplasm, prostate cancer, squamous cell carcinoma of the head and neck, testicular cancer, or urothelial carcinoma.

[0252] A sol-moiety drug conjugate can have the structure of any one of Compounds (3A) to (3AAA) as listed in FIGS. 3A-3K, where each R is independently selected from hydrogen, chloro, fluoro, methyl, and methoxy; and D’ is derived from a taxane such as paclitaxel, docetaxel, cabazitaxel, and tesetaxel.

[0253] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, the drug can be paclitaxel and the paclitaxel derivative -D’ in a sol-moiety drug conjugate of Formula (1) can have the structure of Formula (168) or Formula (169):(168) (169)

[0254] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, the drug can be paclitaxel and the corresponding sol-moiety drug conjugate can be consistent the structure of any one of Compound (168-3A) to Compound (168-3AAA).

[0255] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, the drug can be paclitaxel and the corresponding sol-moiety drug conjugate can have the structure of any one of Compound (169-3A) to Compound (169-3AAA).

[0256] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, the drug can be paclitaxel and the corresponding sol-moiety drug conjugate can be consistent the structure of any one of Compound (3A) to Compound (3AAA), where the sol-moiety is bonded to the oxygen atom of the paclitaxel derivative having the structure of Formula (163).

[0257] For example, a sol-moiety can have the structure of Formula (3A):the paclitaxel derivative can have the structure of Formula (168):and the corresponding sol-moiety paclitaxel conjugate can have the structure of Formula(168-3A):(168-3A).

[0258] For example, in a sol-moiety drug conjugate provided by the present disclosure the paclitaxel derivative can have the structure of Formula (168), the sol-moiety can be consistent with the structure ofFormula (3L) and the corresponding sol-moiety drug conjugate can have the structure of Formula (168-3L):(168-3L).

[0259] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, the drug can be docetaxel having the structure of Formula (80) and the docetaxel derivative -D’ in a sol-moiety docetaxel conjugate of Formula (1) can have the structure of Formula (80) or Formula (81):wherein Y represents the point of attachment to cleavable linker -R6-.

[0260] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, the drug can be docetaxel and the corresponding sol-moiety docetaxel conjugate can be consistent with the structure of any one of Compound (80-3A) to Compound (80-3AAA), where the sol-moiety is bonded to the Y oxygen atom of the docetaxel derivative having the structure of Formula (78).

[0261] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, the drug can be docetaxel and the corresponding sol-moiety docetaxel conjugate can be consistent with the structure of any one of Compound (81-3 A) to Compound (81-3 AAA), where the sol-moiety is bonded to the Y oxygen atom of the docetaxel derivative having the structure of Formula (79).

[0262] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, drug can be cabazitaxel and the cabazitaxel derivative D’ in a sol-moiety drug conjugate of Formula (1) can have the structure of Formula (41):wherein Y represents the point of attachment to cleavable linker -R6- of the sol moiety.

[0263] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, the drug can be cabazitaxel and the corresponding sol-moiety cabazitaxel conjugate can be consistent with the structure of any one of Formula (41-3A) to Compound (41 -3 AAA), where the sol-moiety is bonded to the Y oxygen atom of the cabazitaxel derivative having the structure of Formula (41).

[0264] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, drug can be tesetaxel and the tesetaxel derivative D’ in a sol-moiety drug conjugate of Formula (1) can have the structure of Formulawherein Y represents the point of attachment to cleavable linker -R6- of the sol-moiety

[0265] In a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, the drug can be tesetaxel and the corresponding sol-moiety tesetaxel conjugate can be consistent with the structure of any one of Formula (223-3A) to Compound (223-3AAA), where the sol-moiety is bonded to the Y oxygen atom of the tesetaxel derivative having the structure of Formula (223).

[0266] A compound provided by the present disclosure or pharmaceutically acceptable salt thereof, can comprise a drug of any one of Formula (41), (80), (81), (168), 169) and (223), where the sol-moiety isbonded to the Y oxygen atom of the drug derivative having the structure of any one of Formula (1) to (238).

[0267] For example, a compound provided by the present disclosure or pharmaceutically acceptable salt thereof, can by any one of Compound (41-3A)-(41-3AAA), (8O-3A)-(8O-3AAA), (81-3A)-(81-3AAA), (168-3A)-(168-3AAA), (169-3A)-(169-3AAA) and (223-3 A)-(223-3 AAA),

[0268] In a sol-moiety of Formula (la), each of R1, R2, R3, R4, and R3can be defined as for a sol-moiety drug conjugate of Formula (1).

[0269] A protected sol-moiety intermediate provided by the present disclosure can have the structure of Formula (2):or a salt thereof, wherein,at least one of Rla, R3a, and R5ais -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R5acan independently be selected from -O- P(O)(OR9)2, -P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2,-C(O)(-OR9), -CH2C(O)(- OR9), and -CH(C(O)(-OR9))2;each of the other of Rla, R2a, R3a, R4a, and R3acan independently be selected from hydrogen, halo, methyl, and methoxy;R7can be selected from -CH2-, -CH(CH3)-, and -C(CH3)2-; andeach R9can independently be selected from C1-4 alkyl, benzyl, phenyl, 2- (trimethylsilyl)ethyl, and -C(CH3)3.

[0270] In a compound of Formula (2), R7can be — CH2-.

[0271] In a compound of Formula (2), R7can be -CH(CH3)-.

[0272] In a compound of Formula (2), R7can be -C(CH3)2-.

[0273] In a compound of Formula (2), each R9can be C1-4 alkyl.

[0274] In a compound of Formula (2), each R9can be benzyl.

[0275] In a compound of Formula (2), each R9can be phenyl.

[0276] In a compound of Formula (2), each R9can be 2-(trimethylsilyl)ethyl.

[0277] In a compound of Formula (2), each R9can be -C(CH3)3.

[0278] In a compound of Formula (2), each of Rla, R2a, R3a, R4a, and R3acan be defined as for R1, R2, R3, R4, and R5in Formula (1) consistent with the definitions for Rla, R2a, R3a, R4a, and R3a. For example, if in a compound of Formula (1) three of R1, R2, R3, R4, and R5can be -P(0)(0H)2, in a compound of Formula (2) three of Rla, R2a, R3a, R4a, and R5acan be -P(O)(OR9)2.

[0279] A protected sol-moiety intermediate provided by the present disclosure can have the structure of Formula (2):or a salt thereof, wherein,at least one of Rla, R3a, and R5ais -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R5acan independently be selected from -O- P(O)(OR9)2, -P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2, -C(O)(-OR10), -CH2C(O)(- OR10), and -CH(C(O)(-OR10))2;each of the other of Rla, R2a, R3a, R4a, and R’acan independently be selected from hydrogen, halo, methyl, and methoxy;R7can be selected from -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2-C(CH3)2)-, and - C(CH3)2-CH2-; andeach R9and R10can independently be selected from Ci-4 alkyl, benzyl, phenyl, 2- (trimethylsilyl)ethyl, and -C(CH3)3.

[0280] In a compound of Formula (2), R7can be -CH2-

[0281] In a compound of Formula (2), R7can be -CH(CH3)-.

[0282] In a compound of Formula (2), R7can be -C(CH3)2-.

[0283] In a compound of Formula (2), R7can be -CH2-C(CH3)2-.

[0284] In a compound of Formula (2), R7can be -C(CH3)2-CH2-.

[0285] In a compound of Formula (2), each R9and R10can be Ci-4 alkyl.

[0286] In a compound of Formula (2), each R9and R10can be benzyl.

[0287] In a compound of Formula (2), each R9and R10can be phenyl.

[0288] In a compound of Formula (2), each R9and R10can be 2-(trimethylsilyl)ethyl.

[0289] In a compound of Formula (2), each R9and R10can be -C(CH3)3.

[0290] In a compound of Formula (2), each R9can independently be selected from ethyl and benzyl.

[0291] In a compound of Formula (2), each R9can be ethyl.

[0292] In a compound of Formula (2), each R9can be benzyl.

[0293] In a compound of Formula (2), each R10can independently be selected from tert-butyl and benzyl.

[0294] In a compound of Formula (2), each R10can be tert-butyl.

[0295] In a compound of Formula (2), each R10can be benzyl.In a compound of Formula (2), each of Rla, R2a, R3a, R4a, and R3acan be defined as for R1, R2, R3, R4, and R5in Formula (1) consistent with the definitions for Rla, R2a, R3a, R4a, and R3a. For example, if in a compound of Formula (1) three of R1, R2, R3, R4, and R5can be -P(O)(OH)2, in a compound of Formula (2) three of Rla, R2a, R3a, R4a, and R5acan be -P(O)(OR9)2

[0296] A reactive sol-moiety precursor provided by the present disclosure can have the structure of Formula (3):or a salt thereof, wherein,at least one of Rla, R3a, and R5ais -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R5acan independently be selected from -O- P(O)(OR9)2, -P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2,-C(O)(-OR9), -CH2C(O)(- OR9), and -CH(C(O)(-OR9))2;each of the other of Rla, R2a, R3a, R4a, and R’acan independently be selected from hydrogen, halo, methyl, and methoxy;R7can be selected from -CH2-, -CH(CH3)-, and -C(CH3)2-;R8can be selected from a moiety reactive with a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group; and each R9can independently be selected from C1-4alkyl, benzyl, phenyl, 2- (trimethylsilyl)ethyl, and C(CH3)2.

[0297] In a compound of Formula (3), R7can be -CH2-.

[0298] In a compound of Formula (3), R7can be -CH(CH3)-.

[0299] In a compound of Formula (3), R7can be -C(CH3)2-

[0300] In a compound of Formula (3), each R9can be C1-4alkyl.

[0301] In a compound of Formula (3), each R9can be benzyl.

[0302] In a compound of Formula (3), each R9can be phenyl.

[0303] In a compound of Formula (3), each R9can be 2-(trimethylsilyl)ethyl.

[0304] In a compound of Formula (3), each R9can be -C(CH3)3.

[0305] In a compound of Formula (3), each of Rla, R2a, R3a, R4a, and R3acan be defined as for R1, R2, R3, R4, and R5in Formula (1) consistent with the definitions for Rla, R2a, R3a, R4a, and R3a. For example, if in a compound of Formula (1), three of R1, R2, R3, R4, and R’ can be -P(O)(OH)2 in a compound of Formula (2), three of Rla, R2a, R3a, R4a, and R5acan be -P(O)(OR9)2.

[0306] In a compound of Formula (3), R8can be selected from Br, Cl, I, -OC(=O)CH2C1, --OCH2OC(=O)Cl, -OC(=O)C1, -OC(=O)OPh, -OC(=O)OC6H4NO2, -OC(=O)OC6H3(NO2)2, -OC(=O)OC6F5, -OCH2OC(=O)O-Ai-hydroxysuccinimide, -OCH2SCH3, and -OCH2C1.

[0307] In a compound of Formula (3), R8can be selected from Br, Cl, and I.

[0308] In a compound of Formula (3), R8can be -OC(=O)CH2C1.

[0309] In a compound of Formula (3), R8can be --OCH2OC(=O)Cl.

[0310] In a compound of Formula (3), R8can be -OC(=O)C1.

[0311] In a compound of Formula (3), R8can be -OC(=O)OPh.

[0312] In a compound of Formula (3), R8can be -OC(=O)OC6H4NO2.

[0313] In a compound of Formula (3), R8can be -OC(=O)OC6H3(NO2)2.

[0314] In a compound of Formula (3), R8can be -OC(=O)OC6F5.

[0315] In a compound of Formula (3), R8can be -OCH2OC(=O)O-N-hydroxysuccinimide.

[0316] In a compound of Formula (3), R8can be -OCH2SCH3.

[0317] In a compound of Formula (3), R8can be -OCH2C1.

[0318] In a compound of Formula (3), R8can be -CH2-C(O)-R10, wherein R10can be selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf.

[0319] In a compound of Formula (3), R8can be -CH2-C(O)-OH.

[0320] In a compound of Formula (3), R8can be -CH2-C(O)-C1.

[0321] In a compound of Formula (3), R8can be -CH2-C(O)-O-N-hydroxysuccinimide.

[0322] In a compound of Formula (3), R8can be -CH2-C(O)-OMs.

[0323] In a compound of Formula (3), R8can be -CH2-C(O)-OTs.

[0324] In a compound of Formula (3), R8can be -CH2-C(O)-OTf.

[0325] In a compound of Formula (3),R7can be -CH2-; andR8can be selected from Br, Cl, I, -OC(=O)CH2C1, --OCH2OC(=O)Cl, -OC(=O)C1, -OC(=O)OPh, -OC(=O)OC6H4NO2, -OC(=O)OC6H3(NO2)2, -OC(=O)OC6F5, -OCH2OC(=O)O-N-hydroxysuccinimide, -OCH2SCH3, and -OCH2C1.

[0326] In a compound of Formula (3),R7can be -C(CH3)2-; andR8can be -CH2-C(O)-R10, wherein R10can be selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf.

[0327] A reactive sol-moiety of Formula (3) can have the structure of any one of Formula (4A) to(4 AAA) as listed in FIGS. 4A-4. T, whereeach R’ can independently be selected from C1-4 alkyl, phenyl, benzyl, tert-butyl, allyl, and 2-(trimethylsilyl)ethyl;each R can independently be selected from hydrogen, halo, methyl, and methoxy;W can be selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf; andZ can be selected from halo -OC(=O)CH2C1, -OCH2O(C=O)C1, -O(C=O)C1, - O(C=O)OPh, -O(C=O)OC6H4NO2, -O(C=O)OC6H3(NO2)2, -O(C=O)OC6F5, OCH2O(C=O)O N-hydroxysuccinimide, -OCH2SCH3, and -OCH2C1.

[0328] A reactive sol-moiety precursor provided by the present disclosure can have the structure of Formula (3):or a salt thereof, wherein,at least one of Rla, R3a, and R5ais -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R5acan independently be selected from -O- P(O)(OR9)2, -P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2, -C(O)(-OR10), -CH2C(O)(-OR10), and -CH(C(O)(-OR10))2;each of the other of Rla, R2a, R3a, R4a, and R’acan independently be selected from hydrogen, halo, methyl, and methoxy;R7can be selected from -(CR2)P- where p is selected from 1 and 2, and each R is independently selected from hydrogen and methyl;R8can be selected from a moiety reactive with a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group; and each R9and R10can independently be selected from Ci-4alkyl, benzyl, phenyl, 2-(trimethylsilyl)ethyl, and -C(CH3)3.

[0329] In a compound of Formula (3), R7can be selected from -CH2-, -CH(CH3)-, -C(CH3)2-, -C(CH3)2CH2, and CH2C(CH3)2;

[0330] In a compound of Formula (3), R7can be -CH2-.

[0331] In a compound of Formula (3), R7can be -CH(CH3)-.

[0332] In a compound of Formula (3), R7can be -C(CH3)2-.

[0333] In a compound of Formula (3), R7can be -CH2-C(CH3)2-

[0334] In a compound of Formula (3), R7can be -C(CH3)2-CH2-.

[0335] In a compound of Formula (3), each R9can be C1-4alkyl.

[0336] In a compound of Formula (3), each R9can be benzyl.

[0337] In a compound of Formula (3), each R9can be phenyl.

[0338] In a compound of Formula (3), each R9can be 2-(trimethylsilyl)ethyl.

[0339] In a compound of Formula (3), each R9and R10can be -C(CH3)3.

[0340] In a compound of Formula (3), each R9and R10can independently be selected from ethyl and benzyl.

[0341] In a compound of Formula (3), each R9and R10can be ethyl.

[0342] In a compound of Formula (3), each R9and R10can be benzyl.

[0343] In a compound of Formula (3), each R10can independently be selected from tert-butyl and benzyl.

[0344] In a compound of Formula (3), each R10can be tert-butyl.

[0345] In a compound of Formula (3), each R10can be benzyl.

[0346] In a compound of Formula (3), each of Rla, R2a, R3a, R4a, and R5acan be defined as for R1, R2, R3,R4, and R5in Formula (1) consistent with the definitions for Rla, R2a, R3a, R4a, and R5a. For example, if in a compound of Formula (1), three of R1, R2, R3, R4, and R’ can be -P(O)(OH)2in a compound of Formula (3), three of Rla, R2a, R3a, R4a, and R5acan be -P(O)(OR9)2.

[0347] In a compound of Formula (3), R8can be selected from Br, Cl, I, -OC(=O)CH2C1, -OC(=O)CH(CH3)-C1, --OCH2OC(=O)Cl, -OC(=O)C1, -OC(=O)OPh, -OC(=O)OC6H4NO2, -OC(=O)OC6H3(NO2)2, -OC(=O)OC6F5, -OCH2OC(=O)O-N-hydroxysuccinimide, -OCH2SCH3, -OCH2C1, -C(O)-C1, and -COOH.

[0348] In a compound of Formula (3), R8can be selected from Br, Cl, and I.

[0349] In a compound of Formula (3), R8can be -OC(=O)CH2C1.

[0350] In a compound of Formula (3), R8can be -OCH2OC(=O)Cl.

[0351] In a compound of Formula (3), R8can be -OC(=O)C1.

[0352] In a compound of Formula (3), R8can be -OC(=O)OPh.

[0353] In a compound of Formula (3), R8can be -OC(=O)OC6H4NO2.

[0354] In a compound of Formula (3), R8can be -OC(=O)OC6H3(NO2)2.

[0355] In a compound of Formula (3), R8can be -OC(=O)OC6F5.

[0356] In a compound of Formula (3), R8can be -OCH2OC(=O)O-N-hydroxysuccinimide.

[0357] In a compound of Formula (3), R8can be -OCH2SCH3.

[0358] In a compound of Formula (3), R8can be -OCH2C1.

[0359] In a compound of Formula (3), R8can be -CH2-C(O)-R10, wherein R10can be selected from OH, Cl, O-iV-hydroxysuccinimide, OMs, OTs, and OTf.

[0360] In a compound of Formula (3), R8can be -CH2-C(O)-OH.

[0361] In a compound of Formula (3), R8can be -CH2-C(O)-C1.

[0362] In a compound of Formula (3), R8can be -CH2-C(O)-O-N-hydroxysuccinimide.

[0363] In a compound of Formula (3), R8can be -CH2-C(O)-OMs.

[0364] In a compound of Formula (3), R8can be -CH2-C(O)-OTs.

[0365] In a compound of Formula (3), R8can be -CH2-C(O)-OTf.

[0366] In a compound of Formula (3),R7can be -CH2-; andR8can be selected from Br, Cl, I, -OC(=O)CH2C1, --OCH2OC(=O)Cl, -OC(=O)C1, -OC(=O)OPh, -OC(=O)OC6H4NO2, -OC(=O)OC6H3(NO2)2, -OC(=O)OC6F5, -OCH2OC(=O)O-N-hydroxysuccinimide, -OCH2SCH3, and -OCH2C1.In a compound of Formula (3),R7can be -CH2-; andR8can be -O-C(O)-C1.

[0367] In a compound of Formula (3),R7can be -C(CH3)2-CH2-; andR8can be -C(O)-R10, wherein R10can be selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf.

[0368] A reactive sol-moiety of Formula (3) can have the structure of any one of Compounds (4A) to (4YY) as listed in FIGS. 4A-4J, whereeach R’ can independently be selected from C1.4 alkyl, phenyl, benzyl, zc / -bulyl, allyl, and 2-(trimethylsilyl)ethyl;R can be selected from hydrogen, halo, methyl, and methoxy;W can be selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf; andZ can be selected from halo -OC(=O)CH2Cl, -OCH2O(C=O)Cl, -O(C=O)Cl, -O(C=O)OPh, -O(C=O)OC6H4NO2, -O(C=O)OC6H3(NO2)2, -O(C=O)OC6F5, -OCH2O(C=O)O-N-hydroxysuccinimide, -OCH2SCH3, and -OCH2Cl.

[0369] In a compound of Formula (4A)-(4AAA), for each -PO(OR’)2, -OPO(OR’)2, -CH2-PO(OR’)2, -CH2-OPO(OR’)2, and -CH(-P(O)(OR’)2)2, R’ can be selected from ethyl and benzyl.

[0370] In a compound of Formula (4A)-(4AAA), for each -COOR’, -CH2-COOR’, and -CH(COOR’)2, R’ can be selected from tert-butyl and benzyl.

[0371] In a compound of Formula (4A)-(4AAA), R can be hydrogen.

[0372] In a compound of Formula (4A)-(4AAA), R can be halo.

[0373] In a compound of Formula (4A)-(4AAA), R can be methyl.

[0374] In a compound of Formula (4A)-(4AAA), R can be methoxy.

[0375] In a compound of Formula (4A)-(4PP), Z can be selected from Br, Cl, and I.

[0376] In a compound of Formula (4A)-(4PP), Z can be -OC(=O)CH2C1.

[0377] In a compound of Formula (4A)-(4PP), Z can be --OCH2OC(=O)Cl.

[0378] In a compound of Formula (4A)-(4PP), Z can be -OC(=O)C1.

[0379] In a compound of Formula (4A)-(4PP), Z can be -OC(=O)OPh.

[0380] In a compound of Formula (4A)-(4PP), Z can be -OC(=O)OC6H4NO2.

[0381] In a compound of Formula (4A)-(4PP), Z can be -OC(=O)OC6H3(NO2)2.

[0382] In a compound of Formula (4A)-(4PP), Z can be -OC(=O)OC6F5.

[0383] In a compound of Formula (4A)-(4PP), Z can be -OCH2OC(=O)O-N-hydroxysuccinimide.

[0384] In a compound of Formula (4A)-(4PP), Z can be -OCH2SCH3.

[0385] In a compound of Formula (4A)-(4PP), Z can be -OCH2CI.

[0386] In a compound of Formula (4QQ)-(4AAA), W can be -OH,

[0387] In a compound of Formula (4QQ)-(4AAA), W can be -Cl.

[0388] In a compound of Formula (4QQ)-(4AAA), W can be O-N-hydroxysuccinimide.

[0389] In a compound of Formula (4QQ)-(4AAA), W can be -OMs.

[0390] In a compound of Formula (4QQ)-(4AAA), W can be -OTs.

[0391] In a compound of Formula (4QQ)-(4AAA), W can be -OTf.

[0392] A reactive sol-moiety precursor of Formula (3) can have the structure of Formula (4A) where R is selected from hydrogen, methyl and methoxy.

[0393] A reactive sol-moiety precursor of Formula (3) can have the structure of Formula (4B) where R is hydrogen.

[0394] A reactive sol-moiety precursor of Formula (3) can have the structure of Formula (4D) where R is hydrogen.

[0395] A reactive sol-moiety precursor of Formula (3) can have the structure of Formula (4E) where R is selected from hydrogen, fluoro and methyl.

[0396] A reactive sol-moiety precursor of Formula (3) can have the structure of Formula (4J), (4K), (4L), (4M), or (4AAA).

[0397] A reactive sol-moiety precursor of Formula (3) can have the structure of Formula (4KK), where R is selected from hydrogen and methyl.

[0398] A reactive sol-moiety precursor of Formula (3) can have the structure of Formula (4RR), where each R is independently selected from hydrogen and methyl.

[0399] A reactive sol-moiety precursor of Formula (3) can have the structure of Formula (4ZZ) where R is selected from hydrogen, fluoro and methyl.

[0400] In certain embodiments, a compound is not selected from a compound listed in FIGS. 6A-6. T.

[0401] Examples of reaction schemes for synthesizing sol-moiety intermediates, reactive sol-moieties, and sol-moiety drug conjugates are shown in FIGS. 2A-2C. FIG. 2A shows reaction schemes, FIG. 2B provides the chemical structures of the sol-moiety drug conjugates emphasizing the structure of the drugs, and FIG. 2C shows the structures of the sol-moiety drug conjugates emphasizing the structure of the sol-moieties.

[0402] As shown in FIG. 2A, for example, R can be iso-butyl or benzyl; R” can be selected from ethyl and benzyl; R’ can be selected from hydrogen, fluoro, methyl, or methoxy; and X can be selected from chloro, and 4-NO2C6H4O-.

[0403] Compounds li, liii-lv, 2, 2iv, 4i, 5i, 6i, 8i, 3ii, 7ii, 9ii, 2vi, and 8vi represent sol-moiety drug conjugates of Formula (1).

[0404] Compounds 14 and 20 represent protected sol-moiety intermediates of Formula (2) as provided by the present disclosure.

[0405] Compounds 15, 16, and 21 represent reactive sol-moieties of Formula (3) as provided by the present disclosure.

[0406] A sol-moiety drug conjugate provided by the present disclosure can be synthesized, for example, by (1) reacting a reactive sol-moiety of Formula (3) with a drug to provide a protected sol-moiety drug conjugate; and (2) treating the protected sol-moiety drug conjugate with (a) with TMSBr in CH2Cl2or (b) with hydrogen gas in the presence of Pd / C in ethanol to provide the sol-moiety drug conjugate of Formula (1). The drug can comprise, for example, a hydroxyl group, a primary amine group, a secondary aminegroup, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group.

[0407] A reactive sol-moiety of Formula (3) can be synthesized by reacting, for example, a sol-moiety intermediate of Formula (2) with, for example (a) (ClCO)2CO in CH2Cl2; (b) (4-NO2PhO)2CO and DMAP in a solvent; (c) 4-NO2PhCOCl and DMAP in a solvent; or (d) PPhs and CBr4 in a solvent.

[0408] A compound of Formula (1) or a pharmaceutically acceptable salt thereof can be incorporated into a pharmaceutical composition to be administered to a patient by any appropriate route of administration including intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, peroral, sublingual, intracerebral, intravaginal, transdermal, rectal, inhalation, topical, or topical ophthalmic. A pharmaceutical composition provided by the present disclosure can be an oral formulation. A pharmaceutical composition provided by the present disclosure can be an intravenous formulation. A compound of Formula (1) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof can be administered orally. A compound of Formula (1) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof can be administered intravenously.

[0409] A pharmaceutical composition provided by the present disclosure can comprise a therapeutically effective amount of a compound of Formula (1) or a pharmaceutically acceptable salt thereof together with a suitable amount of one or more pharmaceutically acceptable vehicles so as to provide a composition for proper administration to a patient such as for oral administration to a patient. Suitable pharmaceutical vehicles and methods of preparing pharmaceutical compositions are described in the art.

[0410] A compound of Formula (1) or pharmaceutically acceptable salt thereof can generally be used in an effective amount to achieve the intended purpose. For use to treat a disease such as cancer a compound of Formula (1) or pharmaceutically acceptable salt thereof, may be administered in a therapeutically effective amount.

[0411] A therapeutically effective dose of a compound of Formula (1 ) or pharmaceutically acceptable salt thereof can provide therapeutic benefit without causing substantial toxicity. Toxicity of compounds of Formula (1) or pharmaceutically acceptable salt thereof may be determined using standard pharmaceutical procedures and may be readily ascertained by the skilled artisan. The dose ratio between toxic and therapeutic effect is the therapeutic index. A compound of Formula (1) or pharmaceutically acceptable salt thereof can exhibit a particularly high therapeutic index in treating disease and disorders. A dose of a compound of Formula (1) or pharmaceutically acceptable salt thereof can be within a range of circulating concentrations that include an effective dose with minimal toxicity.

[0412] A compound of Formula (1) or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any of the foregoing can be included in a kit that may be used to administer the compoundto a patient for therapeutic purposes. A kit may include a pharmaceutical composition comprising a compound of Formula (1) or pharmaceutically acceptable salt thereof suitable for administration to a patient and instructions for administering the pharmaceutical composition to the patient. A kit for use in treating a disease in a patient can comprise a compound of Formula (1) or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable vehicle for administering the compound, and instructions for administering the compound or pharmaceutical composition to a patient.

[0413] Instructions supplied with a kit may be printed and / or supplied, for example, as an electronic-readable medium, a video cassette, an audiotape, a flash memory device, or may be published on an internet web site or distributed to a patient and / or health care provider as an electronic communication.

[0414] The amount of a compound of Formula (1) or pharmaceutically acceptable salt thereof that will be effective in the treatment of a particular disorder or condition disclosed herein will depend in part on the nature of the disorder or condition, and can be determined by standard clinical techniques known in the art. In addition, in vitro or in vivo assays may optionally be employed to help identify optimal dosage ranges. The amount of a compound of Formula (1) or pharmaceutically acceptable salt thereof administered can depend on, among other factors, the patient being treated, the weight of the patient, the severity of the affliction, the manner of administration and the judgment of a prescribing physician.

[0415] A compound of Formula (1) or pharmaceutically acceptable salt thereof may be assayed in vitro and in vivo, for the desired therapeutic activity, prior to use in humans. For example, in vitro assays may be used to determine whether administration of a specific compound or a combination of compounds is preferred. The compounds may also be demonstrated to be effective and safe using animal model systems.

[0416] A dose of a compound of Formula (1) or pharmaceutically acceptable salt thereof and appropriate dosing intervals may be selected to maintain a sustained therapeutically effective concentration of a drug in the blood of a patient, and in certain embodiments, without exceeding a minimum adverse concentration.

[0417] A pharmaceutical composition comprising a compound of Formula (1) or pharmaceutically acceptable salt thereof may be administered, for example, 4 times per day, twice a day, once per day, once per week, every 2 weeks, every 3 weeks, every 4 weeks, every 5 weeks, or every 6 weeks. Dosing may be provided alone or in combination with other drugs and may continue as long as required for effective treatment of the disease. Dosing may also be undertaken using continuous or semi-continuous administration over a period of time. Dosing includes administering a pharmaceutical composition to a mammal, such as a human, in a fed or fasted state.

[0418] A pharmaceutical composition may be administered in a single dosage form or in multiple dosage forms or as a continuous or an accumulated dose over a period of time. When multiple dosage forms areused the amount of a compound of Formula (1) or pharmaceutically acceptable salt thereof contained within each of the multiple dosage forms may be the same or different.

[0419] Suitable daily dosage ranges for administration can range, for example, from about 2 pg to about 200 mg of a compound of Formula (1) or pharmaceutically acceptable salt thereof per kilogram body weight.

[0420] Suitable daily dosage ranges for administration may range, for example, from about 1 pg to about 50 mg of compound of Formula (1) or pharmaceutically acceptable salt thereof per square meter (m2) of body surface.

[0421] A compound of Formula (1) or pharmaceutically acceptable salt thereof may be administered to treat a disease in a patient in an amount, for example, from 0.001 mg / day to 100 mg / day, or in any other appropriate daily dose. A dose can be, for example, from 0.01 pg / kg body weight / week to 100 pg / kg body weight / week or any other suitable dose.

[0422] A pharmaceutical composition comprising a compound of Formula (1) may be administered to treat a disease in a patient so as to provide a therapeutically effective concentration of the corresponding drug in the blood or plasma of the patient. A therapeutically effective concentration of a drug in the blood of a patient can be, for example, from 0.01 pg / L to 1,000 pg / L, from 0.1 pg / L to 500 pg / L, from 1 pg / L to 250 pg / L, or from about 10 pg / L to about 100 pg / L. A therapeutically effective concentration of a drug in the blood of a patient can be, for example, at least 0.01 pg / L, at least 0.1 pg / L, at least 1 pg / L, at least about 10 pg / L, or at least 100 pg / L. A therapeutically effective concentration of a drug in the blood of a patient can be, for example, less than an amount that causes unacceptable adverse effects including adverse effects to homeostasis. A therapeutically effective concentration of a drug in the blood of a patient can be an amount sufficient to restore and / or maintain homeostasis in the patient.

[0423] Pharmaceutical compositions provided by the present disclosure may be administered to treat a disease in a patient so as to provide a therapeutically effective concentration of a drug in the blood of a patient for a period of time such as, for example, for 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, 1 day, or 2 days.

[0424] The amount of a compound of Formula (1) or pharmaceutically acceptable salt thereof administered may vary during a treatment regimen.

[0425] Pharmaceutical compositions provided by the present disclosure may further comprise one or more pharmaceutically active compounds in addition to a compound of Formula (1) or pharmaceutically acceptable salt thereof. Such compounds may be provided, for example, to treat the disease being treated with a compound of Formula (1) or to treat a disease, disorder, or condition other than the disease being treated with a compound of Formula (1), to treat a side-effect caused by a drug to augment the efficacy of a drug and / or to modulate the activity of a drug.

[0426] A compound of Formula (1) or pharmaceutically acceptable salt thereof may be administered in combination with at least one other drug. A compound of Formula (1) or pharmaceutically acceptable salt thereof may be administered to a patient together with another compound for treating the disease in the patient. A compound of Formula (1) or pharmaceutically acceptable salt thereof and at least one other drug may act additively or, in certain embodiments, synergistically. At least one additional drug may be included in the same pharmaceutical composition or vehicle comprising a compound of Formula (1) or pharmaceutically acceptable salt thereof or can be in a separate pharmaceutical composition or vehicle. Accordingly, methods provided by the present disclosure further include, in addition to administering a compound of Formula (1) or pharmaceutically acceptable salt thereof, administering one or more drugs effective for treating cancer or a different disease, disorder or condition than cancer. Methods provided by the present disclosure include administering a compound of Formula (1) or pharmaceutically acceptable salt thereof and one or more other drugs provided that the combined administration does not inhibit the therapeutic efficacy of a drug and / or does not produce adverse combination effects.

[0427] A pharmaceutical composition comprising a compound of Formula (1) or pharmaceutically acceptable salt thereof may be administered concurrently with the administration of another drug, which may be part of the same pharmaceutical composition as, or in a different pharmaceutical composition than that comprising a compound of Formula (1) or pharmaceutically acceptable salt thereof. A compound of Formula (1) or pharmaceutically acceptable salt thereof may be administered prior or after administration of another drug. In certain combination therapies, the combination therapy may comprise alternating between administering a compound of Formula (1) or pharmaceutically acceptable salt thereof and a composition comprising another drug, e.g., to minimize adverse drug effects associated with a particular drug. When a compound of Formula (1) or pharmaceutically acceptable salt thereof is administered concurrently with another drug that potentially may produce an adverse drug effect including, for example, toxicity, the other drug may be administered at a dose that falls below the threshold at which the adverse drug reaction is elicited.

[0428] A pharmaceutical composition comprising a compound of Formula (1) or pharmaceutically acceptable salt thereof may be administered with one or more substances, for example, to enhance, modulate and / or control release, bioavailability, therapeutic efficacy, therapeutic potency, and / or stability, of a compound of Formula (1) or pharmaceutically acceptable salt thereof. For example, a pharmaceutical composition comprising a compound of Formula (1) can be co-administered with an active agent having pharmacological effects that enhance the therapeutic efficacy of the drug.

[0429] A compound of Formula (1) or pharmaceutically acceptable salt thereof may be administered in conjunction with an agent known or believed to be effective in treating a disease such as cancer, anautoimmune disease, an inflammatory disease, or an age-related disease in a patient, such as the same disease being treated with a compound of Formula (1) or pharmaceutically acceptable salt thereof.

[0430] The efficacy of administering a compound of Formula (1) or pharmaceutically acceptable salt thereof for treating a disease in a patient such as, for example, cancer, an inflammatory disease, an autoimmune disease, or an age-related disease may be assessed using in vitro and animal studies and in clinical trials.

[0431] A sol-moiety paclitaxel conjugate can be co-administered, for example, with a platinum-based compound such as carboplatin and cisplatin; an anthracycline such as doxorubicin and epirubicin; a biologic agent such as trastuzumab, pertuzumab, bevacizumab, ramucirumab, atezolizumab, and pembrolizumab; other cytotoxic agents such as gemcitabine, 5-fluorouracil, ifosfamide, etoposide, vinorelbine, and capecitabine; anti-emetics such as ondansetron, granisetron, palonosetron, aprepitant, fosaprepitant, and metoclopramide; a growth factor such as filgrastim, peglilgraslim, and erythropoiesisstimulating agents; a neuropathy management agent such as duloxetine, gabapentin, and pregabalin; a bone protection agent such as zoledronic acid and denosumab; and a pharmacokinetic modifier such as verapamil, cyclosporine, and ritonavir.

[0432] A sol-moiety docetaxel conjugate can be co-administered, for example, with a premedication agent such as dexamethasone, diphenhydramine, cimetidine, or ranitidine; a platinum-based agent such as carboplatin or cisplatin; an anthracycline such as doxorubicin or epirubicin; an alkylating agent such as cyclophosphamide or ifosfamide; a targeted therapy or biologic such as trastuzumab, pertuzumab, bevacizumab, ramucirumab, pembrolizumab, or cetuximab; a cytotoxic agent such as 5-fluorouracil (5-FU), capecitabine, gemcitabine, oxaliplatin, leucovorin, or prednisone / prednisolone; an anti-emetic such as ondansetron, granisetron, palonosetron, aprepitant, fosaprepitant, or olanzapine; a hematopoietic growth factor such as filgrastim, pegfilgrastim, or an erythropoiesis-stimulating agent (ESA); a neuropathy management agent such as duloxetine, gabapentin, or pregabalin; a bone-protective agent such as zoledronic acid or denosumab; a prostate cancer-specific agent such as enzalutamide, abiraterone acetate, or darolutamide; or a pharmacokinetic modifier such as ketoconazole, itraconazole, ritonavir, verapamil, or cyclosporine.

[0433] A sol-moiety cabazitaxel conjugate can be co-administered, for example, with a premedication agent such as dexamethasone, diphenhydramine, cimetidine, or ranitidine; a corticosteroid such as prednisone or prednisolone (co-administered daily throughout treatment as standard of care in metastatic castration-resistant prostate cancer); a platinum-based agent such as carboplatin (in aggressive variant prostate cancer protocols) or cisplatin; a prostate cancer-specific hormonal agent such as abiraterone acetate, enzalutamide, or darolutamide; an anti-emetic such as ondansetron, granisetron, palonosetron, aprepitant, fosaprepitant, or olanzapine; a hematopoietic growth factor such as filgrastim or pegfilgrastim(primary prophylaxis is strongly recommended given the high febrile neutropenia risk associated with cabazitaxel); a bone -protective agent such as zoledronic acid or denosumab; a neuropathy management agent such as duloxetine, gabapentin, or pregabalin; an anti-diarrheal agent such as loperamide (given the GI toxicity profile of cabazitaxel); or a pharmacokinetic modifier such as ketoconazole, itraconazole, ritonavir, or verapamil.ASPECTS OF THE INVENTION

[0434] The invention is further defined by one or more of the following aspects.

[0435] Aspect 1. A compound having the structure of Formula (1):or a pharmaceutically acceptable salt thereof, whereinat least one of R1, R3, and R5is -O-P(O)(OH)2;at least one of the other of R1, R2, R3, R4, and R3is independently selected from - P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2;each of the other of R1, R2, R3, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy;R6is a cleavable linker; andX is derived from a therapeutic agent comprising a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, and imide group, or a urea group, wherein R6is bonded to an oxygen atom of the hydroxyl group, or to a nitrogen atom of the primary amine group, the secondary amine group, the tertiary amine group, the NH- heterocycle, the sulfonamide group, tire sulfamide group, the sulfonimine group, the amide group, the imide group, or the urea group.

[0436] Aspect 2. The compound of aspect 1, wherein R1is -O-P(O)(OH)2.

[0437] Aspect 3. The compound of aspect 1, wherein R3is -O-P(O)(OH)2.

[0438] Aspect 4. The compound of aspect 1, wherein R5is -O-P(O)(OH)2.

[0439] Aspect 5. The compound of aspect 1, wherein each of R1and R3is -O-P(O)(OH)2.

[0440] Aspect 6. The compound of aspect 1, wherein each of R1and R3is -O-P(O)(OH)2.

[0441] Aspect 7. The compound of aspect 1, wherein each of R3and R3is -O-P(O)(OH)2.

[0442] Aspect 8. The compound of aspect 1, wherein each of R1, R3,and R3is -O-P(O)(OH)2.

[0443] Aspect 9. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and R5is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0444] Aspect 10. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and R is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and - CH(CO2H)2.

[0445] Aspect 11. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and R5is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0446] Aspect 12. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and Rsis independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0447] Aspect 13. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and R5is - P(O)(OH)2.

[0448] Aspect 14. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and R5is - CH2-P(O)(OH)2.

[0449] Aspect 15. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and R5is - CH2CO2H.

[0450] Aspect 16. The compound of aspect 1, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0451] Aspect 17. The compound of aspect 1, wherein two of the other of R1, R2, R3, R4, and Rsare independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and - CH(CO2H)2.

[0452] Aspect 18. The compound of aspect 1, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0453] Aspect 19. The compound of aspect 1, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0454] Aspect 20. The compound of aspect 1. wherein two of the other of R1, R2, R3, R4, and R5are-P(O)(OH)2.

[0455] Aspect 21. The compound of aspect 1, wherein two of the other of R1, R2, R3, R4, and R5are -CH2-P(O)(OH)2.

[0456] Aspect 22. The compound of aspect 1, wherein two of the other of R1, R2, R3, R4, and R3are -CH2CO2H.

[0457] Aspect 23. The compound of aspect 1, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0458] Aspect 24. The compound of aspect 1, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and - CH(CO2H)2.

[0459] Aspect 25. The compound of aspect 1, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, and -CH(-P(O)(OH)2)2, -CH2CO2H.

[0460] Aspect 26. The compound of aspect 1, wherein three of the other of R1, R2, R3, R4, and Rsare independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0461] Aspect 27. The compound of aspect 1, wherein three of the other of R1, R2, R3, R4, and R5are -P(O)(OH)2.

[0462] Aspect 28. The compound of aspect 1, wherein three of the other of R1, R2, R3, R4, and R5are -CH2-P(O)(OH)2.

[0463] Aspect 29. The compound of aspect 1, wherein three of the other of R1, R2, R3, R4, and R5are -CH2CO2H.

[0464] Aspect 30. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and R5is selected from halo, methyl, and methoxy; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

[0465] Aspect 31. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and R5is halo; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

[0466] Aspect 32. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and Rsis methyl; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

[0467] Aspect 33. The compound of aspect 1, wherein one of the other of R1, R2, R3, R4, and R5is methoxy; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

[0468] Aspect 34. The compound of aspect 1, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from halo, methyl, and methoxy; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

[0469] Aspect 35. The compound of aspect 1, wherein each of the other of R1, R2, R3, R4, and R5is hydrogen.

[0470] Aspect 36. The compound of aspect 1, wherein R1is -O-P(O)(OH)2; one of R2, R3, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and each of the other of R2, R3, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

[0471] Aspect 37. The compound of aspect 36, wherein one of R2, R3, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0472] Aspect 38. The compound of aspect 36, wherein one of R2, R3, R4, and Rsis selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0473] Aspect 39. The compound of aspect 36, wherein one of R2, R3, R4, and R5is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0474] Aspect 40. The compound of any one of aspects 36 to 39, wherein one of R2, R3, R4, and R5is selected from halo, methyl, and methoxy.

[0475] Aspect 41. The compound of any one of aspects 36 to 40, wherein each of the other of R2, R3, R4, and Rsis hydrogen.

[0476] Aspect 42. The compound of aspect 1, wherein R3is -O-P(O)(OH)2; one of R1, R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and each of the other of R1, R2, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

[0477] Aspect 43. The compound of aspect 42, wherein one of R1, R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0478] Aspect 44. The compound of aspect 42, wherein one of R2, R3, R4, and R3is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0479] Aspect 45. The compound of aspect 42, wherein one of R2, R3, R4, and R5is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0480] Aspect 46. The compound of any one of aspects 42 to 45, wherein one of R1, R2, R4, and R5is selected from halo, methyl, and methoxy.

[0481] Aspect 47. The compound of any one of aspects 42 to 46, wherein each of the other of R1, R2, R4, and R5is hydrogen.

[0482] Aspect 48. The compound of aspect 1, wherein R5is -O-P(O)(OH)2; one of R1, R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and each of the other of R1, R2, R3, and R4is independently selected from hydrogen, halo, methyl, and methoxy.

[0483] Aspect 49. The compound of aspect 48, wherein one of R1, R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0484] Aspect 50. The compound of aspect 48, wherein one of R1, R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0485] Aspect 51. The compound of aspect 48, wherein one of R1, R2, R3, and R4is selected from - P(O)(OH)2and -CH2-P(O)(OH)2.

[0486] Aspect 52. The compound of any one of aspects 48 to 51, wherein one of R1, R2, R3, and R4is selected from halo, methyl, and methoxy.

[0487] Aspect 53. The compound of any one of aspects 48 to 52, wherein each of the other of R1,R2, R3, and R4is hydrogen.

[0488] Aspect 54. The compound of aspect 1, wherein each of R1and R3is -O-P(O)(OH)2;one ofR2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and each of the other of R2, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

[0489] Aspect 55. The compound of aspect 54, wherein one of R2, R4, and R5is selected from - P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0490] Aspect 56. The compound of aspect 54, wherein one of R2, R4, and R5is selected from - P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0491] Aspect 57. The compound of aspect 54, wherein one of R2, R4, and R5is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0492] Aspect 58. The compound of any one of aspects 54 to 57, wherein one of R2, R4, and R5is selected from halo, methyl, and methoxy.

[0493] Aspect 59. The compound of any one of aspects 54 to 58, wherein each of the other of R2,R4, and R5is hydrogen.

[0494] Aspect 60 The compound of aspect 1, wherein each of R1and R3is -O-P(O)(OH)2;one ofR2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and each of the other of R2, R3, and R4is independently selected from hydrogen, halo, methyl, and methoxy.

[0495] Aspect 61. The compound of aspect 60, wherein one of R2, R3, and R4is selected from - P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0496] Aspect 62. The compound of aspect 60, wherein one of R2, R3, and R4is selected from - P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0497] Aspect 63. The compound of aspect 60, wherein one of R2, R3, and R4is selected from - P(O)(OH)2and -CH2-P(O)(OH)2.

[0498] Aspect 64. The compound of any one of aspects 60 to 63, wherein one of R2, R3, and R4is selected from halo, methyl, and methoxy.

[0499] Aspect 65. The compound of any one of aspects 60 to 63, wherein each of the other of R2,R3, and R4is hydrogen.

[0500] Aspect 66 The compound of aspect 1, wherein each of R3and R3is -O-P(O)(OH)2;one ofR1, R2, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and each of the other of R1, R2, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

[0501] Aspect 67. The compound of aspect 66, wherein one of R1, R2, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0502] Aspect 68. The compound of aspect 66, wherein one of R1, R2, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0503] Aspect 69. The compound of aspect 66, wherein one of R1, R2, and R4is selected from - P(O)(OH)2 and -CH2-P(O)(OH)2.

[0504] Aspect 70. The compound of any one of aspects 66 to 69, wherein one of R1, R2, and R4is selected from halo, methyl, and methoxy.

[0505] Aspect 71. The compound of any one of aspects 66 to 70, wherein each of the other of R1,R2, and R4is hydrogen.

[0506] Aspect 72. The compound of aspect 1, wherein each of R1, R3, and R5is -O-P(O)(OH)2; one of R2and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and the other of R2and R4is selected from hydrogen, halo, methyl, and methoxy.

[0507] Aspect 73. The compound of aspect 72, wherein one of R2and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0508] Aspect 74. The compound of aspect 72, wherein one of R2and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0509] Aspect 75. The compound of aspect 72, wherein one of R2and R4is selected from - P(O)(OH)2and -CH2-P(O)(OH)2.

[0510] Aspect 76. The compound of any one of aspects 72 to 75, wherein one of R2and R4is selected from halo, methyl, and methoxy.

[0511] Aspect 77. The compound of any one of aspects 72 to 76, wherein the other of R2and R4is hydrogen.

[0512] Aspect 78. The compound of aspect 1, wherein R1is -O-P(O)(OH)2; two of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and each of the other of R2, R3, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

[0513] Aspect 79. The compound of aspect 78, wherein two of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0514] Aspect 80. The compound of aspect 78, wherein two of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0515] Aspect 81. The compound of aspect 78, wherein two of R2, R3, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0516] Aspect 82. The compound of any one of aspects 78 to 81, wherein one of R2, R3, R4, and Rsis selected from halo, methyl, and methoxy.

[0517] Aspect 83. The compound of any one of aspects 78 to 82, wherein each of the other of R2, R3, R4, and R5is hydrogen.

[0518] Aspect 84. The compound of aspect 1, wherein R3is -O-P(O)(OH)2; two of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and each of the other of R1, R2, R4, and R3is independently selected from hydrogen, halo, methyl, and methoxy.

[0519] Aspect 85. The compound of aspect 84, wherein two of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0520] Aspect 86. The compound of aspect 84, wherein two of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0521] Aspect 87. The compound of aspect 84, wherein two of R1, R2, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0522] Aspect 88. The compound of any one of aspects 58 to 87, wherein one of the other of R1, R2, R4, and R5is selected from halo, methyl, and methoxy.

[0523] Aspect 89. The compound of any one of aspects 85 to 88, wherein each of the other of R1, R2, R4, and R5is hydrogen.

[0524] Aspect 90. The compound of aspect 1, wherein R5is -O-P(O)(OH)2; two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and each of the other of R1, R2, R3, and R4is independently selected from hydrogen, halo, methyl, and methoxy.

[0525] Aspect 91. The compound of aspect 90, wherein two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0526] Aspect 92. The compound of aspect 90, wherein two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0527] Aspect 93. The compound of aspect 90, wherein two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0528] Aspect 94. The compound of any one of aspects 90 to 93, wherein one of the other of R1, R2, R3, and R4is selected from halo, methyl, and methoxy.

[0529] Aspect 95. The compound of any one of aspects 90 to 94, wherein each of the other of R1, R2, R3, and R4is hydrogen.

[0530] Aspect 96. The compound of aspect 1, wherein each of R1and R3is -O-P(O)(OH)2;two of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and the other of R2, R4, and R5is selected from hydrogen, halo, methyl, and methoxy.

[0531] Aspect 97. The compound of aspect 96, wherein two of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0532] Aspect 98. The compound of aspect 96, wherein two of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0533] Aspect 99. The compound of aspect 96, wherein two of R2, R4, and R5are s independently elected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0534] Aspect 100. The compound of any one of aspects 96 to 99, wherein one of the other of R2, R4, and R5is selected from halo, methyl, and methoxy.

[0535] Aspect 101. The compound of any one of aspects 96 to 100, wherein the other of R2, R4, and R5is hydrogen.

[0536] Aspect 102. The compound of aspect 1, wherein each of R1and R’ is -O-P(O)(OH)2;two of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and the other of R2, R3, and R4is selected from hydrogen, halo, methyl, and methoxy.

[0537] Aspect 103. The compound of aspect 102, wherein two of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0538] Aspect 104. The compound of aspect 102, wherein two of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0539] Aspect 105. The compound of aspect 102, wherein two of R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0540] Aspect 106. The compound of any one of aspects 102 to 105, wherein the other of R2, R3, and R4is selected from halo, methyl, and methoxy.

[0541] Aspect 107. The compound of any one of aspects 102 to 106, wherein the other of R2, R3, and R4is hydrogen.

[0542] Aspect 108. The compound of aspect 1, wherein each of R3and R’ is -O-P(O)(OH)2;two of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and the other of R1, R2, and R4is selected from hydrogen, halo, methyl, and methoxy.

[0543] Aspect 109. The compound of aspect 108, wherein two of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0544] Aspect 110. The compound of aspect 108, wherein two of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0545] Aspect 111. The compound of aspect 108, wherein two of R1, R2, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0546] Aspect 112. The compound of any one of aspects 108 to 111, wherein the other of R1, R2, and R4is selected from halo, methyl, and methoxy.

[0547] Aspect 113. The compound of any one of aspects 108 to 112, wherein the other of R1, R2, and R4is hydrogen.

[0548] Aspect 114. The compound of aspect 1, wherein each of R1, R3, and Rsis -O-P(O)(OH)2; and two of R2and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0549] Aspect 115. The compound of aspect 114, wherein two of R2and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0550] Aspect 116. The compound of aspect 114, wherein two of R2and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0551] Aspect 117. The compound of aspect 114, wherein two of R2and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0552] Aspect 118. The compound of aspect 1, wherein R1is -O-P(O)(OH)2; three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and the other of R2, R3, R4, and R5is selected from hydrogen, halo, methyl, and methoxy.

[0553] Aspect 119. The compound of aspect 118, wherein three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0554] Aspect 120. The compound of aspect 118, wherein three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0555] Aspect 121. The compound of aspect 118, wherein three of R2, R3, R4, and Rsare independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0556] Aspect 122. The compound of any one of aspects 118 to 121, wherein the other of R2, R3, R4, and R5is selected from halo, methyl, and methoxy.

[0557] Aspect 123. The compound of any one of aspects 118 to 122, wherein the other of R2, R3, R4, and R5is hydrogen.

[0558] Aspect 124. The compound of aspect 1, wherein R3is -O-P(O)(OH)2; three of R1, R2, R4, andR5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and the other of R1, R2, R4, and R5is selected from hydrogen, halo, methyl, and methoxy.

[0559] Aspect 125. The compound of aspect 124, wherein three of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0560] Aspect 126. The compound of aspect 124, wherein three of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0561] Aspect 127. The compound of aspect 124, wherein three of R1, R2, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0562] Aspect 128. The compound of any one of aspects 124 to 127, wherein the other of R1, R2, R4, and R' is selected from halo, methyl, and methoxy.

[0563] Aspect 129. The compound of any one of aspects 124 to 128, wherein the other of R1, R2, R4, and R5is hydrogen.

[0564] Aspect 130. The compound of aspect 1, wherein R5is -O-P(O)(OH)2; three of R1, R2, R3, andR4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and the other of R1, R2, R3, and R4is selected from hydrogen, halo, methyl, and methoxy.

[0565] Aspect 131. The compound of aspect 130, wherein three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0566] Aspect 132. The compound of aspect 130, wherein three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0567] Aspect 133. The compound of aspect 130, wherein three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0568] Aspect 134. The compound of any one of aspects 130 to 133, wherein the other of R1, R2, R3, and R4is selected from halo, methyl, and methoxy.

[0569] Aspect 135. The compound of any one of aspects 130 to 134, wherein the other of R1, R2, R3, and R4is hydrogen.

[0570] Aspect 136. The compound of aspect 1, wherein R1and R3is -O-P(O)(OH)2;and each of R2, R4, and R5is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0571] Aspect 137. The compound of aspect 136, wherein each of R2, R4, and R5is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0572] Aspect 138. The compound of aspect 136, wherein each of R2, R4, and R5is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0573] Aspect 139. The compound of aspect 136, wherein each of R2, R4, and R5is independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0574] Aspect 140. The compound of aspect 1, wherein R1and R5is -O-P(O)(OH)2;and each of R2, R3, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and CH(CO2H)2.

[0575] Aspect 141. The compound of aspect 140, wherein each of R2, R3, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0576] Aspect 142. The compound of aspect 140, wherein each of R2, R3, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0577] Aspect 143. The compound of aspect 140, wherein each of R2, R3, and R4is independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0578] Aspect 144. The compound of aspect 1, wherein R3and R5is -O-P(O)(OH)2;and each of R1, R2, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0579] Aspect 145. The compound of aspect 144, wherein each of R1, R2, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0580] Aspect 146. The compound of aspect 144, wherein each of R1, R2, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0581] Aspect 147. The compound of aspect 144, wherein each of R1, R2, and R4is independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0582] Aspect 148. The compound of any one of aspects 1 to 147, wherein R6is selected from -CH2-O-C(=O)-, -CH(-CH3)-O-C(=O)-, -C(-CH3)2-CH2-C(O)-, -CH2-, -CH2OCH2-, -CH(- CH3)OCH2-, -CH(-CH3)OC(O)OCH2- and -CH2OC(O)OCH2-.

[0583] Aspect 149. The compound of any one of aspects 1 to 147, wherein R6is -CH2-O-C(O)-.

[0584] Aspect 150. The compound of any one of aspects 1 to 147, wherein R6is -C(-CH3)2-CH2- C(O)-.

[0585] Aspect 151. The compound of any one of aspects 1 to 147, wherein R6is -CH2-.

[0586] Aspect 152. The compound of any one of aspects 1 to 147, wherein R6is -CH2OCH2-

[0587] Aspect 153. The compound of any one of aspects 1 to 147, wherein R6is -CH2OC(O)OCH2-

[0588] Aspect 154. The compounds of any one of aspects 1 to 147, wherein R6is -CH(-CH3)-O-C(O)-.

[0589] Aspect 155. The compounds of any one of aspects 1 to 147, wherein R6is -CH(-CH3)OCH2,

[0590] Aspect 156. The compounds of any one of aspects 1 to 147, wherein R6is -CH(-CH3)OC(O)OCH2-.

[0591] Aspect 157. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising a hydroxyl group; and R6is bonded to an oxygen atom of the hydroxyl group.

[0592] Aspect 158. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising a primary amine group; R6is bonded to a nitrogen atom of the primary amine group.

[0593] Aspect 159. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising a secondary amine group; and R6is bonded to a nitrogen atom of the secondary amine group.

[0594] Aspect 160. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising a tertiary amine group; and R6is bonded to a nitrogen atom of the tertiary amine group.

[0595] Aspect 161. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising a NH-heterocycle; and R6is bonded to a nitrogen atom of the NH-heterocycle.

[0596] Aspect 162. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising a sulfonamide group; and R6is bonded to a nitrogen atom of the sulfonamide group.

[0597] Aspect 163. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising a sulfamide group; and R6is bonded to a nitrogen atom of the sulfamide group.

[0598] Aspect 164. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising a sulfonimine group; and R6is bonded to a nitrogen atom of the sulfonimine group.

[0599] Aspect 165. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising an amide group; and R6is bonded to a nitrogen atom of the amide group.

[0600] Aspect 166. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising an imide group; and R6is bonded to a nitrogen atom of the imide group.

[0601] Aspect 167. The compound of any one of aspects 1 to 156, wherein X is derived from a therapeutic agent comprising a urea group; and R6is bonded to a nitrogen atom of the urea group.

[0602] Aspect 168. The compound of any one of aspects 1 to 156, wherein the derivative of a therapeutic agent is selected from any one of Compound (1) to Compound (238) as listed in FIG. 5A and FIG. 5B.

[0603] Aspect 169. The compound of any one of aspects 1 to 167, or a pharmaceutically acceptable salt thereof, wherein the therapeutic agent is selected from an analgesic; an anesthetic; an antibacterial; an anticonvulsant; an antidementia agent; an antidepressant; an antiemetic; an antifungal; an antigout agent; an anti-inflammatory; an antimigraine agent; an anti-myasthenic agent; an anti-mycobacterial; an antineoplastic; an anti-parasitic; an anti-Parkinson agent; an antipsychotic; an anti-spasticity agent; an antiviral; an anxiolytic; a bipolar agent; a blood glucose regulator; a blood product / modifier / volume expander; a cardiovascular agent; a central nervous system agent; a dental and oral agent; a dermatological agent; an enzyme replacements / modifier; a gastrointestinal agent, a genitourinary agent; hormonal agent; an immunological agent; an inflammatory bowel disease agent; a metabolic bone disease agent; an ophthalmic agents an otic agent; a respiratory tract agents a sedative / hypnotic, and a skeletal muscle relaxant.

[0604] Aspect 170. The compound of any one of aspects 1 to 167, or a pharmaceutically acceptable salt thereof, wherein the therapeutic agent is effective for treating cancer.

[0605] Aspect 171. The compound of aspect 170, wherein the cancer is selected from acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, appendix cancer, astrocytoma, atypical teratoid / rhabdoid tumor, basal cell carcinoma (nonmelanoma), B-cell lymphoma, bladder cancer, bone cancer, brain and spinal cord tumors, brain stem cancer, brain tumor, breast cancer, bronchial tumors, Burkitt lymphoma, carcinoid tumor, carcinoma of head and neck, central nervous system embryonal tumors, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, ductal carcinoma, dye cancer, endocrine pancreas tumors (islet cell tumors), endometrial cancer, ependymoblastoma, esophageal cancer, esthesioneuroblastoma, Ewing family of tumors, extracranial germ cell tumor, extrahepatic bile duct cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic tumor, glioblastoma, glioma, hairy cell leukemia, head and neck cancer, heart cancer, hematopoetic tumors of the lymphoid lineage, hepatocellular cancer, Hodgkin lymphoma, hypopharyngeal cancer, hypothalamic and visual pathway glioma, IDs-related lymphoma, intraocular' melanoma, islet cell tumors, Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, lip and oral cavity cancer, male breast cancer, malignant fibroushistiocytoma, malignant germ cell tumors, malignant mesothelioma, medulloblastoma, melanoma, Merkel cell carcinoma, mesothelioma, mouth cancer, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, myelodysplastic, myeloproliferative neoplasms, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-IIodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, pancreatic neuroendocrine tumors (islet cell tumors), papillomatosis, paraganglioma, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal parenchymal tumors, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, pregnancy and breast cancer, primary central nervous system lymphoma, primary liver cancer, primary metastatic squamous neck cancer with occult, prostate cancer, rectal cancer, renal cell cancer, renal pelvis and ureter, respiratory tract carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Sezary syndrome, skin cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma (nonmelanoma), stomach cancer, supratentorial primitive neuroectodermal tumors, T-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer, urethral cancer, uterine sarcoma, vaginal cancer, visual pathway and hypothalamic glioma, vulvar cancer, Waldenstrom macroglobulinemia, Wilms tumor, and systemic and central metastases of any of the foregoing.

[0606] Aspect 172. The compound of aspect 170, wherein therapeutic agent is selected from abemaciclib, abrocitinib, acalabrutinib, afatinib, alectinib, almonertinib, alpelisib, amisulpride, amphotericin b, apalutamide, apatinib, apixaban, aprepitant, asciminib, atogepant, atorvastatin calcium, avacopan, avapritinib, axitinib, baricitinib, Bay-204 / BRD3727, belumosudil, belvarafenib, belzutifan, bicalutamide, binimetinib brigatinib, cabazitaxel, cabozantinib, camizestrant, capivasertib, capmatinib, carvedilol, cefdinir, cefprozil, ceftriaxone, celecoxib, ceritinib, clarithromycin, cobimetinib, copanlisib, crizotinib, cyclosporine, cytarabine, dabrafenib, dacomitinib, daridorexant, daroluamide, dasatinib, dehydrodidemnin, delgocitinib, didemnin B, dihydroergotamine, docetaxal, docetaxel, doravirine, duvelisib, elacestrant, enasidenib, encorafenib, entrectinib, enzalutamide, erdafitinib, eribulin, erlotinib, etoposide, everolimus, ezetimibe, fedratinib, filgotinib, flumatinib, fluphenazine, fruquintinib, fulvestrant, furosemide, futibatinib, gefitinib, gilteritinib, giredestrant, glasdegib, hydrochlorothiazide, ibrutinib, idelalisib, imatinib, imlunestrant, intigratinib, ivacaftor, kahalalide F, KT-253, KT-413, lapatinib, larotrectinib, lazertinib, lenalidomide, leniolisib, lenvatinib, linezolid, lopinavir, lorlatinib, lurbinectedin, mavacamten, meloxicam, mesterolone, metaxalone, midostaurin, mobocertinib, modafinil, MRTX1133 nandrolone, nelfinavir mesylate, neratinib, niclosamide, nilotinib, nintedanib, niraparib, nisoldipine, nutlin (RG7112) or idasanutlin, octreotide, olanzapine, olaparib, olmutinib, olutasidenib, osimertinib,oteseconazole, paclitaxel, pacritinib, palbociclib, paxalisib, pazopanib, peficitinib, pemigatinib, petesicatib (rg7265), pevonedistat, pirtobrutinib, pomalidomide, ponatinib, posaconazole, pralselinib, quetiapine, quizartinib, raloxifene hydrochloride, rapamycin, regorafenib, ribociclib, rilpivirine, rimegepant, ripretinib, ritonavir, rivaroxaban, rucaparib, selpercatinib, selumetinib, simvastatin, sisunatovir, sn-38, sorafenib, subasumstat, sunitinib, tacrolimus, tadalafil, talazoparib, tazemetostat, temsirolimus, teniposide, tesetaxel, tirabrutinib, topotecan, trabectedin, trametinib, trilaciclib, tucatinib, upadacitinib, vandetanib, vardenafil, vemurafenib, venetoclax, vismodegib, volasertib, zanubrutinib, and zotatifin.

[0607] Aspect 173. The compound of any one of aspects 1 to 167, wherein therapeutic agent is selected from paclitaxel, docetaxel, cabazitaxel, and tesetaxel.

[0608] Aspect 174. The compound of aspect 173, wherein the therapeutic agent is paclitaxel and D’ has the structure of Formula (168) or Formula (169):(168) (169)or a pharmaceutically acceptable salt thereof, wherein Y represents the point of attachment to cleavable linker -R6-.

[0609] Aspect 175. The compound of aspect 174, wherein the compound is selected from a compound of any one of Compound (168-3A) to (168-3YY) or a pharmaceutically acceptable salt thereof.

[0610] Aspect 176. The compound of aspect 174, wherein the compound is selected from a compound of any one of Compound (169-3A) to (1693-3YY) or a pharmaceutically acceptable salt thereof.

[0611] Aspect 177. The compound of aspect 173, wherein the therapeutic agent is docetaxel and D’ has the structure of Formula (80) or Formula (81):or a pharmaceutically acceptable salt thereof, wherein Y represents the point of attachment to cleavable linker -R6-.

[0612] Aspect 178. The compound of aspect 177, wherein the compound is selected from a compound of any one of Compound (80-3A) to (80-3 YY) or a pharmaceutically acceptable salt thereof.

[0613] Aspect 179. The compound of aspect 177, wherein the compound is selected from a compound of any one of Compound (81-3 A) to (81-3YY) or a pharmaceutically acceptable salt thereof:

[0614] Aspect 180. The compound of aspect 173, wherein the therapeutic agent is cabazitaxel and D’ has the structure of Formulaor a pharmaceutically acceptable salt thereof, wherein Y represents the point of attachment to cleavable linker -R6-.

[0615] Aspect 181. The compound of aspect 173, wherein the compound is selected from a compound of any one of Compound (41 -3 A) to (41-3YY) or a pharmaceutically acceptable salt thereof.

[0616] Aspect 182. The compound of aspect 173, wherein the therapeutic agent is tesetaxel and D’ has the structure of Formula (223):or a pharmaceutically acceptable salt thereof, wherein Y represents the point of attachment to cleavable linker -R6-.

[0617] Aspect 183. The compound of aspect 182, wherein the compound is selected from a compound of any one of Compound (223-3A) to Compound (223-3YY) or a pharmaceutically acceptable salt thereof.

[0618] Aspect 184. The compound of any one of aspects 1 to 167, wherein the therapeutic agent is effective for treating an autoimmune disease.

[0619] Aspect 185. The compound of aspect 184, wherein the autoimmune disease is selected from the autoimmune disease is selected from Addison’s disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBN nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease, autoimmune myocarditis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal and neuronal neuropathy, Balo disease, Behcet’s disease, benign mucosal pemphigoid, bullous pemphigoid, Castleman disease, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, chronic recurrent multifocal osteomyelitis, Churg-Strauss, cicatricial pemphigoid, Cogan’ syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn’s disease, dermatitis herpetiformis, dermatomyositis, Devic’s disease, discoid lupus, Dressier’s syndrome, endometriosis, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis, giant cell myocarditis, glomerulonephritis, Goodpasture’s syndrome, granulomatosis with polyangiitis, Graves’ disease, Guillain-Bane syndrome, Hashimoto’s thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, herpes gestationis or pemphigoid gestationis, hypogammaglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immune thrombocytopenic purpura, inclusion body myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes, juvenile myositis, Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichensclerosis, ligneous conjunctivitis, linear IgA disease, lupus, Lyme disease chronic, Meniere’s diseases, microscopic polyangiitis, mixed connective tissue disease, Mooren’s ulcer, Mucha- Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis, optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism, PANDAS, paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria, Parry Romberg syndrome, pars planitis, Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, polyglandular syndromes, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, post-pericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia, pyoderma gangrenosum, Raynaud’s phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjogren’s syndrome, sperm and testicular autoimmunity, stiff person syndrome, subacute bacterial endocarditis, Susac’s syndrome, sympathetic ophthalmia, Takayasu’s arteritis, temporal arteritis, thrombocytopenic purpura, Tolosa-Hunt syndrome, transverse myelitis, type 1 diabetes, ulcerative colitis, undifferentiated connective tissue disease, uveitis, vasculitis, vitiligo, and Wegener’s granulomatosis.

[0620] Aspect 186. The compound of aspect 184, wherein the therapeutic agent is selected from corticosteroids such as prednisone, budesonide, and prednisolone; Janus kinase inhibitors such as tofacitinib; calcineurin inhibitors such as cyclosporine and tacrolimus; and mTOR inhibitors such as sirolimus and everolimus; and IMDH inhibitors such as azathioprine, leflunomide, and mycophenolate.

[0621] Aspect 187. The compound of any one of aspects 1 to 167, wherein the therapeutic agent is effective for treating an inflammatory disease.

[0622] Aspect 188. The compound of aspect 187, wherein the inflammatory disease is selected from allergy, Alzheimer’s disease, anemia, ankylosing spondylitis, arthritis, atherosclerosis, asthma, autism, arthritis, carpal tunnel syndrome, celiac disease, colitis, Crohn’s disease, congestive heart failure, dermatitis, diabetes, diverticulitis, eczema, fibromyalgia, fibrosis, gall bladder disease gastroesophageal reflux disease, Hashimoto’s thyroiditis, heart attack, hepatitis, irritable bowel syndrome, kidney failure, lupus, multiple sclerosis, nephritis, neuropathy, pancreatitis, Parkinson’s disease, psoriasis, polymyalgia rheumatica, rheumatoid arthritis, scleroderma, stroke, surgical complications, and ulcerative colitis.

[0623] Aspect 189. The compound of aspect 187, wherein the therapeutic agent is selected from alclometasone, budesonide, butamethasone, celecoxib, clocortolone, desonide, dexamethasone, diclofenac, diflunisal, etodolac, etoricoxib, flurbiprofen, hydrocortisone, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, methylprednisolone, nabumetone, oxaprozin, piroxicam, prednisolone, prednisone, rofecoxib, sulindac, tolmetin, and triamcinolone.

[0624] Aspect 190. The compound of any one of aspects 1 to 167, wherein the therapeutic agent is effective for treating an age-related disease.

[0625] Aspect 191. The compound of aspect 190, wherein the age-related disease is selected from hearing loss, muscle degeneration, Werner’s syndrome, cellular aging, or Alzheimer’s disease.

[0626] Aspect 192. The compound of any one of aspects 1, 157-172, and 183-191, wherein the compound has the structure of any one of Formula (3A)-(3YY) as listed in FIGS. 3A-3K.

[0627] Aspect 193. The compound of any one of aspects 1 to 156, wherein -X has the structure of any one of Formula (1) to Formula (238) as listed in FIG. 5A and FIG. 5B, wherein Y represents the point of attachment to cleavable linker R6.

[0628] Aspect 194. The compound of any one of aspects 1 to 156, wherein the compound has the structure of any one of Formula (3A) to Formula (3YY) as listed in FIGS. 3A-3K; and -X has the structure of any one of Formula (1) to Formula (238) as listed in FIG. 5A and FIG. 5B, wherein Y represents the point of attachment to cleavable linker -R6-.

[0629] Aspect 195. A pharmaceutical composition comprising the compound of any one of aspects 1 to 194 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0630] Aspect 196. The pharmaceutical composition of aspect 195, wherein the pharmaceutical composition is an oral formulation.

[0631] Aspect 197. The pharmaceutical composition of any one of aspects 195 to 196, comprising one or more additional therapeutic agents.

[0632] Aspect 198. A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of any one of aspects any one of aspects 1 to 194 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of aspects 195 to 197.

[0633] Aspect 199. A method of treating cancer in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the compound of any one of aspects any one of aspects 1 to 194 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of aspects 195 to 197.

[0634] Aspect 200. The method of aspect 199, wherein the cancer is selected from acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, appendix cancer, astrocytoma, atypical teratoid / rhabdoid tumor, basal cell carcinoma (nonmelanoma), B-cell lymphoma, bladder cancer, bone cancer, brain and spinal cord tumors, brain stem cancer, brain tumor, breast cancer, bronchial tumors, Burkitt lymphoma, carcinoid tumor, carcinoma of head and neck, central nervous system embryonal tumors, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, colorectal cancer,craniopharyngioma, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, ductal carcinoma, dye cancer, endocrine pancreas tumors (islet cell tumors), endometrial cancer, ependymoblastoma, esophageal cancer, esthesioneuroblastoma, Ewing family of tumors, extracranial germ cell tumor, extrahepatic bile duct cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic tumor, glioblastoma, glioma, hairy cell leukemia, head and neck cancer, heart cancer, hematopoetic tumors of the lymphoid lineage, hepatocellular cancer, Hodgkin lymphoma, hypopharyngeal cancer, hypothalamic and visual pathway glioma, IDs-related lymphoma, intraocular melanoma, islet cell tumors, Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, lip and oral cavity cancer, male breast cancer, malignant fibrous histiocytoma, malignant germ cell tumors, malignant mesothelioma, medulloblastoma, melanoma, Merkel cell carcinoma, mesothelioma, mouth cancer, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, myelodysplastic, myeloproliferative neoplasms, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, pancreatic neuroendocrine tumors (islet cell tumors), papillomatosis, paraganglioma, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal parenchymal tumors, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, pregnancy and breast cancer, primary central nervous system lymphoma, primary liver cancer, primary metastatic squamous neck cancer with occult, prostate cancer, rectal cancer, renal cell cancer, renal pelvis and ureter, respiratory tract carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Sezary syndrome, skin cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma (nonmelanoma), stomach cancer, supratentorial primitive neuroectodermal tumors, T-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer, urethral cancer, uterine sarcoma, vaginal cancer, visual pathway and hypothalamic glioma, vulvar cancer, Waldenstrom macroglobulinemia, Wilms tumor, and systemic and central metastases of any of the foregoing.

[0635] Aspect 201. The method of aspect 199, wherein the therapeutic agent is selected from abemaciclib, abrocitinib, acalabrutinib, afatinib, alectinib, almonertinib, alpelisib, amisulpride, amphotericin b, apalutamide, apatinib, apixaban, aprepitant, asciminib, atogepant, atorvastatin calcium, avacopan, avapritinib, axitinib, baricitinib, Bay-204 / BRD3727, belumosudil, belvarafenib, belzutifan, bicalutamide, binimetinib brigatinib, cabazitaxel, cabozantinib, camizestrant, capivasertib, capmatinib, carvedilol, cefdinir, cefprozil, ceftriaxone, celecoxib, ceritinib, clarithromycin, cobimetinib, copanlisib, crizotinib, cyclosporine, cytarabine, dabrafenib, dacomitinib, daridorexant, daroluamide, dasatinib,dehydrodidemnin, delgocitinib, didemnin B, dihydroergotamine, docetaxal, docetaxel, doravirine, duvelisib, elacestrant, enasidenib, encorafenib, entrectinib, enzalutamide, erdafitinib, eribulin, erlotinib, etoposide, everolimus, ezetimibe, fedratinib, filgotinib, flumatinib, fluphenazine, fruquintinib, fulvestrant, furosemide, futibatinib, gefitinib, gilteritinib, giredestrant, glasdegib, hydrochlorothiazide, ibrutinib, idelalisib, imatinib, imlunestrant, inhgratinib, ivacaftor, kahalalide F, KT-253, KT-413, lapatinib, larotrectinib, lazeriinib, lenalidomide, leniolisib, Icnvalimb, linezolid, lopinavir, lorlatinib, lurbinectedin, mavacamten, meloxicam, mesterolone, metaxalone, midostaurin, mobocertinib, modafinil, MRTX1133 nandrolone, nelfinavir mesylate, neratinib, niclosamide, nilotinib, nintedanib, niraparib, nisoldipine, nutlin (RG7112) or idasanutlin, octreotide, olanzapine, olaparib, olmutinib, olutasidenib, osimertinib, oteseconazole, paclitaxel, pacritinib, palbociclib, paxalisib, pazopanib, peficitinib, pemigatinib, petesicatib (rg7265), pevonedistat, pirtobrutinib, pomalidomide, ponatinib, posaconazole, pralsetinib, quetiapine, quizartinib, raloxifene hydrochloride, rapamycin, regorafenib, ribociclib, rilpivirine, rimegepant, ripretinib, ritonavir, rivaroxaban, rucaparib, selpercatinib, selumetinib, simvastatin, sisunatovir, sn-38, sorafenib, subasumstat, sunitinib, tacrolimus, tadalafil, talazoparib, tazemetostat, temsirolimus, teniposide, tesetaxel, tirabrutinib, topotecan, trabectedin, trametinib, trilaciclib, tucatinib, upadacitinib, vandetanib, vardenafil, vemurafenib, venetoclax, vismodegib, volasertib, zanubrutinib, and zotatifin.

[0636] Aspect 202. The method of aspect 199, wherein the therapeutic agent is selected from paclitaxel, docetaxel, cabazitaxel, and tesetaxel.

[0637] Aspect 203. The method of aspect 199, wherein the therapeutic agent is paclitaxel; and the cancer is selected from breast cancer, ovarian cancer, non-small cell lung cancer, AIDS-related Kaposi’s sarcoma, bladder cancer, colorectal cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, esophageal cancer, endometrial cancer, melanoma, non-small cell lung cancer, ovarian cancer, urinary cancer, and lymphoma.

[0638] Aspect 204. The method of aspect 199, wherein the therapeutic agent is docetaxel; and the cancer is selected from breast cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, squamous cell carcinoma of the head and neck, stomach adenocarcinoma, gastroesophageal junction adenocarcinoma, endometrial cancer, breast cancer, gastric cancer, squamous cell carcinoma, and gastric cancer.

[0639] Aspect 205. The method of aspect 199, wherein the therapeutic agent is cabazitaxel; and the cancer is selected from prostate cancer, esophageal cancer, gastric cancer, squamous cell carcinoma, non-small cell lung cancer, breast cancer, ovarian cancer, testicular cancer, glioblastoma, and adrenocortical carcinoma.

[0640] Aspect 206. The method of aspect 199, wherein the therapeutic agent is tesetaxel; and the cancer is selected from prostate cancer, breast cancer, melanoma, gastric carcinoma, and colorectal cancer.

[0641] Aspect 207. A compound of any one of aspects 1 to 194 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of aspects 195 to 197 for use in a method of treating a disease in a patient in need of such treatment, the method comprising administered to the palient a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition.

[0642] Aspect 208. A method of treating an autoimmune disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of any one of aspects 1 to 194 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of aspects 195 to 197.

[0643] Aspect 209. The method of aspect 208, wherein the autoimmune disease is selected from Addison’s disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBN nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease, autoimmune myocarditis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal and neuronal neuropathy, Balo disease, Behcet’s disease, benign mucosal pemphigoid, bullous pemphigoid, Castleman disease, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, chronic recurrent multifocal osteomyelitis, Churg-Strauss, cicatricial pemphigoid, Cogan’ syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn’s disease, dermatitis herpetiformis, dermatomyositis, Devic’s disease, discoid lupus, Dressier’s syndrome, endometriosis, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis, giant cell myocarditis, glomerulonephritis, Goodpasture’s syndrome, granulomatosis with polyangiitis, Graves’ disease, Guillain-Barre syndrome, Hashimoto’s thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, herpes gestationis or pemphigoid gestationis, hypogammaglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immune thrombocytopenic purpura, inclusion body myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes, juvenile myositis, Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosis, ligneous conjunctivitis, linear IgA disease, lupus, Lyme disease chronic, Meniere’s diseases, microscopic polyangiitis, mixed connective tissue disease, Mooren’s ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis, optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism, PANDAS, paraneoplastic cerebellar degeneration, paroxysmal nocturnalhemoglobinuria, Parry Romberg syndrome, pars planitis, Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, polyglandular syndromes, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, post-pericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia, pyoderma gangrenosum, Raynaud’s phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjogren’s syndrome, sperm and testicular autoimmunity, stiff person syndrome, subacute bacterial endocarditis, Susac’s syndrome, sympathetic ophthalmia, Takayasu’s arteritis, temporal arteritis, thrombocytopenic purpura, Tolosa-Hunt syndrome, transverse myelitis, type 1 diabetes, ulcerative colitis, undifferentiated connective tissue disease, uveitis, vasculitis, vitiligo, and Wegener’s granulomatosis.

[0644] Aspect 210. A compound of any one of aspects 1 to 194 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of aspects 195 to 197 for use in a method of treating an autoimmune disease in a patient in need of such treatment, the method comprising administered to the patient a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition.

[0645] Aspect 211. A method of treating an inflammatory disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of any one of aspects 1 to 194 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of aspects 195 to 197.

[0646] Aspect 212. The method of aspect 213, wherein the inflammatory disease is selected from allergy, Alzheimer’s disease, anemia, ankylosing spondylitis, arthritis, atherosclerosis, asthma, autism, arthritis, carpal tunnel syndrome, celiac disease, colitis, Crohn’s disease, congestive heart failure, dermatitis, diabetes, diverticulitis, eczema, fibromyalgia, fibrosis, gall bladder disease gastroesophageal reflux disease, Hashimoto’s thyroiditis, heart attack, hepatitis, irritable bowel syndrome, kidney failure, lupus, multiple sclerosis, nephritis, neuropathy, pancreatitis, Parkinson’s disease, psoriasis, polymyalgia rheumatica, rheumatoid arthritis, scleroderma, stroke, surgical complications, and ulcerative colitis.

[0647] Aspect 213. A compound of any one of aspects 1 to 156 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of aspects 195 to 197 for use in a method of treating an inflammatory disease in a patient in need of such treatment, the method comprising administered to the patient a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition.

[0648] Aspect 214. A method of treating an age-related disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of any one of aspects 1 to 194 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of aspects 195 to 197.

[0649] Aspect 215. The method of aspect 214, wherein the age-related disease is selected from hearing loss, muscle degeneration, Werner’s syndrome, cellular aging, or Alzheimer’s disease.

[0650] Aspect 216. A compound of any one of aspects 1 to 194 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of aspects 195 to 197 for use in a method of treating an age-related disease in a patient in need thereof, the method comprising administered to the patient a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition.

[0651] Aspect 217. A compound having the structure of Formula (2):or a salt thereof, whereinat least one of R1, R3, and R5is -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R5ais independently selected from -O-P(O)(OR9)2, - P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2, -C(O)(-OR9), -CH2C(O)(-OR9), and - CH(C(O)(-OR9))2;each of the other of Rla, R2a, R3a, R4a, and R3ais independently selected from hydrogen, halo, methyl, and methoxy;R7is selected from -CH2-, -CH(CH3)-, and -C(CH3)2-; andeach R9is independently selected from C1-4 alkyl, benzyl, phenyl, 2-(trimethylsilyl)ethyl, and -C(CH3)3.

[0652] Aspect 218. The compound of aspect 217, wherein Rla, R2a, R3a, R4a, and R5aare defined as for R1, R2, R3, R4, and R3in any one of aspects 1 to 147 consistent with the definitions for Rla, R2a, R3a, R4a, and R3ain aspect 217.

[0653] Aspect 219. The compound of any one of aspects 217 to 218, wherein R7is -CH2-.

[0654] Aspect 220. The compound of any one of aspects 217 to 218, wherein R7is -CH(CH3)-.

[0655] Aspect 221. The compound of any one of aspects 217 to 218, wherein R7is -C(CH3)2-.

[0656] Aspect 222. The compound of any one of aspects 217 to 218, wherein each R9is Ci-4 alkyl.

[0657] Aspect 223. The compound of any one of aspects 217 to 218, wherein each R9is benzyl.

[0658] Aspect 224. The compound of any one of aspects 217 to 218, wherein each R9is phenyl.

[0659] Aspect 225. The compound of any one of aspects 217 to 218, wherein each R9is 2- (trimethyl sil y l)ethy 1.

[0660] Aspect 226. The compound of any one of aspects 217 to 218, wherein each R9is -C(CH3)3.

[0661] Aspect 227. A compound having the structure of Formula (3):or a salt thereof, whereinat least one of R1, R3, and R5is -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R5ais independently selected from -O-P(O)(OR9)2, - P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2,-C(O)(-OR9), -CH2C(O)(-OR9), and - CH(C(O)(-OR9))2;each of the other of Rla, R2a, R3a, R4a, and R’ais independently selected from hydrogen, halo, methyl, and methoxy;R7is selected from -CH2-, -CH(CH3)-, and -C(CH3)2-;R8is selected from a moiety reactive with a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group; and each R9is independently selected from Ci-4 alkyl, benzyl, phenyl, 2-(trimethylsilyl)ethyl, and -C(CH3)3.

[0662] Aspect 228. The compound of aspect 231, wherein Rla, R2a, R3a, R4a, and RSaare defined as for R1, R2, R3, R4, and R5in any one of aspects 1 to 147 consistent with the definitions for Rla, R2a, R3a,R4a, and R’ain aspect 231.

[0663] Aspect 229. The compound of any one of aspects 227 to 228, wherein R7is -CH2-

[0664] Aspect 230. The compound of any one of aspects 227 to 228, wherein R7is -CH(CH3)-.

[0665] Aspect 231. The compound of any one of aspects 227 to 228, wherein R7is -C(CH3)2-

[0666] Aspect 232. The compound of any one of aspects 227 to 228, wherein each R9is Ci-4alkyl.

[0667] Aspect 233. The compound of any one of aspects 227 to 228, wherein each R9is benzyl.

[0668] Aspect 234. The compound of any one of aspects 227 to 228, wherein each R9is phenyl.

[0669] Aspect 235. The compound of any one of aspects 227 to 228, wherein each R9is 2- (trimethylsilyl)ethyl.

[0670] Aspect 236. The compound of any one of aspects 227 to 228, wherein each R9is -C(CH3)3.

[0671] Aspect 237. The compound of any one of aspects 227 to 236, wherein R8is selected from Br,Cl, I, -OC(=O)CH2C1, --OCH2OC(=O)Cl, -OC(=O)C1, OC(=O)OPh, -OC(=O)OC6H4NO2, -OC(=O)OC6H3(NO2)2, -OC(=O)OC6F5, -OCH2OC(=O)O-7V-hydroxysuccinimide, -OCH2SCH3, and - OCH2CI.

[0672] Aspect 238. The compound of any one of aspects 227 to 236, wherein R8is -OC(=O)CH2C1.

[0673] Aspect 239. The compound of any one of aspects 227 to 236, wherein R8is - -OCH2OC(=O)Cl.

[0674] Aspect 240. The compound of any one of aspects 227 to 236, wherein R8is -OC(=O)C1.

[0675] Aspect 241. The compound of any one of aspects 227 to 236, wherein R8is -OC(=O)OPh.

[0676] Aspect 242. The compound of any one of aspects 227 to 236, wherein R8is - OC(=O)OC6H4NO2.

[0677] Aspect 243. The compound of any one of aspects 227 to 236, wherein R8is - OC(=O)OC6H3(NO2)2.

[0678] Aspect 244. The compound of any one of aspects 227 to 236, wherein R8is -OC(=O)OC6F5.

[0679] Aspect 245. The compound of any one of aspects 227 to 236, wherein R8is -OCH2OC(=O)O- / V-hydroxysuccinimide.

[0680] Aspect 246. The compound of any one of aspects 227 to 236, wherein R8is -OCH2SCH3.

[0681] Aspect 247. The compound of any one of aspects 227 to 236, wherein R8is -OCH2CI.

[0682] Aspect 248. The compound of any one of aspects 227 to 236, wherein R8is -CH2-C(O)-R10, wherein R10is selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf.

[0683] Aspect 249. The compound of any one of aspects 227 to 236, wherein R8is -CH2-C(O)-OH.

[0684] Aspect 250. The compound of any one of aspects 227 to 236, wherein R8is -CH2-C(O)-C1.

[0685] Aspect 251. The compound of any one of aspects 227 to 236, wherein R8is -CH2-C(O)-O-N-hydroxysuccinimide.

[0686] Aspect 252. The compound of any one of aspects 227 to 236, wherein R8is -CH2-C(O)- OMs.

[0687] Aspect 253. The compound of any one of aspects 227 to 236, wherein R8is -CH2-C(O)-OTs.

[0688] Aspect 254. The compound of any one of aspects 227 to 236, wherein R8is -CH2-C(O)-OTf.

[0689] Aspect 255. The compound of any one of aspects 227 to 236, wherein R7is -CH2-; and R8is selected from Br, Cl, I, -OC(=O)CH2C1, --OCH2OC(=O)Cl, -OC(=O)C1, -OC(=O)OPh, - OC(=O)OC6Il4NO2, -OC(=O)OC6Il3(NO2)2, -OC(=O)OC6F5, -OCII2OC(=O)O-N-hydroxysuccinimide, -OCH2SCH3, and -OCH2CI.

[0690] Aspect 256. The compound of any one of aspects 227 to 236, wherein R7is -C(CH3)2-; and R8is -CH2-C(O)-R10, wherein R10is selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf.

[0691] Aspect 257. The compound of aspect 227, wherein the compound has the structure of any one of Compound (4 A) to Compound (4YY), whereinR is selected from C1-4 alkyl, phenyl, benzyl, tert-butyl, allyl, and TSE;R’ is selected from hydrogen, halo, methyl, and methoxy;W is selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf; andZ is selected from halo -OC(=O)CH2C1, -OCH2O(C=O)C1, -O(C=O)C1, -O(C=O)OPh, -O(C=O)OC6H4NO2, -O(C=O)OC6H3(NO2)2, -O(C=O)OC6F5, -OCT I2O(C=O)O- -N- -hydroxysuccinimide, -OCH2SCH3, and -OCH2CI.

[0692] Aspect 258. A method of synthesizing a compound of Formula (1) comprising: reacting a therapeutic agent comprising a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group with the compound of any one of aspects 227 to 257, in the presence of a base to provide a protected intermediate; and treating the protected intermediate (a) with TMSBr in CH2CI2 or (b) with hydrogen gas in the presence of Pd / C in ethanol; to provide the compound of Formula (1).

[0693] The invention is further defined by one or more of the following aspects.

[0694] Aspect 1. A sol-moiety drug conjugate having the structure of Formula (1):or a pharmaceutically acceptable salt thereof, whereinat least one of R1, R3, and R5is -O-P(O)(OH)2;at least one of the other of R1, R2, R3, R4, and R5is independently selected from - P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; each of the other of R1, R2, R3, R4. and R5is independently selected from hydrogen, halo, methyl, and methoxy;R6is a cleavable linker; andD’ is derived from a taxane,wherein R6is bonded to the taxane.

[0695] Aspect 1A. The conjugate of aspect 1, wherein R6is bonded to and oxygen atom of the taxane.

[0696] Aspect 2. The conjugate of aspect 1, wherein R1is -0-P(0)(0H)2.

[0697] Aspect 3. The conjugate of aspect 1, wherein R3is -0-P(0)(0H)2.

[0698] Aspect 4. The conjugate of aspect 1, wherein R’is -O-P(O)(OH)2.

[0699] Aspect 5. The conjugate of aspect 1, wherein each of R1and R3is -O-P(O)(OH)2.

[0700] Aspect 6. The conjugate of aspect 1, wherein each of R1and R5is -O-P(O)(OH)2.

[0701] Aspect 7. The conjugate of aspect 1, wherein each of R3and R5is -O-P(O)(OH)2.

[0702] Aspect 8. The conjugate of aspect 1, wherein each of R1, R3, and Rsis -O-P(O)(OH)2.

[0703] Aspect 9. The conjugate of any one of aspects 1 to 8, wherein one of the other of R1, R2, R3,R4, and R5is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, - CH2CO2H, and -CH(CO2H)2.

[0704] Aspect 10. The conjugate of any one of aspects 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0705] Aspect 11. The conjugate of any one of aspects 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0706] Aspect 12. The conjugate of any one of aspects 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0707] Aspect 13. The conjugate of any one of aspects 1 to 8, wherein one of the other of R1, R2, R3, R4, and Rsis -P(O)(OH)2.

[0708] Aspect 14. The conjugate of any one of aspects 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is -CH2-P(O)(OH)2.

[0709] Aspect 15. The conjugate of any one of aspects 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is -CH2CO2H.

[0710] Aspect 16. The conjugate of any one of aspects 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0711] Aspect 17. The conjugate of any one of aspects 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0712] Aspect 18. The conjugate of any one of aspects 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0713] Aspect 19. The conjugate of any one of aspects 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0714] Aspect 20. The conjugate of any one of aspects 1 to 8, wherein two of the other of R1, R2, R3, R4, and Rsare -P(O)(OH)2.

[0715] Aspect 21. The conjugate of any one of aspects 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are -CH2-P(O)(OH)2.

[0716] Aspect 22. The conjugate of any one of aspects 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are -CH2CO2H.

[0717] Aspect 23. The conjugate of any one of aspects 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0718] Aspect 24. The conjugate of any one of aspects 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0719] Aspect 25. The conjugate of any one of aspects 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH(-P(O)(OH)2)2, and -CH2CO2H.

[0720] Aspect 26. The conjugate of any one of aspects 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0721] Aspect 27. The conjugate of any one of aspects 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are -P(O)(OH)2.

[0722] Aspect 28. The conjugate of any one of aspects 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are -CH2-P(O)(OH)2.

[0723] Aspect 29. The conjugate of any one of aspects 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are -CH2CO2H.

[0724] Aspect 30. The conjugate of any one of aspects 1 to 22, wherein one of the other of R1, R2, R3, R4, and R5is selected from halo, methyl, and methoxy; and each of the other of R1, R2, R3, R4, and R3is hydrogen.

[0725] Aspect 31. The conjugate of any one of aspects 1 to 22, wherein one of the other of R1, R2, R3, R4, and R5is halo; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

[0726] Aspect 32. The conjugate of any one of aspects 1 to 22, wherein one of the other of R1, R2, R3, R4, and R5is methyl; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

[0727] Aspect 33. The conjugate of any one of aspects 1 to 22, wherein one of the other of R1, R2, R3, R4, and R5is methoxy; and each of the other of R1, R2, R3, R4, and R3is hydrogen.

[0728] Aspect 34. The conjugate of any one of aspects 1 to 22, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from halo, methyl, and methoxy; and each of the other of R1, R2, R3, R4, and Rsis hydrogen.

[0729] Aspect 35. The conjugate of any one of aspects 1 to 22, wherein each of the other of R1, R2, R3, R4, and R5is hydrogen.

[0730] Aspect 36. The conjugate of any one of aspects 1 to 22, wherein at least one of R1, R2, R3, R4, and R5is independently halo, wherein halo is fluoro.

[0731] Aspect 37. The conjugate of aspect 1, whereinR1is -O-P(O)(OH)2;one of R2, R3, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R3, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

[0732] Aspect 38. The conjugate of aspect 37, wherein one of R2, R3, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0733] Aspect 39. The conjugate of aspect 37, wherein one of R2, R3, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0734] Aspect 40. The conjugate of any one of aspects 37 to 40, wherein one of R2, R3, R4, and R5is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0735] Aspect 41. The conjugate of any one of aspects 37 to 41, wherein one of R2, R3, R4, and R5is selected from halo, methyl, and methoxy.

[0736] Aspect 42. The conjugate of aspect 37, wherein each of the other of R2, R3, R4, and R3is hydrogen.

[0737] Aspect 43. The conjugate of aspect 1, wherein,R3is -O-P(O)(OH)2;one of R1, R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

[0738] Aspect 44. The conjugate of aspect 43, wherein one of R1, R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0739] Aspect 45. The conjugate of aspect 43, wherein one of R1, R2, R4, and R' is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0740] Aspect 46. The conjugate of aspect 43, wherein one of R1, R2, R4, and R5is selected from - P(O)(OH)2and -CH2-P(O)(OH)2.

[0741] Aspect 47. The conjugate of any one of aspects 43 to 46, wherein one of R1, R2, R4, and R5is selected from halo, methyl, and methoxy.

[0742] Aspect 48. The conjugate of any one of aspects 43 to 47, wherein each of the other of R1, R2, R4, and R5is hydrogen.

[0743] Aspect 49. The conjugate of aspect 1, wherein,R5is -O-P(O)(OH)2;at least one of R1, R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(- P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R3, and R4is independently selected from hydrogen, halo, methyl, and methoxy.

[0744] Aspect 50. The conjugate of aspect 49, wherein one of R1, R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0745] Aspect 51. The conjugate of aspect 49, wherein one of R1, R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0746] Aspect 52. The conjugate of aspect49, wherein one of R1, R2, R3, and R4is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0747] Aspect 53. The conjugate of any one of aspects 49 to 52, wherein one of R1, R2, R3, and R4is selected from halo, methyl, and methoxy.

[0748] Aspect 54. The conjugate of any one of aspects 49 to 54, wherein each of the other of R1, R2, R3, and R4is hydrogen.

[0749] Aspect 55. The conjugate of aspect 1, whereineach of R1and R3is -O-P(O)(OH)2;one of R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, - CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R4, and R3is independently selected from hydrogen, halo, methyl, and methoxy.

[0750] Aspect 56. The conjugate of aspect 55, wherein one of R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0751] Aspect 57. The conjugate of aspect 55, wherein;one of R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0752] Aspect 58. The conjugate of aspect 55, wherein one of R2, R4, and R3is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0753] Aspect 59. The conjugate of any one of aspects 55 to 58, wherein one of R2, R4, and R5is selected from halo, methyl, and methoxy.

[0754] Aspect 60. The conjugate of any one of aspects 55 to 59, wherein each of the other of R2, R4, and R3is hydrogen.

[0755] Aspect 61. The conjugate of aspect 1, whereineach of R1and R5is -O-P(O)(OH)2;one of R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R3, and R4is independently selected from hydrogen, halo, methyl, and methoxy.

[0756] Aspect 62. The conjugate of aspect 61, wherein one of R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0757] Aspect 63. The conjugate of aspect 61, wherein one of R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0758] Aspect 64. The conjugate of aspect 61, wherein one of R2, R3, and R4is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0759] Aspect 65. The conjugate of any one of aspects 61 to 64, wherein one of R2, R3, and R4is selected from halo, methyl, and methoxy.

[0760] Aspect 66. The conjugate of any one of aspects 61 to 65, wherein each of the other of R2, R3, and R4is hydrogen.

[0761] Aspect 67. The conjugate of aspect 1, wherein

[0762] each of R3and R5is -O-P(O)(OH)2;

[0763] one of R1, R2, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; and

[0764] each of the other of R1, R2, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

[0765] Aspect 68. The conjugate of aspect 67, wherein one of R1, R2, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0766] Aspect 69. The conjugate of aspect 67, wherein one of R1, R2, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0767] Aspect 70. The conjugate of aspect 67, wherein one of R1, R2, and R4is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0768] Aspect 71. The conjugate of any one of aspects 67 to 70, wherein one of R1, R2, and R4is selected from halo, methyl, and methoxy.

[0769] Aspect 72. The conjugate of any one of aspects 67 to 71, wherein each of the other of R1, R2, and R4is hydrogen.

[0770] Aspect 73. The conjugate of aspect 67, whereineach of R1, R3, and R5is -O-P(O)(OH)2;one of R2and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2and R4is selected from hydrogen, halo, methyl, and methoxy.

[0771] Aspect 74. The conjugate of aspect 73, wherein one of R2and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0772] Aspect 75. The conjugate of aspect 73, wherein one of R2and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0773] Aspect 76. The conjugate of any one of aspects 73 to 75, wherein one of R2and R4is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0774] Aspect 77. The conjugate of any one of aspects 73 to 76, wherein one of R2and R4is selected from halo, methyl, and methoxy.

[0775] Aspect 78. The conjugate of aspect 73, wherein the other of R2and R4is hydrogen.

[0776] Aspect 79. In a conjugate of Formula (1),R1is -O-P(O)(OH)2;two of R2, R3, R4, and R3are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R3, R4, and Rsis independently selected from hydrogen, halo, methyl, and methoxy.

[0777] Aspect 80. The conjugate of aspect 79, wherein two of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0778] Aspect 81. The conjugate of aspect 79, wherein two of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0779] Aspect 82. The conjugate of aspect 79, wherein two of R2, R3, R4, and R3are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0780] Aspect 83. The conjugate of any one of aspects 79 to 82, wherein one of R2, R3, R4, and R5is selected from halo, methyl, and methoxy.

[0781] Aspect 84. The conjugate of any one of aspects 79 to 83, wherein each of the other of R2, R3, R4, and R5is hydrogen.

[0782] Aspect 85. The conjugate of aspect 1, whereinR3is -O-P(O)(OH)2;two of R1, R2, R4, and R3are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R4, and Rsis independently selected from hydrogen, halo, methyl, and methoxy.

[0783] Aspect 86. The conjugate of aspect 85, wherein two of R1, R2, R4, and R3are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0784] Aspect 87. The conjugate of aspect 85, wherein two of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0785] Aspect 88. The conjugate of aspect 85, wherein two of R1, R2, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0786] Aspect 89. The conjugate of any one of aspects 85 to 88, wherein one of the other of R1, R2, R4, and R5is selected from halo, methyl, and methoxy.

[0787] Aspect 90. The conjugate of any one of aspects 85 to 89, wherein each of the other of R1, R2, R4, and R5is hydrogen.

[0788] Aspect 91. The conjugate of aspect 1, whereinR5is -O-P(O)(OH)2;two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R3, and R4is independently selected from hydrogen, halo, methyl, and methoxy.

[0789] Aspect 92. The conjugate of aspect 91, wherein two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0790] Aspect 93. The conjugate of aspect 91, wherein two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0791] Aspect 94. The conjugate of aspect 91, wherein two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0792] Aspect 95. The conjugate of any one of aspects 91 to 94, wherein one of the other of R1, R2, R3, and R4is selected from halo, methyl, and methoxy.

[0793] Aspect 96. The conjugate of any one of aspects 91 to 95, wherein each of the other of R1, R2, R3, and R4is hydrogen.

[0794] Aspect 97. The conjugate of aspect 1, whereineach of R1and R3is -O-P(O)(OH)2;two of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(- P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2, R4, and R5is selected from hydrogen, halo, methyl, and methoxy.

[0795] Aspect 98. The conjugate of aspect 97, wherein two of R2, R4, and R3are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0796] Aspect 99. The conjugate of aspect 97, wherein two of R2, R4, and R3are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0797] Aspect 100. The conjugate of aspect 97, wherein two of R2, R4, and R3are independently elected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0798] Aspect 101. The conjugate of any one of aspects 97 to 100, wherein one of the other of R2, R4, and Rsis selected from halo, methyl, and methoxy.

[0799] Aspect 102. The conjugate of any one of aspects 97 to 101, wherein the other of R2, R4, and R5is hydrogen.

[0800] Aspect 103. The conjugate of aspect 1, whereineach of R1and R5is -O-P(O)(OH)2;two of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(- P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2, R3, and R4is selected from hydrogen, halo, methyl, and methoxy.

[0801] Aspect 104. The conjugate of aspect 103, wherein two of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0802] Aspect 105. The conjugate of aspect 103, wherein two of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0803] Aspect 106. The conjugate of aspect 103, wherein two of R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0804] Aspect 107. The conjugate of any one of aspects 103 to 106, wherein the other of R2, R3, and R4is selected from halo, methyl and methoxy.

[0805] Aspect 108. The conjugate of any one of aspects 103 to 107, wherein the other of R2, R3, and R4is hydrogen.

[0806] Aspect 109. In a conjugate of Formula (1),each of R3and R5is -O-P(O)(OH)2;two of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R1, R2, and R4is selected from hydrogen, halo, methyl, and methoxy.

[0807] Aspect 110. The conjugate of aspect 109, wherein two of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0808] Aspect 111. The conjugate of aspect 109, wherein two of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0809] Aspect 112. The conjugate of aspect 109, wherein two of R1, R2, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0810] Aspect 113. The conjugate of aspect 109, wherein the other of R1, R2, and R4is selected from halo, methyl, and methoxy.

[0811] Aspect 114. The conjugate of aspect 109, wherein the other of R1, R2, and R4is hydrogen.

[0812] Aspect 115. The conjugate of aspect 1, whereineach of R1, R3, and R5is -O-P(O)(OH)2; andtwo of R2and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0813] Aspect 116. The conjugate of aspect 115, wherein two of R2and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0814] Aspect 117. The conjugate of aspect 115, wherein two of R2and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0815] Aspect 118. The conjugate of aspect 115, wherein two of R2and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0816] Aspect 119. The conjugate of aspect 1, whereinR1is -O-P(O)(OH)2;three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2, R3, R4, and Rsis selected from hydrogen, halo, methyl, and methoxy.

[0817] Aspect 120. The conjugate of aspect 119, wherein three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0818] Aspect 121. The conjugate of aspect 119, wherein three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0819] Aspect 122. The conjugate of aspect 119, wherein three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0820] Aspect 123. The conjugate of any one of aspects 119 to 122, wherein the other of R2, R3, R4, and R5is selected from halo, methyl, and methoxy.

[0821] Aspect 124. The conjugate of any one of aspects 119 to 123, wherein the other of R2, R3, R4, and R' is hydrogen.

[0822] Aspect 125. The conjugate of aspect 1, whereinR3is -O-P(O)(OH)2;three of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, - CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R1, R2, R4, and Rsis selected from hydrogen, halo, methyl, and methoxy.

[0823] Aspect 126. The conjugate of aspect 125, wherein three of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0824] Aspect 127. The conjugate of aspect 125, wherein three of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0825] Aspect 128. The conjugate of aspect 125, wherein three of R1, R2, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0826] Aspect 129. The conjugate of any one of aspects 125 to 128, wherein the other of R1, R2, R4, and R5is selected from halo, methyl, and methoxy.

[0827] Aspect 130. The conjugate of any one of aspects 125 to 129, wherein the other of R1, R2, R4, and R5is hydrogen.

[0828] Aspect 131. The conjugate of aspect 1, whereinR5is -O-P(O)(OH)2;three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R1, R2, R3, and R4is selected from hydrogen, halo, methyl, and methoxy.

[0829] Aspect 132. The conjugate of aspect 131, wherein three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0830] Aspect 133. The conjugate of aspect 131, wherein three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0831] Aspect 134. The conjugate of aspect 131, wherein three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0832] Aspect 135. The conjugate of any one of aspects 131 to 134, wherein the other of R1, R2, R3, and R4is selected from halo, methyl, and methoxy.

[0833] Aspect 136. The conjugate of any one of aspects 131 to 135, wherein R5is -O-P(O)(OH)2; the other of R1, R2, R3, and R4is hydrogen.

[0834] Aspect 137. The conjugate of aspect 1, whereinR1and R3is -O-P(O)(OH)2;andeach of R2, R4, and R3are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0835] Aspect 138. The conjugate of aspect 137, wherein each of R2, R4, and R’ are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0836] Aspect 139. The conjugate of aspect 137 wherein each of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0837] Aspect 140. The conjugate of aspect 137 wherein each of R2, R4, and R3are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0838] Aspect 141. The conjugate of aspect 1, whereinR1and R5is -O-P(O)(OH)2;andeach of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0839] Aspect 142. The conjugate of aspect 141, wherein each of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0840] Aspect 143. The conjugate of aspect 141, wherein each of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0841] Aspect 144. The conjugate of aspect 141, wherein each of R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0842] Aspect 145. The conjugate of aspect I, wherein

[0843] R3and R5is -O-P(O)(OH)2;and

[0844] each of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

[0845] Aspect 146. The conjugate of aspect 145, wherein each of R1, R2, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

[0846] Aspect 147. The conjugate of aspect 145, wherein each of R1, R2, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

[0847] Aspect 148 The conjugate of aspect 145, wherein each of R1, R2, and R4is independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

[0848] Aspect 149. The conjugate of any one of aspects 1 to 148, wherein the cleavable linker R6is selected from -(CR2)P-, -(CR2)P-O-(CR2)P-, -(CR2)P-C(O)-, and -(CR2)P-O-C(O)-, wherein each p is independently selected from 1 and 2, and each R is independently selected from hydrogen and methyl.

[0849] Aspect 150. The conjugate of aspect 149, wherein each p is 1.

[0850] Aspect 151. The conjugate of aspect 149, wherein each p is 2.

[0851] Aspect 152. The conjugate of any one of aspects 149 to 151, wherein each R is hydrogen.

[0852] Aspect 153. The conjugate of any one of aspects 149 to 151, wherein the cleavable linker R6is selected from -CH2-O-C(O)- and -C(CH3)2-CH2-C(O)-.

[0853] Aspect 154. The conjugate of any one of aspects 149 to 151, wherein the cleavable linker R6is selected from -CH2-O- and -CH(-CH3)-O-.

[0854] Aspect 155. The conjugate of any one of aspects 1 to 154, wherein the taxane is selected from paclitaxel, docetaxel, and cabazitaxel.

[0855] Aspect 156. The conjugate of aspect 155, wherein D’ has the structure of any one of Formula (41), (80), (81), (168), (169), or (223).

[0856] Aspect 157. The conjugate of aspect 1, wherein the drug is paclitaxel and the sol-moiety drug conjugate has the structure of any one of Formula (168-3A) to Formula (168-3AAA).

[0857] Aspect 158. The conjugate of aspect 1, wherein the drug is paclitaxel and the sol-moiety drug conjugate has the structure of any one of Formula (169-3A) to Formula (169-3AAA).

[0858] Aspect 159. The conjugate of aspect 1, wherein the drug is docetaxel and the sol-moiety drug conjugate has the structure of any one of Formula (80-3A) to Formula (80-3AAA).

[0859] Aspect 160. The conjugate of aspect 1, wherein the drug is docetaxel and the sol-moiety drug conjugate has the structure of any one of Formula (81-3A) to Formula (81-3AAA).

[0860] Aspect 161. The conjugate of aspect 1, wherein the drug is cabazitaxel and the sol-moiety drug conjugate has the structure of any one of Formula (41-3 A) to Formula (41-3 AAA).

[0861] Aspect 162. The conjugate of any one of aspects 1 to 161, wherein the pharmaceutically acceptable salt is selected from a sodium salt, a calcium salt, a magnesium salt, a tromethamine salt, an N-methyl D-glutamine salt, and a lysine salt.

[0862] Aspect 163. A pharmaceutical composition comprising the sol-moiety drug conjugate or a pharmaceutically acceptable salt thereof of any one of aspects 1 to 162 and a pharmaceutically acceptable excipient.

[0863] Aspect 164. The pharmaceutical composition of aspect 163 wherein the pharmaceutical composition is an oral formulalion.

[0864] Aspect 165. A kit comprising the sol-moiety drug conjugate or a pharmaceutically acceptable salt thereof of any one of aspects 1 to 162.

[0865] Aspect 166. A kit comprising the pharmaceutical composition of any one of aspects 163 to 164.

[0866] Aspect 167 A method of treating cancer in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the sol-moiety drug conjugate or a pharmaceutically acceptable salt thereof of any one of aspects any one of aspects 1 to 162 or a pharmaceutical composition of any one of aspects 163 to 164.

[0867] Aspect 168. The method of aspect 167, wherein the drug is paclitaxel.

[0868] Aspect 169. The method of aspect 168, wherein the cancer is selected from bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, fallopian tube cancer, gastric cancer, gastroesophageal junction adenocarcinoma, head and neck cancer, kidney cancer, liver cancer, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, prostate cancer, small cell lung cancer, soft tissue sarcoma, testicular cancer, and thyroid cancer.

[0869] Aspect 170. The method of aspect 167, wherein the drug is docetaxel.

[0870] Aspect 171. The method of aspect 170, wherein the cancer is selected from adrenocortical carcinoma, bladder cancer, breast cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma, kidney cancer, leukemia, liver cancer, melanoma, non-small cell lung cancer,, ovarian cancer, pancreatic cancer, prostate cancer, small cell lung cancer, soft tissue sarcoma, testicular cancer, and thyroid cancer.

[0871] Aspect 172. The method of aspect 167, wherein the drug is cabazitaxel.

[0872] Aspect 173. The method of aspect 172, wherein cancer is selected from adrenocortical carcinoma, bladder cancer, brain cancer, breast cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma, liposarcoma, liver cancer, lung cancer, ovarian cancer, penile neoplasm, prostate cancer, renal cell carcinoma, and testicular cancer.

[0873] Aspect 174. The method of any one of aspects 167 to 173, wherein administering comprises orally administering.

[0874] Aspect 175. A protected sol-moiety intermediate having the structure of Formula (2):or a salt thereof, wherein,at least one of Rla, R3a, and R5ais -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R5ais independently selected from -O-P(O)(OR9)2, - P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2, -C(O)(-OR10), -CH2C(O)(-OR10), and - CH(C(O)(-OR10))2;each of the other of Rla, R2a, R3a, R4a, and R’ais independently selected from hydrogen, halo, methyl, and methoxy;R7is selected from -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2-C(CH3)2)-, and -C(CH3)2- CH2-; andeach R9and R10is independently selected from C1-4 alkyl, benzyl, phenyl, 2- (trimethylsilyl)ethyl, and -C(CH3)3.

[0875] Aspect 176. The intermediate of aspect 175, wherein R7is -CH2-.

[0876] Aspect 177. The intermediate of aspect 175, wherein R7is -CH(CH3)-.

[0877] Aspect 178. The intermediate of aspect 175, wherein R7is -C(CH3)2-.

[0878] Aspect 179. The intermediate of aspect 175, wherein R7is CH2C(CH3)2.

[0879] Aspect 180. The intermediate of aspect 175, wherein R7is -C(CH3)2-CI 12-.

[0880] Aspect 181. The intermediate of any one of aspects 175 to 180, wherein each R9and R10is Ci.4alkyl.

[0881] Aspect 182. The intermediate of any one of aspects 175 to 180, wherein each R9and R10is benzyl.

[0882] Aspect 183. The intermediate of any one of aspects 175 to 180, wherein each R9and R10is phenyl.

[0883] Aspect 184. The intermediate of any one of aspects 175 to 180, wherein each R9and R10is 2-(trimethylsilyl)ethyl.

[0884] Aspect 185. The intermediate of any one of aspects 175 to 180, wherein each R9and R10is -C(CH3)3.

[0885] Aspect 186. The intermediate of any one of aspects 175 to 180, wherein each R9is independently selected from ethyl and benzyl.

[0886] Aspect 187. The intermediate of any one of aspects 175 to 180, wherein each R9is ethyl.

[0887] Aspect 188. The intermediate of any one of aspects 175 to 180, wherein each R9is benzyl.

[0888] Aspect 189. The intermediate of any one of aspects 175 to 180, wherein each R10is independently selected from tert-butyl and benzyl.

[0889] Aspect 190. The intermediate of any one of aspects 175 to 180, wherein each R10is tert-butyl.

[0890] Aspect 191. The intermediate of any one of aspects 175 to 180, wherein each R10is benzyl.

[0891] Aspect 192. The intermediate of aspect 175 to 191, wherein each of Rla, R2a, R3a, R4a, and R5ais defined as for R1, R2, R3, R4, and R5in Formula (1).

[0892] Aspect 193. A reactive sol-moiety precursor having the structure of Formula (3):or a salt thereof, wherein,at least one of R1a, R3a, and R5ais -0-P(0)(0H)2;at least one of Rla, R2a, R3a, R4a, and R5ais independently selected from -O-P(O)(OR9)2, - P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2, -C(O)(-OR10), -CH2C(O)(-OR10), and - CH(C(O)(-OR10))2;each of the other of Rla, R2a, R3a, R4a, and R’ais independently selected from hydrogen, halo, methyl, and methoxy;R7is selected from -(CR2)P- where p is selected from 1 and 2, and each R is independently selected from hydrogen and methyl;R8is selected from a moiety reactive with a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, an NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group; and each R9and R10is independently selected from C1-4 alkyl, benzyl, phenyl, 2- (trimethylsilyl)ethyl, and -C(CH3)2.

[0893] Aspect 194. The precursor of aspect 193, wherein each of Rla, R2a, R3a, R4a, and R5ais defined as for R1, R2, R3, R4, and R5in Formula (1) consistent with the definitions for Rla, R2a, R3a, R4a, and R8a.

[0894] Aspect 195. The precursor of aspect 194, wherein R7is selected from -CH2-, -CH(CH3)-, -C(CH3)2-, -C(CH3)2-CH2-, and -CH2-C(CH3)2-.

[0895] Aspect 196. The precursor of aspect 194, wherein R7is -CH2-.

[0896] Aspect 197. The precursor of aspect 194, wherein R7is -CH(CH3)-.

[0897] Aspect 198. The precursor of aspect 194, wherein R7is -C(CH3)2-.

[0898] Aspect 199. The precursor of aspect 194, wherein R7is -CH2-C(CH3)2-.

[0899] Aspect 200. The precursor of aspect 194, wherein R7is -C(CH3)2-CH2-.

[0900] Aspect 201. The precursor of any one of aspects 194 to 200, wherein each R9is C1-4 alkyl.

[0901] Aspect 202. The precursor of any one of aspects 194 to 200, wherein each R9is benzyl.

[0902] Aspect 203. The precursor of any one of aspects 194 to 200, wherein each R9is phenyl.

[0903] Aspect 204. The precursor of any one of aspects 194 to 200, wherein each R9is 2-(trimethylsilyl)ethyl.

[0904] Aspect 205. The precursor of any one of aspects 194 to 200, wherein each R9and R10is - C(CH3)3.

[0905] Aspect 206. The precursor of any one of aspects 194 to 200, wherein each R9and R10is independently selected from ethyl and benzyl.

[0906] Aspect 207. The precursor of any one of aspects 194 to 200, wherein each R9and R10is ethyl.

[0907] Aspect 208. The precursor of any one of aspects 194 to 200, wherein each R9and R10is benzyl.

[0908] Aspect 209. The precursor of any one of aspects 194 to 200, wherein each R10is independently selected from tert-butyl and benzyl.

[0909] Aspect 210. The precursor of any one of aspects 194 to 200, wherein each R10is tert-butyl.

[0910] Aspect 211. The precursor of any one of aspects 194 to 200, wherein each R10is benzyl.

[0911] Aspect 212. The precursor of any one of aspects 193 to 211, wherein R8is reactive with a hydroxyl group.

[0912] Aspect 213. The precursor of any one of aspects 194 to 211, wherein R8is selected from Br,Cl, I, -OC(=O)CH2C1, -OC(=O)CH(CH3)-C1, --OCH2OC(=O)Cl, -OC(=O)C1, -OC(=O)OPh, - OC(=O)OC6H4NO2, -OC(=O)OC6H3(NO2)2, -OC(=O)OC6F5, -OCH2OC(=O)O-N-hydroxysuccinimide,-OCH2SCH3, -OCH2CI, -C(O)-C1, and -COOH.

[0913] Aspect 214. The precursor of any one of aspects 194 to 211, wherein R8is selected from Br,Cl, and I.

[0914] Aspect 215. The precursor of any one of aspects 194 to 211, wherein R8is -OC(=O)CH2C1.

[0915] Aspect 216. The precursor of any one of aspects 194 to 211, wherein R8is --OCH2OC(=O)Cl.

[0916] Aspect 217. The precursor of any one of aspects 194 to 211, wherein R8is -OC(=O)C1.

[0917] Aspect 218. The precursor of any one of aspects 194 to 211, wherein R8is -OC(=O)OPh.

[0918] Aspect 219. The precursor of any one of aspects 194 to 211, wherein R8is - OC(=O)OC6H4NO2.

[0919] Aspect 220. The precursor of any one of aspects 194 to 211, wherein R8is - OC(=O)OC6H3(NO2)2.

[0920] Aspect 221. The precursor of any one of aspects 194 to 211, wherein R8is -OC(=O)OC6F5.

[0921] Aspect 222. The precursor of any one of aspects 194 to 211, wherein R8is -OCH2OC(=O)O- A-hydroxysuccinimide.

[0922] Aspect 223. The precursor of any one of aspects 194 to 211, wherein R8is OCH2SCH3.

[0923] Aspect 224. The precursor of any one of aspects 194 to 211, wherein R8is -OCH2Cl.

[0924] Aspect 225. The precursor of any one of aspects 194 to 211, wherein R8is -CH2-C(O)-R10, wherein R10is selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf.

[0925] Aspect 226. The precursor of any one of aspects 194 to 211, wherein R8is -CH2-C(O)-OH.

[0926] Aspect 227. The precursor of any one of aspects 194 to 211, wherein R8is -CH2-C(O)-C1.

[0927] Aspect 228. The precursor of any one of aspects 194 to 211, wherein R8is -CH2-C(O)-O-N-hydroxysuccinimide.

[0928] Aspect 229. The precursor of any one of aspects 194 to 211, wherein R8is -CH2-C(0)-0Ms

[0929] Aspect 230. The precursor of any one of aspects 194 to 211, wherein R8is -CH2-C(O)-OTs.

[0930] Aspect 231. The precursor of any one of aspects 194 to 211, wherein R8is -CH2-C(O)-OTf.

[0931] Aspect 232. The precursor of any one of aspects 193 to 194, whereinR7is -CH2-; andR8is selected from Br, Cl, I, -OC(=O)CH2C1, --OCH2OC(=O)Cl, -OC(=O)C1, -OC(=O)OPh, - OC(=O)OC6H4NO2, -OC(=O)OC6H3(NO2)2, -OC(=O)OC6F5, -OCH2OC(=O)O-N-hydroxysuccinimide, -OCH2SCH3, and -OCH2C1.

[0932] Aspect 233. The precursor of any one of aspects 193 to 194, whereinR7is -CH2-; andR8is -O-C(O)-C1.

[0933] Aspect 234. The precursor of any one of aspects 193 to 194, whereinR7is -C(CH3)2-CH2-; andR8is -C(O)-R10, wherein R10is selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf.

[0934] Aspect 235. The precursor of aspect 194, wherein the precursor has the structure of any one of Formula (4A)-4AAA) as listed in FIGS. 4A-4J, whereineach R’ is independently selected from C1-4 alkyl, phenyl, benzyl, / erz-butyl, allyl, and 2-(trimethylsilyl)ethyl;R is selected from hydrogen, halo, methyl, and methoxy;W is selected from OH, Cl, O-iV-hydroxysuccinimide, OMs, OTs, and OTf; andZ is selected from halo -OC(=O)CH2C1, -OCH2O(C=O)C1, -O(C=O)C1, -O(C=O)OPh, -O(C=O)OC6H4NO2, -O(C=O)OC6H3(NO2)2, -O(C=O)OC6F5, -OCH2O(C=O)O-N-hydroxysuccinimide, -OCH2SCH3, and -OCH2C1.

[0935] Aspect 236. The precursor of aspect 235, wherein the precursor has the structure of any one of Formula (4A)-(4AAA), for each -PO(OR’)2, -OPO(OR’)2, -CH2-PO(OR’)2, -CH2-OPO(OR’)2, and - CH(-P(O)(OR’)2)2; and each R’ is independently selected from ethyl and benzyl.

[0936] Aspect 237. The precursor of aspect 236, wherein the precursor has the structure of any one of Formula (4A)-(4AAA), for each -COOR’, -CH2-COOR’, and -CH(C00R’)2, R’ is selected from tertbutyl and benzyl.

[0937] Aspect 238. The precursor of any one of aspects 235 to 237, wherein R is hydrogen.

[0938] Aspect 239. The precursor of any one of aspects 235 to 237, wherein R is methyl.

[0939] Aspect 240. The precursor of any one of aspects 235 to 237, wherein R is methoxy.

[0940] Aspect 241. The precursor of any one of aspects 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is selected from Br, Cl, and I.

[0941] Aspect 242. The precursor of any one of aspects 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)CH2CL

[0942] Aspect 243. The precursor of any one of aspects 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OCH2OC(=O)Cl.

[0943] Aspect 244. The precursor of any one of aspects 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)C1.

[0944] Aspect 245. The precursor of any one of aspects 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)OPh.

[0945] Aspect 246. The precursor of any one of aspects 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)OC6H4NO2.

[0946] Aspect 247. The precursor of any one of aspects 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)OC6H3(NO2)2.

[0947] Aspect 248. The precursor of any one of aspects 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)OCeF5.

[0948] Aspect 249. The precursor of any one of aspects 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OCH2OC(=O)O-N-hydroxysuccinimide.

[0949] Aspect 250. The precursor of any one of aspects 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OCH2SCH3.

[0950] Aspect 251. The precursor of any one of aspects 236 to 240, wherein in a precursor of Formula (4A)-(4PP), Z is -OCH2C1.

[0951] Aspect 252. The precursor ofany one of aspects 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is -OH.

[0952] Aspect 253. The precursor of any one of aspects 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is -Cl.

[0953] Aspect 254. The precursor of any one of aspects 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is O-A'-hydroxysucci m mide.

[0954] Aspect 255. The precursor of any one of aspects 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is -OMs.

[0955] Aspect 256. The precursor of any one of aspects 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is -OTs.

[0956] Aspect 257. The precursor of any one of aspects 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is -OTf.

[0957] Aspect 258. A method of synthesizing the sol-moiety drug conjugate of aspect 1 comprising reacting a therapeutic agent comprising a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group with a reactive sol-moiety compound, in the presence of a base to provide a protected intermediate; and treating the protected intermediate (a) with TMSBr in CH2CI2 or (b) with hydrogen gas in the presence of Pd / C in ethanol; to provide the compound of Formula (1).EXAMPLES

[0958] The following examples describe in detail methods of preparing protected sol-moiety intermediates, reactive sol-moieties, and sol-moiety drug conjugates provided the present disclosure, properties of the sol-moiety intermediates, reactive sol-moieties, and sol-moiety drug conjugates, and methods of using the sol-moiety intermediates, reactive sol-moieties, and sol-moiety drug conjugates. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.Example 1Synthesis of 7-Hvdroxy-2,2-dimethyl-4H-benzo[d][l,3]dioxin-4-one (1)

[0959] In a round bottom flask, 2,4-dihydroxybenzoic acid (9 g, 58 mmol) was suspended in 2,2,2-trifluoroacetic acid (80 mL, 1050 mmol). The mixture was cooled in an ice bath. (2,2,2-Trifluoroacetyl)2,2,2-trifluoroacetate (54 mL, 391 mmol) was added dropwise followed by dropwise addition of acetone (25 mL). The reaction was then stirred at 20 °C. After over 2 h, the reaction cleared to a solution. After 16 h, the reaction was concentrated, and the concentrate diluted with water (100 mL) and neutralized with the addition of a sodium bicarbonate solution. After stirring a solid formed from the oil. The solid was washed with petroleum ether and diethyl ether and then dried under high vacuum. Washing with diethyl ether removed the major unknown by-product to provide the title compound (1) as an off-white solid of 5.85 g (52% yield). Purity by reverse phase LC (UV 254 nm) is -92%. LR / MS (ESI) [M+H]+calculated (for C10H10O4) 195.06 found 194.9. Retention time = 2.87 m. 'll NMR (500 MHz, DMSO) 5 10.84 (s, 1H), 7.68 (d, J = 8.7 Hz, 1H), 6.59 (dd, J = 8.6, 2.2 Hz, 1H), 6.38 (d, J = 22 Hz, 1H), 1.65 (s, 6H).Example 2Synthesis of 2,2-Dimethyl-4-oxo-4H-benzo[d][l,3]dioxin-7-yl trifluoromethanesulfonate (2)

[0960] In a round bottom flask, 7-hydroxy-2,2-dimethyl-l,3-benzodioxin-4-one (9.07 g, 46.7 mmol) was dissolved in dichloromethane (155 mL) and pyridine (7.6 mL). The reaction was cooled in an ice bath. Trifluoromethanesulfonate (9.4 mL, 56 mmol) was added dropwise resulting in a dark solution. The mixture was stirred at 20 °C in the ice bath. TLC [(5% 2-MeTHF / DCM): starting material (Rf -0.6), new spots (Rt-0.9, -0.25); (50% ethyl acctatc / hcxancs): product (Rt0.8), starting material -0.5] and LC / MS showed some starting material and product after 2 h. After 4.5 h, water was added followed by ethyl acetate and sodium bicarbonate solution. The phases were separated and the organic phase was washed with water and a sodium chloride solution and dried over sodium sulfate. After filtration and evaporation, a residue of -15 g was obtained. The residue was purified using silica gel chromatography (0-20% ethyl acetate / hexanes). A colorless crystalline residue (6.52 g) was obtained from the main portion of the peak. An amount of 0.86 g was recovered from the trailing fractions. The trailing fractions were concentrated from ethyl acetate / hexanes leaving a residual amount of solvent from which crystallization started. After cooling in a freezer, the solvent was decanted and evaporated to 40 mg. The crystals were collected (0.63 g) and combined with the main portion (-50% yield including amounts recovered from a test reaction) to provide the title compound (2). II NMR (500 MHz, DMSO) 58.08 (d, J = 8.7 Hz, 1H), 7.47 (d, J = 2.3 Hz, 1H), 7.35 (dd, 7= 8.7, 2.4 Hz, 1H), 1.73 (s, 6H).13C NMR (126 MHz, DMSO) 5 158.94, 156.64,153.89, 132.05, 122.27-114.18 (m), 116.36, 113.48, 111.29, 107.60, 25.22. LR / MS (ESI) [M+H]+calculated (for C11H9F3O6S) 327.01 found 327.0. Retention time = 4.0 m.Example 3Synthesis of Dibenzyl (2,2-dimethyl-4-oxo-4H-benzo[d][l,3]dioxin-7-yl)phosphonate (3)

[0961] In a round bottom flask, (2,2-dimethyl-4-oxo-l,3-benzodioxin-7-yl) trifluoromethanesulfonate (0.57 g, 1.75 mmol) was dissolved in acetonitrile (~7 mL). The solution was purged with N- gas.Benzyloxyphosphonoyloxymethylbenzene (458 mg, 1.75 mmol) was added with an acetonitrile rinse (-1 mL)., V, A )iisopropylclhylaminc (0.46 mL, 2.6 mmol) was added dropwisc resulting in a cloudy soludon. Palladiumjtriphenylphosphane (101 mg, 0.09 mmol) was then added and the mixture was heated to 100 °C in a heat block. After 16 h, the reaction mixture was evaporated to provide 1.52 g of a heterogenous oil. The oil was purified using silica gel chromatography (0-80% ethyl acetate / hexanes). Fractions were concentrated to an oil of the title compound (3) (-0.56 g, 73% yield).rH NMR (500 MHz, CDCL) 57.98 (dd, 7 = 7.9, 4.9 Hz, 1H), 7.46 (ddd, 7= 12.7, 7.9, 1.3 Hz, 1H), 7.38 (dd, 7= 14.8, 1.2 Hz, 1H), 7.34-7.31 (m, 10H), 5.14-5.05 (m, 4H), 1.72 (s, 6H). LR / MS (ESI) [M+H]+calculated (for C24H23O6P) 439.1 found 439.2. Retention time = 4.05 m.Example 4Synthesis of dibenzyl (3-hvdroxy-4-(hvdroxymethyl)phenyl)phosphonate (4)

[0962] In a round bottom flask, 7-dibenzyloxyphosphoryl-2,2-dimethyl-l,3-benzodioxin-4-one (120 mg, 0.27 mmol) was dissolved in THF (2.5 mL) and cooled in an ice bath. Lithium aluminum hydride (0.12 mL, 0.27 mmol of 2.3 M solution in 2-MeTHF) was added dropwise. The reaction was allowed to warm to room temperature and then cooled with in an ice bath. The excess lithium aluminum hydride and solution was quenched by the drop-wise addition of acetone., followed by addition of a solution ofRochelle salt (potassium sodium tartrate (tetrahydrate) ~3 g / 5 mL water). The resulting mixture was diluted with ethyl acetate and water. The organic phase was extracted, dried (Na2SO4 ), and evaporated to dryness under reduced pressure to give the title compound (65 mg) as arH NMR (500 MHz, DMSO) 5 7.47 (dd,. / = 7.6, 5.5 Hz, III), 7.39-7.31 (m, 1011), 7.24-7.16 (m, 211), 5.17 (t, 7 = 5.6 IIz, III), 5.05^1.96 (m, 4H), 4.52-4.47 (m, 3H).Example 5Synthesis ofdibenzyl [5-dibenzyloxyphosphoryl-2-(hvdroxymethyl)phenyl1 phosphate (5)

[0963] A 100 ml. round bottom flask with a stir bar was charged with 5-dibenzyloxyphosphoryl-2-(hydroxymethyl)phenol (900 mg, 2.34 mmol), anhydrous THF (14 L) [benzyloxy(chloro)phosphoryl]oxymethylbenzene (764 mg, 2.58 mmol), and cooled to 0 °C. With vigorous stirring sodium hydride (112 mg, 2.81 mmol) (60 wt% in mineral oil) was added in one portion. The mixture was stirred for 30 minutes (slowly warming to room temperature), the ice was refreshed, and excess sodium hydride was quenched with the addition of a saturated aqueous solution of ammonium chloride. The mixture was diluted with ethyl acetate and washed with water, brine, dried (NasSCL), and evaporated to dryness under reduced pressure. Chromatography (0-40% (EtOAc in EtOH 3:l) / hexanes) provided the title product (1.20 g, 1.72 mmol, 73%) as a clear colorless oil. LRMS (ESI) calcd for molecular formula [C35H340sP2+H]+ 645.4; found 645.2. Retention time = 4.165 min. 'll NMR (500 MHz, CDCh) 57.65-7.61 (m, 2H), 7.53 (dd, J = 7.9, 5.3 Hz, 1H), 7.33-7.27 (m, 20H), 5.09-5.03 (m, 6H), 4.98 (dd, 7= 11.8, 8.1 Hz, 2H), 4.61 (s, 2H).Example 6Synthesis of 4-(bis(benzyloxy)phosphoryl)-2-((bis(benzyloxy)phosphoryl)oxy)benzyl carbonochloridate(6)

[0964] Dibenzyl [5-dibenzyloxyphosphoryl-2-(hydroxymethyl)phenyl] phosphate (417 mg, 0.65 mmol) was dissolved in THF (3 mL) and cooled to 0 °C under an argon atmosphere. Bis(trichloromcthyl) carbonate (211 mg, 0.71 mmol) was added in one portion, followed by diisopropylethylamine (0.14 mL, 0.78 mmol) dropwise and stirred for 45 minutes. The reaction was quenched with water, extracted with ethyl acetate, washed with brine, dried (Na2SO4) and evaporated to dryness under reduced pressure to provide the title product (424 mg, 92%) which was used without further purification, 'll NMR (500 MHz, CDCh) 57.80 (dt, J= 14.6, 1.2 Hz, 1H), 7.71-7.52 (m, 1H), 7.52-7.37 (m, 1H), 7.33-7.27 (m, 20H), 5.26 (s, 2H), 5.09 (d, 7 = 9.1 Hz, 4H), 5.08X.97 (m, 4H).Example 7Synthesis of 6-bromo-2,2-dimethyl-4g- 1,3-benzodioxine (7)

[0965] To a stirred solution of 4-bromo-2-(hydroxymethyl)phenol (100 g, 492.54 mmol) in acetone (1.2 L) were added 2,2-dimethoxypropane (308 g, 2.95 mol), sodium sulfate (210 g, 1477 mmol), and PTSA (8.47 g, 49.25 mmol) at 0 °C. The mixture was heated to 55 °C for about 18 h and the progress of the reaction was monitored using TLC. After completion, the reaction mixture was diluted with water, extracted into EtOAc, washed with sat’d aq. NaHCCL solution, brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCh; 2% ethyl acetate in hexanes) provided 6-bromo-2,2-dimcthyl-4H-l,3-bcnzodioxinc (7) (40 g, 33% yield).Example 8Synthesis of 2,2-dimethyl-4 / f-l,3-benzodioxine-6-carbaldehyde (8)

[0966] 1.6 M n-Butyllithium (2.73 mL, 4.94 mmol) was added dropwise to a slirred solution of 6-bromo-2,2-dimethyl-4H- 1,3-benzodioxine (600 mg, 2.47 mmol) in THF (10 mL) at -78 °C. After stirring for 1 h at -78 °C, DMF (2.3 mL) was added dropwise to the solution. After stirring for 3 h, the excess acid was quenched with the addition of saturated aqueous NILC1 soludon and then extracted into ethyl acetate, washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiO2; 10% ethyl acetate in hexanes) provided the desired product (250 mg, 52% yield).Example 9Synthesis of (A’)-A,’-((2.2-dimcthyl-4A / -benzo| | [ 1,3]dioxin-6-yl)methylene)-4- methylbenzenesulfonohydrazide (9)

[0967] 4-Methylbenzenesulfonohydrazide (242 mg, 1.3 mmol) was added dropwise to a stirred solution of 2,2-dimethyl-4H-l,3-benzodioxine-6-carbaldehyde (250 mg, 1.3 mmol) in THF (50 mL) at 0 °C. The reaction mixture was heated to 60 °C for 30 minutes and then evaporated to dryness under reduced pressure to obtain the crude product (200 mg, 42% yield).Example 10Synthesis of dibenzyl ((2,2-dimethyl-4tf-benzo[rf][1.3]dioxin-6-yl)methyl)phosphonate (10)

[0968] DBP (3.46 g, 13.32 mmol) was added to a stirred solution of A-[(E)-(2,2-dimethyl-4H- 1,3-bcnzodioxin-6-yl)mcthylcncamino]-4-mcthyl-bcnzcncsulfonamidc (9) (6 g, 16.65 mmol) and Cs2CO3 (6.76 g, 20.81 mmol) in 1,2-dimethoxyethane (10 mL). The reaction was purged with argon for 30 min, followed by the addition of Cui (263 mg, 1.38 mmol). The mixture was stirred in a sealed tube at 80 °C for 3 h, cooled to room temperature, diluted with water, and extracted into ethyl acetate. The organic phase was dried (Na^SCL) and evaporated to dryness under reduced pressure. Chromatography purification (SiO2; 10-100% ethyl acetate in hexanes) provided the title product (3 g, 41% yield) as a viscous oil.Example 11Synthesis of Dibenzyl (4-hydroxy-3-(hydroxymethyl)benzyl)phosphonate (I I )

[0969] A solution of 6-(dibenzyloxyphosphorylmethyl)-2,2-dimethyl-4 / 7-l,3-benzodioxine (2 g, 4.56 mmol), PTSA (451 mg, 2.28 mmol) in acetonitrile (15 mL), and water (5 mL) was stirred for 2 hours at room temperature (23 °C) and then poured into water. The mixture was extracted into ethyl acetate, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCL; 40% ethyl acetate in hexanes) yielded the desired product (500 mg, 27%) as a viscous oil.Example 12Synthesis of dibenzyl (4-((bis(benzyloxy)phosphoryl)methyl)-2-(hvdroxymethyl)phenyl) phosphate (12)

[0970] A 100 mL round bottom flask with a stir bar was charged with 4-(dibenzyloxyphosphorylmethyl)-2-(hydroxymethyl)phenol (11) (1 g, 2.51 mmol), and anhydrous THF (20 mL). The mixture was cooled to 0 °C with an ice / water bath and sodium hydride (110 mg, 2.76 mmol) was added with vigorous stirring. The mixture was stirred for 5 minutes, and a solution of [benzyloxy(chloro)phosphoryl]oxymethylbenzene (744 mg, 2.51 mmol) in anhydrous THE (2 mL) was added dropwise. The ice bath was removed and the mixture warmed to room temperature (23 °C) and stirred for 30 minutes (LCMS analysis showed no remaining starting material). Excess sodium hydride was quenched by the addition of a saturated aqueous ammonium chloride solution. The resulting biphasic mixture was diluted with water and EtOAc. The aqueous phase was extracted with EtOAc (2 x 10 mL) and the combined organic exlracls were washed with brine, dried using anhydrous magnesium sulfate, filtered, concentrated, and further purified using silica gel chromatography (0-35% [EtOAc: EtOII(3: l)] / hex - 25 g) to afford dibenzyl [4-(dibenzyloxyphosphorylmethyl)-2-(hydroxymethyl)phenyl] phosphate (12) (1300 mg, 1.6778 mmol, 66.84% yield) as a yellow oil with minor impurities. LRMS (ESI) calcd for molecular formula [CseHssO^ + H]+ 659.2; found 659.2. II NMR (500 MHz, CDCh) 5 7.35-7.22 (m, 21H), 7.08 (dt, J= 8.4, 2.4 Hz, 1H), 7.03 (dt, J = 8.4, 1.0 Hz, 1H), 5.11 (dd, J = 8.7, 1.5 Hz, 4H), 4.98-4.88 (m, 4H), 4.48 (d, J= 5.3 Hz, 2H), 3.11 (d, J = 21.6 Hz, 2H).Example 13Synthesis of 5-((bis(benzyloxy)phosphoryl)methyl)-2-((bis(benzyloxy)phosphoryl)oxy)benzyl carbonochloridate (13)

[0971] Diisopropylethylamine (0.14 mL, 0.78 mmol) was added dropwise to a solution of dibenzyl [5-dibenzyloxyphosphoryl-2-(hydroxymethyl)phenyl] phosphate (12) (417 mg, 0.65 mmol) and bis(trichloromethyl) carbonate (211 mg, 0.71 mmol) in THF (3 mL) at 0 °C under an atmosphere of argon. After stirring for 45 minutes the reaction was diluted with water, extracted with ethyl acetate, washed with brine, dried (ISfeSCU), and evaporated to dryness under reduced pressure to provide the desired product (424 mg, 92%) which was used without further purification, 'll NMR (500 MHz, CDCI3) 87.80 (dt, J = 14.6, 1.2 Hz, 1H), 7.71-7.52 (m, 1H), 7.52-7.37 (m, 1H), 7.33-7.27 (m, 20H), 5.26 (s, 2H), 5.09 (d, 7 = 9.1 Hz, 4H), 5.08^1.97 (m, 4H).Example 14Synthesis of dibenzyl (2,2-dimethyl-4H-benzo[d1[l,3]dioxin-6-yl)phosphonate (14)

[0972] A 30 mL microwave tube was charged with 6-bromo-2,2-dimethyl-4H-benzo[d][l,3]dioxine (1.0 g, 4.115 mmol), triethylamine (0.50 g, 4.938 mmol), dibenzyl phosphonate (1.08 g, 4.115 mmol), and Pd(PPh3)4 (0.48 g, 0.411 mmol). To the tube, 1,4-dioxane (20 mL) was added. The mixture was stirred in a microwave reactor for 30 minutes at 120 °C. The mixture was cooled to 23 °C. An additional 30 such batches were reacted in parallel. All batches were combined. The resulting mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (ISfeSCL), and evaporated to dryness under reduced pressure. Chromatography (SiCL; 33% ethyl acetate in petroleum ether) provided the title product (24.0 g, 45%) as a yellow solid. LRMS (ESI) calcd for molecular formula [C24H2sO5P+H]+ 425.14; found 425.0.Example 15Synthesis of dibenzyl (4-hvdroxy-3-(hvdroxymethyl)phenyl)phosphonate (15)

[0973] A solution of dibenzyl (2,2-dimethyl-4H-benzo[d][l,3]dioxin-6-yl)phosphonate (24.0 g, 56.6 mmol) in HC1 (2.0 M in water, 60 mb) and acetone (60 mL) was stirred for 24 hours at 23 °C. The reaction was quenched with water. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with brine (2x), dried (Na2SO4), and evaporated to dryness under reduced pressure. The resulting solid was triturated with petroleum ether / ethyl acetate (5:1) for 1 hour to afford the title product (13.5 g, 62%) as a yellow solid used in the next reaction without further purification.Example 16Synthesis of dibenzyl (4-(bis(benzyloxy)phosphoryl)-2-(hydroxymethyl)phenyl) phosphate! 16)

[0974] To a solution of dibenzyl(4-hydroxy-3-(hydroxymethyl)phenyl) phosphonate (12.5 g, 32.6 mmol) and A, A-diisopropylethylamine (6.3 g, 48.8 mmol) in dichloromethane (125 mL) was added dibenzyl phosphorochloridate (11.6 g, 39.1 mmol). The reaction was stirred for 2 hours at 23 °C. The reaction was quenched with water. The reaction was evaporated under reduced pressure to remove dichloromethane. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure.Chromatography (SiCh; 33% ethyl acetate in petroleum ether) provided the title product (13.5 g, 64%) as an off-white solid. LRMS (ESI) calcd for molecular formula [C35H340sP2+H]+ 645.17; found 645.0.Example 17Synthesis of 6-bromo-2,2,8-trimethyl-4H-benzo[<f][l,3]dioxine (17)

[0975] To a solution of 4-bromo-2-(hydroxymethyl)-6-methyl-phenol (80 g, 368.56 mmol) in acetone (525 mL) and tetrahydrofuran (347 mL) at 0 °C was added aluminum trichloride (22 g, 164.99 mmol) portion wise. The reaction was brought to 23 °C and stirred for 16 hours. The reaction was quenchedwith 10% sodium hydroxide solution. The resulting mixture was extracted with ethyl acetate (2x). The combined organic layers were dried (Na2SO4) and evaporated to dryness under reduced pressure.Chromatography (SiCL; 10% ethyl acetate in hexanes) to afford the title product (50 g, 53%) as a yellow liquid. LRMS (ESI) calcd for molecular formula [CnIIi3BrO2+II]+ 257.01; found 257.19.Example 18Synthesis of dibenzyl t2.2.8-lriiiicihyl-4 / / -bcnzo|d|| 1.3|dioxin-6-yl)phosnhonalc (18)

[0976] A microwave vial was charged with 6-bromo-2,2,8-trimethyl-4H-l,3-benzodioxine (50 g, 194.45 mmol), benzyloxyphosphonoyloxymethylbenzene (45.8 g, 174.65 mmol), cesium carbonate (29.5 g, 213.77 mmol), and tetrakis(triphenylphosphane)palladium(0) (11.2 g, 9.7 mmol). The vial was placed under inert atmosphere via evacuation and backfilling with nitrogen gas for three cycles. To the vial, 1,4-dioxane (250 mb) was added via syringe. The reaction was stirred for 30 minutes at 120 °C in a micro wave reactor. The reaction was brought to 23 °C, quenched with water, and extracted with ethyl acetate (2x). The combined organic layers were dried (Na2SO4) and evaporated to dryness under reduced pressure. Chromatography (SiCh; 20% ethyl acetate in hexanes) to afford the title product (25 g, 29%) as a brown liquid. LRMS (ESI) calcd for molecular formula [C25H27O5P+HJ+ 439.16; found 439.35.Example 19Synthesis of dibenzyl (4-hvdroxy-3-(hvdroxymethyl)-5-methylphenyl)phosphonate (19)

[0977] To a solution of 6-dibenzyloxyphosphoryl-2,2,8-trimethyl-4H-l,3-benzodioxine (25 g, 57.02 mmol) in acetonitrile (188 mL) and water (50 mL) was added 4-methylbenzene-l- sulfonic acid (14.71 g, 85.53 mmol). The reaction was stirred for 16 hours at 23 °C. The reaction was diluted with water and extracted with ethyl acetate (2x). The combined organic layers were dried (ISfeSCL) and evaporated to dryness under reduced pressure. Chromatography (Si O2; 40% ethyl acetate in hexanes) provided the title product (17.3 g, 74%) as a pale-yellow solid. LRMS (ESI) calcd for molecular formula [C22H230sP+H]+ 399.13; found 399.30.NMR (400 MHz, DMSO) 59.23 (br s, 1H), 7.57 (d, 7= 13.6 Hz, 1H), 7.35 (s, 10H), 5.38 (br s, 1H), 5.03^1.94 (m, 4H), 4.56 (s, 2H), 2.10 (s, 3H).Example 20Synthesis of dibenzyl (4-(bis(benzyloxy (phosphoryl )-2-(hydroxymethyl )-6-methylphenyl ) phosphate (20)

[0978] To a solution of dibenzyl (4-hydroxy-3-(hydroxymethyl)-5-methylphenyl)phosphonate (5 g, 0.01 mol) in tetrahydrofuran (25 ml) at 0 °C was added A'. A'-diisopropylclhylamine (3 g, 0.03 mol). To the solution, dibenzyl phosphorochloridate (7 g, 0.02 mol) in tetrahydrofuran (5 mL) was added dropwise. The reaction was brought to 23 °C and stirred for 6 hours. The reaction was quenched with water. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (NajSO^, and evaporated to dryness under reduced pressure. Chromatography (SiCL; 40-100% ethyl acetate in hexanes) followed by chromatography (Cis; 5-100% acetonitrile in water) provided the title product (975 mg, 10%) as a pale oil. LRMS (ESI) calcd for molecular formula [CselheO^+II]-!-659.19; found 659.2. ¹H NMR (400 MHz, DMSO) 57.77 (d, J= 13.6 Hz, 1H), 7.50 (d, J = 13.3 Hz, 1H), 7.42-7.29 (m, 20H), 5.37 (t, J = 5.8 Hz, 1H), 5.19-5.10 (m, 4H), 5.09-5.00 (m, 4H), 4.63 (d, J = 5.7 Hz, 2H), 2.27 (s, 3H).31P NMR (162 MHz, DMSO) 8 18.99-18.44 (m), -6.02-6.48 (m).Example 21Synthesis of 6-bromo-8-methoxy-2,2-dimethyl-4H-benzo[<7][l,3]dioxine (21)

[0979] To a solution of 4-bromo-2-(hydroxymethyl)-6-methoxy-phenol (70 g, 300.35 mmol) in acetone (80 mL) were added NaiSOi (12 g), 4-methylbenzene- 1 -sulfonic acid (5.17 g, 30.04 mmol), and 2,2-dimethoxypropane (187.42 g, 1802 mmol). The reaction was stirred for 12 horns at 40 °C. The reaction was cooled to 23 °C, quenched with saturated sodium bicarbonate solution, and extracted with dichloromethane. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCh; 5% ethyl acetate in hexanes) provided the title product (25 g, 29%) as a yellow solid. LRMS (ESI) calcd for molecular formula [CnHi3BrO3+H]+ 273.00; found 273.11.Example 22Synthesis of dibenzyl (8-mcthoxy-2,2-dimcthyl-4H-bcnzo[<7|[l,3]dioxin-6-yl)phosphonatc (22)

[0980] A microwave vial was charged with 6-bromo-8-methoxy-2,2-dimethyl-4H-l,3-benzodioxine (6 g, 21.97 mmol), benzyloxyphosphonoyloxymethylbenzene (5.19 g, 19.77 mmol), cesium carbonate (7.85 g, 24.17 mmol), and tetrakis(triphenylphosphane)palladium(0) (1.27 g, 1.1 mmol). The vial was placed under inert atmosphere via evacuation and backfilling with argon gas for three cycles. To the vial, tetrahydrofuran (30 mL) was added via syringe. The reaction was stirred for 10 minutes at 120 °C in a micro wave reactor. The reaction was brought to 23 °C, quenched with water, and extracted with ethyl acetate. The combined organic layers were washed widi brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCf; 30% ethyl acetate in hexanes) provided the title product (2.7 g, 21%) as a yellow gum. LRMS (ESI) calcd for molecular formula [C2sH270fiP+H]+ 455.15; found 455.31.Example 23Synthesis of dibenzyl (4-hvdroxy-3-(hvdroxymethyl)-5-methoxyphenyl)phosphonate (23)

[0981] To a solution of 6-dibenzyloxyphosphoryl-8-methoxy-2,2-dimethyl-4H- 1,3 -benzodioxine ( 14 g, 30.81 mmol) in acetonitrile (120 mL) and water (20 mL) was added 4-methylbenzene-l -sulfonic acid (2.93 g, 15.4 mmol). The reaction was stirred for 12 hours at 23 °C. The reaction was quenched with icewater and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (Si C); 60% ethyl acetate in hexanes) afforded a wliite solid which was triturated with pentanes to provide the title product (7.8 g, 61%) as a pale yellow liquid. LRMS (ESI) calcd for molecular formula [C22H230eP+H]+ 415.12; found 415.20. H NMR (400 MHz, DMSO) 59.48 (br s, 1H), 7.35 (m, 11H), 7.07 (d, 7= 14 Hz, 1H) 5.15 (br s, 1H), 5.00-5.02 (dd, 7=2.8, 2.8Hz, 4H), 4.49 (s, 2H) and 3.77 (s, 3H).31P NMR (162 MHz, DMSO) 821.09.Example 24Synthesis of dibenzyl (4-(bis(benzyloxy)phosphoryl)-2-(hvdroxymethyl)-6-methoxyphenyl) phosphate(24)

[0982] To a suspension of, N,N-dimethylpyridin-4-amine (31 mg, 0.25 mmol) in carbon tetrachloride (0.49 ml, 5.06 mmol at -10 °C were added dibenzyl phosphonate (0.37 mL, 1.64 mmol) dropwise, followed by N,N-diisopropylethylamine (0.66 mL, 3.79 mmol) dropwise. The resulting solution was stirred for 15 minutes at -10 °C. To the solution, 4-dibenzyloxyphosphoryl-2-(hydroxymethyl)-6-methoxy-phenol (524 mg, 1.26 mmol) in acetonitrile (5 mL) was added dropwise. The reaction brought to 23 °C slowly and slirred for 3 hours. The reaction was diluted with ethyl acetate. The organic layer was washed with water and brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiO2; 20-80% ethyl acetate in hexanes) provided the title product (433 mg, 51%) as a colorless oil. LRMS (ESI) calcd for molecular formula [C36H36O9P2+H]+ 675.18; found 675.2. ’ll NMR (500 MHz, CDC13) 57.45 (dd, J = 13.5, 1.7 Hz, 1H), 7.40-7.27 (m, 20H), 7.19 (dd, J = 14.8, 1.7 Hz, 1H), 5.16 (dt, J = 8.1, 3.8 Hz, 4H), 5.12-5.00 (m, 4H), 4.59 (d, J = 7.1 Hz, 2H), 3.92 (t, J = 7.1 Hz, 1H), 3.63 (s, 3H).Example 25Synthesis of 5-bromo-2-(hvdroxymethyl)-4-methoxyphenol (25)To a solution of 4-bromo-2-hydroxy-5-methoxy-benzaldehyde (1 g, 4.33 mmol) in methanol (10 mL) at 0 °C was added sodium borohydride (247 mg, 6.49 mmol) portion wise. The reaction was brought to 23 °C and stirred for 6 hours. The reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in ethyl acetate. The organic layer was washed with IN HC1, dried (Na2SO4), and evaporated to dryness under reduced pressure. The residue was washed with pentanes to afford the title product (500 mg, 50%) as an off-white solid used in the next reaction without further purification.Example 26Synthesis of 7-bromo-6-methoxy-2,2-dimethyl-4H-benzo l,31dioxine (26)

[0983] To a solution of 5-bromo-2-(hydroxymethyl)-4-methoxy-phenol (1 g, 4.29 mmol) in acetone (6 mL) and tetrahydrofuran (4 mL) at 0 °C was added aluminum trichloride (229.13 mg, 1.72 mmol) portion wise. The reaction was brought to 23 °C and stirred for 4 hours. The reaction was cooled to 0 °C and quenched with 10% sodium hydroxide solution. The mixture was brought to 23 °C and extracted with ethyl acetate. The organic layer was dried (Na2SO4) and evaporated to dryness under reduced pressure. Chromatography (SiO2; 2% ethyl acetate in hexanes) provided the title product (440 mg, 38%) as an off-white solid.Example 27Synthesis of dibenzyl (6-methoxy-2,2-dimethyl-4H-benzo[<7][l,3]dioxin-7-yl)phosphonate (27)

[0984] To a microwave vial, 7-bromo-6-methoxy-2,2-dimethyl-4H-l,3-benzodioxine (6 g, 21.97 mmol), dibenzyl phosphonate (5.76 g, 21.97 mmol), cesium carbonate (11.8 mL, 26.36 mmol), and tetrakis(triphenylphosphane)palladium(0) (1.3 g, 1.10 mmol) were added. The vial was placed under inert atmosphere via evacuation and backfilling with nitrogen gas for three cycles. To the vial, toluene (25 mL) was added via syringe. The reaction stirred for 1 hour at 100 °C in a micro wave reactor. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was dried (Na2SO4) and evaporated to dryness under reduced pressure. Chromatography (SiCh; 25% ethyl acetate in hexanes) provided the title product (1.2 g, 12%) as a pale-yellow liquid.Example 28Synthesis of dibenzyl (5-hvdroxy-4-(hvdroxymethyl)-2-methoxyphenyl)phosphonate (28)

[0985] To a solution of 7-dibenzyloxyphosphoryl-6-methoxy-2,2-dimethyl-4H-l,3-benzodioxine (150 mg, 0.33 mmol) in acetonitrile (1.2 mL) and water (2.8 mL) was added 4-methylbenzene-l- sulfonic acid (264.93 mg, 1.54 mmol). The reaction was stirred for 16 hours at 23 °C. The reaction was quenched with ice water and extracted with ethyl acetate. The organic layer was dried (NazSCT) and evaporated to dryness under reduced pressure. Chromatography (SiO2; 80% ethyl acetate in hexanes) provided the title product (700 mg, 55%) as a light-yellow liquid. LRMS (ESI) calcd for molecular formula [C22H23O6P+H]+ 415.12; found 415.31.Example 29Synthesis of dibenzyl (5-(bis(benzyloxy)phosphoryl)-2-(hvdroxymethyl)-4-methoxyphenyl) phosphate

[0986] To a solution of 5-dibenzyloxyphosphoryl-2-(hydroxymethyl)-4-methoxy-phenol (6 g, 14.48 mmol) in acetonitrile (413 mL) at -10 °C were added carbon tetrachloride (6.99 mL, 72.4 mmol), N, N-diisopropylethylamine (5.29 mL, 30.41 mmol), and N,N-dimethylpyridin-4-amine (176.65 mg, 1.45 mmol). To the solution, dibenzyl phosphonate (5.7 g, 21.72 mmol) was added dropwise. The reaction was stirred for 2 hours at -10 °C. The reaction was quenched with ice-water, extracted with ethyl acetate, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiO2; 80% ethyl acetate in hexanes) provided the title product (8.2 g, 84%) as a pale-yellow gum. LRMS (ESI) calcd for molecular formula [C36H36O9P2+H]+ 675.18; found 675.61. ¹H NMR (400 MHz, DMSO) 57.61 (br s, 1H), 7.33 (s, 20H), 7.21 (br s, 1H), 5.45 (t, J = 5.2 Hz, 1H), 5.12-5.00 (m, 8H), 4.57 (d, J = 5.2 Hz, 2H), 3.80 (s, 3H).Example 30Synthesis of 6,8-dibromo-2,2-dimethyl-4H-benzo[<f][l,3]dioxine (30)

[0987] To a solution of 2,4-dibromo-6-(hydroxymethyl) phenol (20 g, 70.939 mmol), Na2SO4 (40 g, 283.75 mmol) and 4-methylbenzene-l -sulfonic acid (2.44 g, 14.19 mmol) in acetone (200 mL) under nitrogen atmosphere was added 2,2-dimethoxypropane (11.08 g, 106.41 mmol) portion wise. Thereaction was stirred for 2 hours at 40 °C. The reaction was brought to 23 °C. The mixture was evaporated to dryness under reduced pressure. Chromatography (Cis; 30-80% acetonitrile in water buffered with 10 mmol / L ammonium bicarbonate) provided the title product (18.56 g, 81%) as a yellow oil.Synthesis of tetrabenzyl ((2,2-dimethyl-4H-benzo[rt|[l,3]dioxine-6.8- diyl)bis(methylene))bis(phosphonate)

[0988] To a solution of dibenzyl methylphosphonate (32.17 g, 116.46 mmol) in tetrahydrofuran (75 mL) under nitrogen atmosphere was added TMPZnCl·LiCl (1.95 mol. equiv) dropwise. The reaction was stirred for 2 hours at 23 °C. To the mixture, tris(dibenzylideneacetone)dipalladium (8.53 g, 9.32 mmol) and Q-Phos (6.62 g, 9.32 mmol) were added portion wise. To the mixture, 6,8-dibromo-2,2-dimethyl-4H-1,3-benzodioxine (15 g, 46.58 mmol) were added dropwise. The reaction was stirred for 16 hours at 50 °C. The reaction was cooled to 0 °C, quenched with saturated ammonium chloride solution, and extracted with ethyl acetate. The organic layer was evaporated to dryness under reduced pressure.Chromatography (Cis; 40-80% acetonitrile in water) provided the title product (10.6 g, 32%).Example 31Synthesis of tetrabenzyl ((4-hydroxy-5-(hvdroxymethyl)- 1,3-phenylene)bis(methylene))bis(phosphonate)(31)

[0989] To a solution of dibenzyl (6-[(dibenzyloxyphosphoryl)methyl]-2,2-dimethyl-4H-l,3-benzodioxin-8-ylmethylphosphonate (10 g, 14.031 mmol) in 1,4-dioxane (25 mL) and acetone (25 mL) under nitrogen atmosphere was added HC1 (2 M in water, 25 mL) dropwise. The reaction was stirred for 12 hours at 23 °C. The reaction was quenched with water and extracted with ethyl acetate. The combined organic layers were evaporated to dryness under reduced pressure. Chromatography (Cis; 25-60% acetonitrile in water) provided the title product (6.03 g, 64%). LRMS (ESI) calcd for molecular formula [C37H3sO7P2+H]+ 673.20; found 673.2.Example 32Synthesis of dibenzyl (2,4-bis((bis(benzyloxy)phosphoryl)methyl)-6-(hvdroxymethyl)phenyl) phosphate

[0990] To a solution of dibenzyl {5-[(dibenzyloxyphosphoryl)methyl]-2-hydroxy-3-(hydroxymethyl)phenyl}methylphosphonate (6 g, 8.92 mmol) in acetonitrile (200 mL) at -10 °C under nitrogen atmosphere were added carbon tetrachloride (6.86 g, 44.6 mmol) in acetonitrile (25 mL) dropwise, then N,N-diisopropylethylamine (2.42 g, 18.73 mmol) in acetonitrile (25 mL) dropwise, then N,N-dimethylpyridin-4-amine (0.11 g, 0.892 mmol) in acetonitrile (25 mL) dropwise, then dibenzyl phosphorochloridate (5.02 g, 16.95 mmol) in acetonitrile (25 mL) dropwise. The reaction was brought to 23 °C and stirred for 2 hours. The reaction was quenched with saturated monopotassium phosphate solution and extracted with ethyl acetate. The combined organic layers were evaporated to dryness under reduced pressure. Chromatography (Cig; 50-75% acetonitrile in water) provided the title product (4.89 g, 59%). LRMS (ESI) calcd for molecular formula [CsiHsiOnPs+H]-!- 933.26; found 933.2.Example 33Synthesis of 2,4-dibromo-6-hvdroxybenzoic acid (33)

[0991] To a solution of 2-amino-4,6-dibromobenzoic acid (1.0 mol. equiv.) in sulfuric acid (24% in water, 10 vol equiv.) and 1,4-dioxane (10 vol equiv.) at 0 °C was added sodium nitrite (1.1 mol. equiv.) portion wise. The reaction was stirred for 1 hour at 0 °C. The reaction was heated to 98 °C. To the reaction, sulfuric acid (24% in water, 10 vol equiv) was added dropwise. The reaction was stirred for 1 hour at 98 °C. The reaction was brought to 23 °C and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure to provide the title product used in the next reaction without purification.Example 34Synthesis of 3,5-dibromo-2-(hvdroxymethyl)phenol (34)

[0992] To a solution of 2,4-dibromo-6-hydroxybenzoic acid (1.0 mol. equiv.) in tetrahydrofuran (10 V) at 0 °C was added lithium aluminum hydride (2 M in tetrahydrofuran, 1.5 mol. equiv.) portion wise. The reaction was brought to 23 °C and stirred for 2 hours. The reaction was quenched with IN HC1 and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (NazSCh), and evaporated to dryness under reduced pressure. Chromatography (Cis; 10-100% acetonitrile in water buffered with 0.05% trifluoroacetic acid) provided the title product.Example 35Synthesis of 5,7-dibromo-2,2-dimethyl-

[0993] A solution of 3,5-dibromo-2-(hydroxymethyl)phenol (1.0 mol. equiv.), 2,2-dimethoxypropane (10.0 mol. equiv.), and 4-methylbenzene-l- sulfonic acid (0.1 mol. equiv.) in acetone (10 V) was stirred for 2 hours at 50 °C. The reaction was brought to 23 °C and evaporated to dryness under reduced pressure. The residue was dissolved in water and ethyl acetate. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCh; 17% ethyl acetate in petroleum ether) provided the title product.Example 36Synthesis of tetrabenzyl ((2,2-dimethyl-4H-benzo[d][1,3]dioxine-5,7- diyl)bis(methylene))bis(phosphonate) (36)

[0994] To a solution of dibenzyl methylphosphonate (20.59 g, 74.53 mmol) in tetrahydrofuran (75 mL) under nitrogen atmosphere was added TMPZnCh’LiCl (1.95 mol equiv) dropwise. The mixture wasstirred for 2 hours at 23 °C. To the mixture, tris(dibenzylideneacetone)dipalladium (4.55 g, 4.97 mmol) and Q-Phos (3.53 g, 4.969 mmol) were added. To the mixture, 5,7-dibromo-2,2-dimethyl-4H-benzo[d][l,3]dioxine (8.00 g, 24.845 mmol) was added. The reaction was stirred for 16 hours at 50 °C. The reaction was cooled to 0 °C and quenched with saturated ammonium chloride solution. The mixture was extracted with ethyl acetate. The combined organic layers were evaporated to dryness under reduced pressure. Chromatography (Cis; 40-80% acetonitrile in water) provided the title product (4.2 g, 24%) as a black-red oil.Example 37Synthesis of tetrabenzyl ((5-hydroxy-4-(hvdroxymethyl)- 1,3-phenylene)bis(methylene))bis(phosphonate)

[0995] To a solution of tetrabenzyl((2,2-dimethyl-4H-benzo[d][1,3]dioxine-5,7-diyl)bis(methylene))bis(phosphonate) (9.5 g, 13.338 mmol) in 1,4-dioxane (23.75 niL) and acetone (23.75 mL) at 0 °C under nitrogen atmosphere was added HC1 (3.0 M in water, 23.75 mL) dropwise. The reaction was stirred for 16 hours at 23 °C. The reaction was diluted with water and extracted with ethyl acetate. The combined organic layers were evaporated to dryness under reduced pressure.Chromatography (Cis; 25-60% acetonitrile in water) provided the title product (5.24 g, 72%) as a white solid.Example 38Synthesis of dibenzyl (3,5-bis((bis(benzyloxy)phosphoryl)methyl)-2-(hvdroxymethyl)phenyl) phosphate

[0996] To a solution of tetrabenzyl ((5-hydroxy-4-(hydroxymethyl)-l,3-phenylene)bis(methylene))bis(phosphonate) (4.8 g, 7.653 mmol) in acetonitrile (330 mL) at -10 °C under nitrogen atmosphere were added carbon tetrachloride (5.49 g, 35.7 mmol) in acetonitrile (50 mL) dropwise, then N,N-diisopropylethylamine (1.84 g, 11.425 mmol) in acetonitrile (50 mL) dropwise,then N,N-dimethylpyridin-4-amine (87 mg, 0.714 mmol) in acetonitrile (50 mL) dropwise, then dibenzyl phosphorochloridate (3.38 g, 9.997 mmol) in acetonitrile (50 mL) dropwise. The reaction was stirred for 2 hours at 23 °C. The reaction was quenched with saturated monopotassium phosphate solution, extracted with ethyl acetate, and evaporated to dryness under reduced pressure. Chromatography (Cis; 50-100% acetonitrile in water) provided the title product (5.24 g, 43%) as a white solid.Example 39Synthesis of 4,5-dibromo-2-(hvdroxymethyl)phenol (39)

[0997] To a solution of methyl 4,5-dibromo-2-hydroxybenzoate (23 g, 74.208 mmol) in tetrahydrofuran (120 mL) at 0 °C was added borane-tetrahydrofuran complex (1.0 M in THE, 370 mL) dropwise over 30 minutes. The reaction was brought to 23 °C and stirred for 1 hour. The reaction was quenched with icewater and extracted with ethyl acetate. The combined organic layers were dried (Na2SO4) and evaporated to dryness under reduced pressure to provide the title product (20.86 g, 100% yield) as a white solid used in the next reaction without purification. LRMS (ESI) calcd for molecular formula [C7H8Br2O2+H]+ 280.87; found 280.8.Example 40Synthesis of 6,7-dibromo-2,2-dimethyl-4H-benzo[<7][ L31dioxine (40)

[0998] To a solution of 4,5-dibromo-2-(hydroxymethyl)phenol (17 g, 60.3 mmol) and 4-methylbenzene-1-sulfonic acid (1.038 g, 6.03 mmol) in acetone (170 mL) under nitrogen atmosphere was added 2,2-dimethoxypropane (62.81 g, 603.08 mmol) portion wise. The reaction was stirred for 1 hour at 50 °C. The reaction was brought to 23 °C and evaporated to dryness under reduced pressure. Chromatography (Cis; 30-80% acetonitrile in water buffered with 10 mmol / L ammonium bicarbonate) provided the title product (16 g, 82%) as a yellow oil. LRMS (ESI) calcd for molecular formula [C10H10Br2O2+NH4]+ 336.94; found 336.3.Example 41Synthesis of tetrabenzyl ((2,2-dimethyl-4HT>enzo [l,3]dioxine-6,7-diyl)bis(methylene))bis(phosphonate) (41)

[0999] To a solution of dibenzyl methylphosphonate (24.01 g, 86.98 mmol) in tetrahydrofuran (1 mL) under nitrogen atmosphere was added TMPZnCl·LiCl (717.5 mL, 57.41 mmol) dropwise. The mixture was stirred for 2 hours at 23 °C. To the mixture, tris(dibenzylideneacetone)dipalladium (7.965 g, 8.69 mmol) and Q-Phos (6.175 g, 8.69 mmol) were added portion wise. To the mixture, 6,7-dibromo-2,2-dimethyl-4H-l,3-benzodioxine (14 g, 43.49 mmol) was added dropwise. The reaction was stirred for 16 hours at 50 °C. The reaction was cooled to 0 °c and quenched by the addition of saturated ammonium chloride solution. The aqueous layer was extracted with ethyl acetate. The combined organic layers were evaporated to dryness under reduced pressure. Chromatography (Cis; 40-80% acetonitrile in water) provided the title product (9.88 g, 32%) as a red oil. LRMS (ESI) calcd for molecular formula [C40H42O8P2+H]+ 713.24; found 713.4.Example 42Synthesis of tetrabenzyl ((4-hvdroxy-5-(hvdroxymethyl)-l,2-phenylene)bis(methylene))bis(phosphonate)(42)

[1000] To a solution of tetrabenzyl ((2,2-dimethyl-4H-benzo[d][1,3]dioxine-6,7-diyl)bis(methylene))bis(phosphonate) (9.7 g, 13.62 mmol) in 1,4-dioxane (24.25 mL) and acetone (24.25 mL) at 0 °C under nitrogen atmosphere was added HC1 (2 M in water, 24.25 mL) dropwise. The reaction was brought to 23 °C and stirred for 16 hours. The reaction was diluted with water and extracted with ethyl acetate. The combined organic layers were evaporated to dryness under reduced pressure.Chromatography (Cis; 25-60% acetonitrile in water) provided the title product (7.24 g, 79%) as a white solid. LRMS (ESI) calcd for molecular formula [C37H38O8P2+H]+ 673.20; found 673.3.Example 43Synthesis of dibenzyl (4,5-bis((bis(benzyloxy)phosphoryl)methyl)-2-(hvdroxymethyl)phenyl) phosphate11001| l’o a solution of tetrabenzyl ((4-hydroxy-5-(hydroxymethyl)-l,2 phenylene)bis(methylene))bis(phosphonate) (5.4 g, 8.028 mmol) in acetonitrile (340 mL) at -10 °C under nitrogen atmosphere were added carbon tetrachloride (6.17 g, 40.14 mmol) in acetonitrile (50 mL) dropwise, then N,N-diisopropylethylamine (2.08 g, 16.056 mmol) in acetonitrile (50 mL) dropwise, then N,N-dimethylpyridin-4-amine (0.1 g, 0.819 mmol) in acetonitrile (50 mL) dropwise, then dibenzyl phosphorochloridate (3.81 g, 12.845 mmol) in acetonitrile (50 mL) dropwise. The reaction was brought to 23 °C and stirred for 2 hours. The reaction was quenched with saturated monopotassium phosphate solution and extracted with ethyl acetate. The combined organic layers were evaporated to dryness under reduced pressure. Chromatography (Cig; 50-90% acetonitrile in water) provided the title product (5.9 g, 79%) as a light- yellow oil. LRMS (ESI) calcd for molecular formula [CsiHsiOnPs+H]-!- 933.26; found 933.3.Example 44Synthesis of 3-bromo-4-(hvdroxymethyl)phenol (44)

[1002] To a solution of 3-bromo-4-(hydroxymethyl)phenol (9.6 g, 47.282 mmol) in dichloromethane (96 mL) under nitrogen were added terr-butyl(chloro)di(methyl)silane (17.2 g, 118.205 mmol) and imidazole (16.09 g, 236.41 mmol). The reaction was stirred for 2 hours at 23 °C. The reaction was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (Si O2; 100% petroleum ether) provided the title product (14.5 g, 71%) as a colorless oil. LRMS (ESI) calcd for molecular formula [C19H35BrO2Si2+H]+ 431.14; found 432.00.Example 45Synthesis of dibenzyl (5-((rert-butyldimethylsilyl)oxy)-2-(((rert- butyldimethylsilyl)oxy)methyl)phenyl)phosphonate (45)oris

[1003] To a microwave vial, (3-bromo-4-(((tert-butyldimethylsilyl)oxy)methyl)phenoxy)(tert-butyl)dimethylsilane (1 g, 2.317 mmol), cesium carbonate (2.26 g, 6.951 mmol) and dibenzyl phosphonate (1.82 g, 6.951 mmol), tris(dibenzylideneacetone)dipalladium (0.21 g, 0.232 mmol) and X-phos (0.22 g, 0.463 mmol) were added. The vial was placed under inert atmosphere via evacuation and backfilling with nitrogen gas for three cycles. 1,4-Dioxane (8 mL) and water (2 niL) were added via syringe. The reaction was stirred for 30 minutes at 120 °C in a microwave reactor. The reaction was cooled to 23 °C. An additional 24 batches were submitted in parallel. The batches were combined and evaporated to dryness under reduced pressure. Chromatography (Cis; 80-100% acetonitrile in water) provided the title product (2.8 g, 8%) as a pale-yellow oil. TRMS (ESI) calcd for molecular formula [C33H49O5PSi2+H]+ 613.29; found 613.30.Example 46Synthesis of dibenzyl (2-(((ren-butyldimethylsilyl)oxy)methyl)-5-hvdroxyphenyl)phosphonate (46)

[1004] To a solution of dibenzyl (5-((tcrt-butyldimcthylsilyl)oxy)-2-(((tcrt-butyldimethylsilyl)oxy)methyl)phenyl)phosphonate (1.65 g, 2.69 mmol) in tetrahydrofuran (16 mL) was added tetrabutylammonium fluoride (0.35 g, 1.346 mmol). The reaction was stirred for 1 hour at 23 °C. The reaction was evaporated to dryness under reduced pressure. Chromatography (Cis; 80-100% acetonitrile in water) provided the title product (1.54 g, 69%) as a pale-yellow solid. ERMS (ESI) calcd for molecular formula [C27H35O5PSi+H]+ 499.20; found 499.25.Example 47Synthesis of dibenzyl (3-(bis(benzyloxy)phosphoryl)-4-(( butyldimethylsilyl)oxy)niethyl)phenyl)phosphate (47)

[1005] To a solution of dibenzyl 2-{ [(tert-butyldimethylsilyl)oxy]methyl]-5-hydroxyphenylphosphonate (950 mg, 1.905 mmol) in acetonitrile (10 mL) at -10 °C under nitrogen atmosphere were added 4-dimethylaminopyridine (22.91 mg, 0.188 mmol) and, V, / V-diisopropylclhylamine (462.68 mg, 3.581 mmol). The mixture was stirred for 5 minutes at -10 °C. To the mixture, carbon tetrachloride (1310.97 mg, 8.525 mmol) dropwise, then dibenzyl phosphite (894 mg, 3.41 mmol) in acetonitrile (10 mL) were added. The reaction was stirred for 1 hour at 0 °C. The reaction was evaporated to dryness under reduced pressure. Chromatography (Cis; 80-100% acetonitrile in water) provided the title product (1.8 g, 90%) as a pale-yellow oil. LRMS (ESI) calcd for molecular formula [C4iH4sOsP2Si+Na]+ 781.24; found 781.25.Example 48Synthesis of dibenzyl (3-(bis(benzyloxy)phosphoryl)-4-(hvdroxymethyl)phenyl) phosphate (48)

[1006] To a solution of dibenzyl (3-(bis(benzyloxy)phosphoryl)-4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl) phosphate (1.7 g, 2.2 mmol) in tetrahydrofuran (17 mL) at 0 °C was added pyridine hydrofluoride (0.69 g, 22.4 mmol, 65%). The reaction was stirred for 16 hours at 0 °C. The reaction was quenched by pouring it into ice-water. The mixture was basified to pH 8 with sodium bicarbonate. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (Cis; 60-80% acetonitrile in water) provided the title product (830 mg, 58%) as a yellow oil. LRMS (ESI) calcd for molecular formula [C35H340sP2+H]+ 645.17; found 645.15.Example 49Synthesis of tert-butyl((4-( butyldimethylsilyl)oxy)benzyl)oxy)dimethylsilane (49)

[1007] To a solution of 4-(hydroxymethyl)phenol (50 g, 403 mmol) in A, A-dimethylformamide (1 L) under nitrogen atmosphere was added imidazole (137 g, 2.01 mol). The mixture was slirred for 10 minutes. To the mixture was added terr-butyl(chloro)di(methyl)silane (152 g, 1.01 mol) dropwise. The reaction was stirred for 24 hours at 23 °C. The reaction was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, dried (NajSCT), and evaporated to dryness under reduced pressure. Chromatography (SiCE; 5% ethyl acetate in petroleum ether) provided the title product (128.5 g, 90%) as a white solid. LRMS (ESI) calcd for molecular formula [CisFhsChSi?-H]- 351.23; found 351.00.Example 50Synthesis of 4-(((tert-butyldimethylsilyl)oxy)methyl)phenol (50)

[1008] A solution of tert-butyl(4-{[(tert-butyldimethylsilyl)oxy]methyl}phenoxy)dimethylsilane (110 g, 312 mmol) and tetrabutylammonium fluoride (81.6 g, 312 mmol) in tetrahydrofuran (3.08 L) was stirred for 20 min at 0 °C under nitrogen atmosphere. The reaction was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCT; 10% ethyl acetate in petroleum ether) provided the title product (70.4 g, 95%) as a light-yellow oil.Example 51Synthesis of 2-bromo-4-(((re -butyldimethylsilyl)oxy)methyl)phenol (51)

[1009] To a solution of 4-{ [(tert-butyldimethylsilyl)oxy]methyl}phenol (10 g, 42.0 mmol) in N, N-dimethylformamide (100 mb) at 0 °C under nitrogen atmosphere was added 1 -bromopyrrolidine-2, 5-dionc (8.36 g, 47.0 mmol). The reaction was quenched with ice-water and extracted with ethyl acetate. The combined organic layers were washed with water, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (Cis; 50-100% acetonitrile in water) provided the title product (5.9 g, 44%) as a light- yellow oil. LRMS (ESI) calcd for molecular formula [CislLiBrCLSi-H]- 315.05; found 315.00.Example 52Synthesis of dibenzyl (2-bromo-4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl) phosphate (52)

[1010] To a solution of 2-bromo-4-{[(tert-butyldimethylsilyl)oxy]methyl [phenol (4 g, 12.6 mmol) in acetonitrile (200 mL) at -10°C under nitrogen atmosphere were added 4-dimethylaminopyridine (0.15 g, 1.26 mmol), A -diisopropylelhylamine (3.42 g, 26.5 mmol), and carbon tetrachloride (9.69 g, 63.0 mmol). The mixture was stirred for 10 minutes at -10 °C. To the mixture, dibenzyl phosphite (6.28 g, 24.0 mmol) was added dropwise. The reaction was stirred for 1 hour at -10 °C. The reaction was quenched with saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate. The combined organic layers were washed with water, dried (NaiSO^, and evaporated to dryness under reduced pressure. Chromatography (Cig; 50-100% acetonitrile in water buffered with 10 mmol / L ammonium bicarbonate) provided the title product (6 g, 82%) as a light-yellow oil. LRMS (ESI) calcd for molecular formula [C27H34BrOsSi+H]+ 577.11; found 577.00.Example 53Synthesis of dibenzyl (5-(((terr-butyldimethylsilyl)oxy)methyl)-2-hvdroxyphenyl)phosphonate (53)

[1011] To a solution of dibenzyl 2-bromo-4-{[(tert-butyldimethylsilyl)oxy]methyl]phenyl phosphate (6 g, 10.4 mmol) in tetrahydrofuran (240 mL) at -78 °C under nitrogen atmosphere was added n-butyllithium solution (2.5 M in hexanes, 5 mL, 12.5 mmol) dropwise. The reaction was stirred for 3 hours at -78 °C. The reaction was quenched with saturated ammonium chloride solution, brought to 23 °C, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (Cis; 50-100% acetonitrile in water buffered with 10 mmol / L ammonium bicarbonate) provided the title product (4.5 g, 87%) as a light-yellow oil. LRMS (ESI) calcd for molecular formula [C27H35O5PSi+H]+ 499.20; found 499.00.Example 54Synthesis of dibenzyl (2-(bis(benzyloxy)phosphoryl)-4-(((n?rt-butyldimethylsilyl)oxy)methyl)phenyl) phosphate (54)

[1012] To a solution of dibenzyl 5-{ [(tert-butyldimethylsilyl)oxy]methyl]-2-hydroxyphenylphosphonate (4.5 g, 9.03 mmol) in acetonitrile (225 mL) at -10 °C under nitrogen atmosphere were added 4-dimethylaminopyridine (0.11 g, 0.903 mmol), A'-diisopropylcihylaminc (2.45 g, 19.0 mmol), and carbon tetrachloride (6.94 g, 45.1 mmol) followed by dibenzyl phosphite (4.50 g, 17.1 mmol) dropwise. The reaction was stirred for 1 hour at -10 °C. The reaction was quenched with saturated sodium bicarbonate solution. The mixture was brought to 23 °C and extracted with ethyl acetate. The combined organic layers were washed with water, dried (NaiSC, and evaporated to dryness under reduced pressure. Chromatography (Cis; 50-100% acetonitrile in water buffered with 10 mmol / L ammonium bicarbonate) provided the title product (5.5 g, 80%) as a light-yellow oil. TRMS (ESI) calcd for molecular formula [C4iH48O8P2Si+H]+ 759.26; found 759.00.Example 55Synthesis of dibenzyl (2-(bis(benzyloxy)phosphoryl)-4-(hvdroxymethyl)phenyl) phosphate (55)

[1013] To a solution of dibenzyl 5-{ [(tert-butyldimethylsilyl)oxy]methyl}-2-[(dibenzyloxyphosphoryl)oxy] phenylphosphonate (5.5 g, 7.25 mmol) in ethanol (68.7 mL) under nitrogen atmosphere was added 2 M HC1 (13.7 mL). The reaction was stirred for 2 hours at 23 °C. The mixture was brought to pH 7 with saturated sodium bicarbonate solution. The reaction was extracted with ethyl acetate. The combined organic layers were washed with water, dried (ISfeSCL), and evaporated to dryness under reduced pressure to afford the title product (5.0 g, crude) as a light-yellow oil used in the next step without purification. LRMS (ESI) calcd for molecular formula [C35H34O8P2+H]+ 645.17; found 645.00.Example 56Synthesis of tert-butyl((4-((tert-butyldimethylsilyl)oxy)-3-methylbenzyl)oxy)dimethylsilane (56)

[1014] To a solution of 4-(hydroxymethyl)-2-methylphenol (9.3 g, 0.066 mol) in N, N-dimethylformamide (372 mL) at 0 °C was added imidazole (18.1 g, 0.266 mol) and tert-butyl(chloro)dimethylsilane (40.1 g, 0.266). The reaction was stirred for 4 hours at 23 °C. The reaction was cooled to 0 °C and quenched with saturated ammonium chloride solution. The mixture was brought to 23 °C and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCL; 0-1% ethyl acetate in petroleum ether) provided the title product (17.7 g, 99%) as a colorless oil.Example 57Synthesis of 4-(( butyldimethylsilyl)oxy)methyl)-2-methylphenol (57)

[1015] To a solution of tert-butyl(4-{[(tert-butyldimethylsilyl)oxy]methyl}-2-methylphenoxy)dimethylsilane (17.0 g, 0.046 mol) in tetrahydrofuran (476 mL) at 0 °C was added tetra-n-butylammonium fluoride (46.5 L, 0.046 mol). The reaction was stirred for 30 minutes at 0 °C. The reaction was brought to 23 °C and quenched with saturated ammonium chloride solution and 2-methoxy-2-methylpropane. The aqueous layer was extracted with 2-methoxy-2-methylpropane. The combined organic layers were washed with brine, dried (ISfeSCL), and evaporated to dryness under reduced pressure. Chromatography (SiCL; 5-10% EtOAc in petroleum ether) provided the title product (10.3 g, 88%) as a light- yellow oil.Example 58Synthesis of 2-bromo-4-(((terr-butyldimethylsilyl )oxy)methyl )-6-methylphenol (58)

[1016] To a solution of 4-{ [(tert-butyldimethylsilyl)oxy]methyl}-2-methylphenol (10.0 g, 0.4 mol) in i-dimethylformamide (250 mL) was added 1 -bromopyrrolidine-2, 5-dione (7.9 g, 0.44 mol) in N, N-dimethylformamide (250 mL). The reaction was stirred for 90 minutes at 23 °C. The reaction was quenched with ice-water and extracted with dichloromethane. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCh; 0-1% ethyl acetate in petroleum ether) provided the title product (8.6 g, 66%) as a light-yellow oil.Example 59Synthesis of dibenzyl (2-bromo-4-(((tert-butyldimethylsilyl )oxy)methyl )-6-methylphenyl) phosphate (59)

[1017] To a solution of 2-bromo-4-{[(tert-butyldimethylsilyl)oxy]methyl}-6-methylphenol (8.5 g, 0.026 mol) in anhydrous acetonitrile (255 mL) at -10 °C were added carbon tetrachloride (12.4 mL, 0.129 mol), 4-dimethylaminopyridine (0.3 g, 0.003 mol,) and A iisopropylclhylaininc (7.0 g, 0.054 mol). To the reaction, dibenzyl phosphite (12.8 g, 0.49 mol) was added dropwise. The reaction was stirred for 2 hours at -10 °C. The reaction was quenched with ice- water. The reaction was brought to 23 °C and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCL; 10-13% ethyl acetate in petroleum ether) provided the title product (12.2 g, 80%) as a white solid.Example 60Synthesis of dibenzyl (5-(( )methyl)-2-hydroxy-3-methylphenyl)phosphonate

[1018] To a solution of dibenzyl 2-bromo-4-{ [(tert-butyldimethylsilyl)oxy]methyl]-6-methylphenyl phosphate (5.5 g, 0.009 mol) in tetrahydrofuran (220 mL) at -78 °C under nitrogen atmosphere was added n-bulyllilhium (4.5 mL, 0.011 mol) dropwise over 30 minutes. The reaction was slowly brought to 23 °C and stirred for 3 hours. The reaction was quenched with saturated ammonium chloride solution and extracted with dichloromethane. The combined organic layers were washed with brine, dried (Na2SO4),and evaporated to dryness under reduced pressure. Chromatography (SiCh; 4-5% ethyl acetate in petroleum ether) provided the title product (3.3 g, 69%) as a light-yellow oil.Example 61Synthesis of dibenzyl (2-(bis(benzyloxy )phosphoryl )-4-(((terr-butyldimethylsilyl)oxy)methyl)-6- methylphenyl) phosphate (61)

[1019] To a solution of dibenzyl 5-{ [(tert-butyldimethylsilyl)oxy]methyl}-2-hydroxy-3-methylphenylphosphonate (3.0 g, 0.006 mol) in acetonitrile (189 mL) at -10 °C were added carbon tetrachloride (2.8 mL, 0.029 mol), 4-dimethylaminopyridine (0.07 g, 0.586 mmol), and N, N-diisopropylethylamine (1.6 g, 0.012 mol), then dibenzyl phosphite (2.9 g, 0.011 mol) dropwise. The reaction was stirred for 3 hours at -10 °C. The reaction was brought to 0 °C, quenched with ice-water, then brought to 23 °C. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine (3x), dried (Na2SO4), and evaporated to dryness under reduced pressure.Chromatography (SiCh; 25-30% ethyl acetate in petroleum ether) provided the title product (3.1 g, 68%) as a white oil.Example 62Synthesis of dibenzyl (2-(bis(benzyloxy)phosphoryl)-4-(hvdroxymethyl)-6-methylphenyl) phosphate (62)

[1020] To a solution of dibenzyl 5-{ [(tert-butyldimethylsilyl)oxy]methyl }-2-[(dibenzyloxyphosphoryl)oxy]-3-methylphenylphosphonate (3.0 g, 0.004 mol) in tetrahydrofuran (30 mL) at 0 °C was added pyridine hydrofluoride (2.4 g, 0.019 mol). The reaction was brought to 23 °C and stirred for 24 hours. The reaction was quenched with ice- water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCL; 100% EtOAc in petroleum ether) provided the title product (1.9 g, 76%) as a yellow oil.Example 63Synthesis of 7-bromo-4,4,5-trimethylchroman-2-one (63)

[1021] To a solution of 3-bromo-5-methylphenol (50.0 g, 268.8 mmol) and methyl 3-methylbut-2-enoate (33.7 g, 295.7 mmol) in methanesulfonic acid (51.6 g, 537.6 mmol) at room temperature. The reaction was stirred for 3 hours at 120 °C. The reaction was cooled to room temperature and quenched with icewater. The mixture was extracted with ethyl acetate. The combined organic layers were washed with 10% sodium bicarbonate solution and brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCL; 50% ethyl acetate in petroleum ether) provided the title product (10.2 g, 14%) as an off-white solid. LRMS (ESI) calcd for molecular formula [CnHisBrCL+H]-!- 269.01; found 269.00.Example 64Synthesis of 5-bromo-2-(4-hvdroxy-2-methylbutan-2-yl)-3-methylphenol (64)

[1022] To a solution of 7-bromo-4,4,5-trimethylchroman-2-one (10.2 g, 38.1 mmol) in tetrahydrofuran (102 mL) at 0 °C was added lithium aluminum hydride (2 M in THF, 20.9 mL) dropwise. The reaction was brought to 23 °C and stirred for 2.5 hours. The reaction was poured into a mixture (1:1) of 10% potassium sodium tartrate solution and 10% ammonium chloride solution. The mixture was stirred for 30 minutes at 23 °C. The aqueous phase was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure.Chromatography (SiCh; 100% ethyl acetate in petroleum ether) provided the title product (8.9 g, 86%) as an off-white solid. LRMS (ESI) calcd. for molecular formula [C^HpBrCh-H]- 271.04; found 271.10.Example 65Synthesis of (3-(4-bromo-2- bulyldimelhylsilyl)oxy)-6-mcihylnhcnyl)-3-mclhylbuioxy)( / c / 7-butvDdimethylsilane (65)

[1023] A solution of 5-bromo-2-(4-hydroxy-2-methylbutan-2-yl)-3-methylphenol (8.9 g, 32.7 mmol), tert-butyl(chloro)dimethylsilane (12.8 g, 85.1 mmol) and imidazole (11.1 g, 163.6 mmol) in N, N-dimethylformamide (89 mL) was stirred for 5 hours at 65 °C. The reaction was brought to 23 °C and quenched with ice-water. The mixture was cxlracted with petroleum ether. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure.Chromatography (SiCh; 9% ethyl acetate in petroleum ether) provided the title product (15.1 g, 92%) as a colorless oil. II NMR (400 MHz, CDCh): 56.88-6.73 (m, 2H), 3.46 (dd,.7 = 8.0, 7.0 Hz, 2H), 2.47 (s, 3H), 2.20-2.06 (m, 2H), 1.49 (s, 6H), 1.02 (s, 9H), 0.83 (s, 9H), 0.32 (s, 6H), -0.05 (s, 6H).Example 66Synthesis of dibenzyl (3-( butyldimethylsilyl)oxy)-4-(4-( butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-5-methylphenyl)phosphonate (66)

[1024] To a microwave vial were added (3-(4-bromo-2-((tert-butyldimethylsilyl)oxy)-6-methylphenyl)-3-methylbutoxy)(tert-butyl)dimethylsilane (1.0 g, 2.0 mmol), triethylamine (242.9 mg, 2.4 mmol) and dibenzyl phosphonate (524.0 mg, 2.0 mmol) in 1,4-dioxane (15 mL). The vial was placed under inert atmosphere via evacuation and backfilling with nitrogen gas for three cycles. To the vial, tetrakis(triphenylphosphane)palladium(0) (231.1 mg, 0.2 mmol) was added. The vial was placed under inert atmosphere via evacuation and backfilling with nitrogen gas for three cycles. The reaction was stirred for 30 minutes at 120 °C in a microwave reactor. The reaction was cooled to 23 °C. An additional 13 batches were submitted in parallel. The mixtures were combined and filtered. The filtrate was evaporated to dryness under reduced pressure to afford the title product (29.1 g, crude) as a yellow oil. LRMS (ESI) calcd for molecular formula [C38H59O5PSi2+H]+ 683.36; found 683.35.Example 67Synthesis of dibenzyl (4-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3-hydroxy-5- methylphenyl)phosphonate (67)

[1025] To a solution of dibenzyl (3-((tert-butyldimethylsilyl)oxy)-4-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-5-methylphenyl)phosphonate (29.0 g, 42.52 mmol) in N,N-dimethyl formamide (290 mb) was added lithium hydroxide (1.02 g, 42.52 mmol). The reaction was stirred for 3 hours at 23 °C. The reaction was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine (3x), dried (Na2SO4), and evaporated to dryness under reduced pressure.Chromatography (SiCh; 67% ethyl acetate in petroleum ether) provided the title product (3.0 g, 18% for two steps) as a yellow oil. LRMS (ESI) calcd for molecular formula [C32H45O5PSi+H]+ 569.28; found 569.30.Example 68Synthesis of dibenzyl (5-(bis(benzyloxy)phosphoryl)-2-(4-( butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3-methylphenyl) phosphate (68)

[1026] To a solution of dibenzyl (4-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3-hydroxy-5-methylphenyl)phosphonate (2.6 g, 4.58 mmol) in tetrahydrofuran (26 mL) under nitrogen atmosphere at 0 °C was added 60% sodium hydride (238.0 mg, 5.95 mmol). The reaction was stirred for 15 min at 0 °C. To the reaction, dibenzyl phosphorochloridate (1.76 g, 5.95 mmol) was added. The reaction was slowly brought to 23 °C and stirred for 1 hour. The reaction was quenched with ice-water and extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiO2; 17% ethyl acetate in petroleum ether)provided the title product (2.8 g, 74%) as a yellow oil. LRMS (ESI) calcd for molecular formula [C46H58O8P2Si+H]+ 829.34; found 829.30.Example 69Synthesis of dibenzyl (5-(bis(benzyloxy)phosphoryl)-2-(4-hvdroxy-2-methylbutan-2-yl)-3-methylphenyl) phosphate (69)

[1027] To a solution of dibenzyl (5-(bis(benzyloxy)phosphoryl)-2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3-methylphenyl) phosphate (2.5 g, 3.02 mmol) in tetrahydrofuran (25 mL) was added pyridine hydrofluoridc (0.6 g, 6.04 mmol). The reaction was stirred for 2 hours at 23 °C. The reaction was poured into ice-water. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure.Chromatography (SiCh; 67% ethyl acetate in petroleum ether) provided the title product (1.3 g, 60%) as a yellow oil. LRMS (ESI) calcd for molecular formula [C40H44O8P2+H]+ 715.25; found 715.20.Example 70Synthesis of 3-(4-(bis(benzyloxy)phosphoryl)-2-((bis(benzyloxy)phosphoryl)oxy)-6-methylphenyl)-3- methylbutanoic acid (70)

[1028] To a solution of dibenzyl (5-(bis(benzyloxy)phosphoryl)-2-(4-hydroxy-2-methylbutan-2-yl)-3-methylphenyl) phosphate (600 mg, 0.8 mmol) in acetonitrile (6.0 mL) and water (6.0 mL) under nitrogen atmosphere at 0 °C were added (2,2,6,6-tetramethylpiperidin-l-yl)oxyl (6.6 mg, 0.1 mmol), monopotassium phosphate (57.2 mg, 0.4 mmol), dipotassium phosphate (73 mg, 0.4 mmol), sodium chloride (142.4 mg, 1.3 mmol) and sodium hypochlorite (238 mg, 1.0 mmol). The reaction was brought to 23 °C and stirred for 2 hours. The reaction was quenched with saturated sodium sulfite solution and acidified to pH 2-3 with 2 M HC1. The reaction was extracted with dichloromethane. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressureto afford the title product (642.8 mg, 84%) as a yellow oil. LRMS (ESI) calcd for molecular formula [C40H42O9P2+H]+ 729.23; found 729.20.Example 71Synthesis of 5-bromo-7-hvdroxy-4,4-dimethylchroman-2-one (71)

[1029] A mixture of 5-bromobenzene-l,3-diol (100 g, 531.9 mmol) and methyl 3-methylbut-2 -enoate (66.7 g, 585.1 mmol) in methanesulfonic acid (102 g, 1063.8 mmol) was stirred for 12 hours at 80 °C. The reaction was brought to 23 °C and quenched with ice water. The mixture was extracted with ethyl acetate. The combined organic layers were washed with 10% sodium bicarbonate solution and brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiO2; 50% ethyl acetate in petroleum ether) provided the title product (51 g, 36%) as an off-white solid. LRMS (ESI) calcd for molecular formula [CnHnBrO3+H]+ 270.99; found 271.00.Example 72Synthesis of 5-bromo-4,4-dimethyl-2-oxochroman-7-yl trifluoromethanesulfonate (72)

[1030] To a solution of 5-bromo-7-hydroxy-4,4-dimethylchroman-2-one (50.0 g, 185.2 mmol) and pyridine (29.3 g, 370.4 mmol) in dichloromethane (500 mL) was added trifluoromethanesulfonic anhydride (52.2 g, 185.2 mmol). The reaction was stirred for 12 hours at 23 °C. The reaction was poured into ice-water. The mixture was evaporated under reduced pressure to remove dichloromethane. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure to provide the title product (70 g, 92%) as a yellow oil. 1H NMR (300 MHz, CDCl3); δ7.34 (d, J = 2.7 Hz, 1H), 7.00 (d, J = 2.7 Hz, 1H), 2.69 (s, 2H), 1.60 (s, 6H).Example 73Synthesis of 5-bromo-4,4-dimethylchroman-2-one (73)

[1031] To a solution of 5-bromo-4,4-dimethyl-2-oxochroman-7-yl trifluoromethanesulfonate (67.0 g, 166.7 mmol) and triethylsilane (96.7 g, 833.5 mmol) in N,N-dimethyl formamide (670 mL) under nitrogen atmosphere were added palladium(II) acetate (7.5 g, 33.3 mmol) and (propane-1,3-diyl)bis(diphenylphosphane) (13.7 g, 33.3 mmol). The reaction was stirred for 12 hours at 45 °C. The reaction was brought to 23 °C and quenched with ice-water. The mixture was extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiO2; 25% ethyl acetate in petroleum ether) provided the title product (22 g, 52%) as a yellow oil. LRMS (ESI) calcd for molecular formula [C11H11BrO2+H]+ 254.99; found 255.05.Example 74Synthesis of 3-bromo-2-(4-hydroxy-2-methylbutan-2-yl)phenol (74)

[1032] To a solution of 5-bromo-4,4-dimethylchroman-2-one (22.0 g, 86.6 mmol) in tetrahydrofuran (220 mL) at 0 °C was added lithium aluminum hydride (2M in THF, 48.0 mL) dropwise. The reaction was brought to 23 °C and stirred for 2.5 hours. The reaction was poured into a mixture (1:1) of 10% potassium sodium tartrate and 10% ammonium chloride solution at 0 °C. The mixture was stirred for 30 minutes at 23 °C. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure to provide the title product (21.6 g, 97%) as a colorless oil. LRMS (ESI) calcd for molecular formula [C11H15BrO2-H]-257.03; found 256.90.Example 75Synthesis of (3-bromo-2-(4-((re -butyldimethylsilyl)oxy)-2-methylbutan-2-yl)phenoxy)(rert- butvDdimethylsilane (75)

[1033] A solution of 3-bromo-2-(4-hydroxy-2-methylbutan-2-yl)phenol (21.0 g, 81.4 mmol), tert-butyl(chloro)dimethyl silane (31.5 g, 211.6 mmol) and imidazole (27.7 g, 407.0 mmol) in N,N-dimethylformamide (210 mL) was stirred for 5 hours at 65 °C. The reaction was cooled to 23 °C and quenched with ice- water. The mixture was extracted with petroleum ether. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure.Chromatography (SiCh; 9% ethyl acetate in petroleum ether) provided the title product (16.2, 41%) as a colorless oil. 1H NMR (300 MHz, CDCl3): δ7.22 (dd, J = 7.8, 1.6 Hz, 1H), 6.83 (t, J = 8.0 Hz, 1H), 6.75 (dd, J= 8.1, 1.6 Hz, 1H), 3.57-3.45 (m, 2H), 2.31 (dd, J= 8.5, 7.1 Hz, 2H), 1.65 (s, 6H), 1.03 (s, 9H), 0.86 (d, J = 2.7 Hz, 9H), 0.33 (s, 6H), -0.01 (s, 6H).Example 77Synthesis of dibenzyl (3-( butyldimethylsilyl)oxy)-2-(4-((ren-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)benzyl)phosphonate (77)

[1034] To a solution TMPZnCl·LiCl (92.6 mL, 0.33 M in THF, 30.6 mmol) and dibenzyl methylphosphonate (7.7 g, 27.8 mmol) in tetrahydrofuran (45 mL) pre-stirred for 2 hours at 23 °C was added (3-bromo-2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)phenoxy)(tert-butyl)dimethylsilane (9.0 g, 18.5 mmol). To the reaction tris(dibenzylideneacetone)dipalladium (1.05 g, 1.9 mmol) and Q-Phos (1.31 g, 1.9 mmol) were added. The reaction was placed under inert atmosphere via evacuation and backfilling with nitrogen gas for three cycles. The reaction was stirred for 3 hours at 50 °C. The reaction was cooled to 23 °C and quenched with saturated ammonium chloride solution. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure to afford the title product (18.4 g, crude) as a yellow oil used in the next step without purification. LRMS (ESI) calcd for molecular formula [C38H59O5PSi2+Na]+ 705.35; found 705.45.Example 78Synthesis of dibenzyl (2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3- hydroxybenzvDphosphonate (78)

[1035] To a solution of dibenzyl (3-((tert-butyldimethylsilyl)oxy)-2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)benzyl)phosphonate (16.2 g, 23.8 mmol) in N,N-dimethylformamide (162 mL) was added lithium hydroxide (1.4 g, 23.8 mmol). The reaction was stirred for 3 hours at 23 °C. The reaction was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure to provide the title product (4.4 g, 47.5%) as a yellow oil. LRMS (ESI) calcd for molecular formula [C32H45O5PSi+Na]+ 569.28; found 569.25.Example 79Synthesis of dibenzyl (3-((bis(benzyloxy)phosphoryl)methyl)-2-(4-((ten-butyldimethylsilyl)oxy)-2- methylbutan-2-yl)phenyl) phosphate (79)

[1036] To a solution of dibenzyl (2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3-hydroxybenzyl)phosphonate (4.5 g, 7.9 mmol) in tetrahydrofuran (45 mL) at 0 °C was added 60% sodium hydride (411.8 mg, 10.3 mmol). The reaction was stirred for 15 minutes at 0 °C. To the reaction, dibenzyl phosphorochloridate (2.3 g, 10.3 mmol) was added. The reaction was stirred for 1 hour at 23 °C. The reaction was quenched with ice-water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4). and evaporated to dryness under reduced pressure to provide the title product (6.6 g, crude) as a yellow oil used in the next step without purification. LRMS (ESI) calcd for molecular formula [C46H58O8P2Si+H]+ 829.34; found 829.35.Example 80Synthesis of dibenzyl (3-((bis(benzyloxy)phosphoryl)methyl)-2-(4-hvdroxy-2-methylbutan-2-yl)phenyl) phosphate (80)

[1037] To a solution of dibenzyl (3-((bis(benzyloxy)phosphoryl) methyl)-2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)phenyl) phosphate (6.6 g, 8.0 mmol) in tetrahydrofuran (66 mL) was added pyridine hydrofluoride (4.7 g, 16.0 mmol). The reaction was stirred for 2 hours at 23 °C. The reaction was poured into ice-water. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiO2; 67% ethyl acetate in petroleum ether) provided the title product (1.45 g, 25%) as a yellow oil. LRMS (ESI) calcd for molecular formula [C40H44O8P2+H]+ 715.25; found 715.25.Example 81Synthesis of 3-(2-((bis(benzyloxy)phosphoryl)methyl)-6-((bis(benzyloxy)phosphoryl)oxy)phenyl)-3- methylbutanoic acid (81)

[1038] To a solution of dibenzyl (3-((bis(benzyloxy)phosphoryl) methyl)-2-(4-hydroxy-2-methylbutan-2-yl)phenyl) phosphate (1.5 g, 2.1 mmol) in acetonitrile (15 mL) and water (15 mL) under nitrogen atmosphere at 0 °C were added (2,2,6,6-tetramethylpiperidin-l-yl)oxyl (16.5 mg, 0.1 mmol), monopotassium phosphate (143.0 mg, 1.0 mmol), dipotassium phosphate (183.0 mg, 1.0 mmol), sodium chlorite (356.1 mg, 3.2 mmol), and sodium hypochlorite (596.4 mg, 2.5 mmol). The reaction was slowly warmed to 23 °C and stirred for 2 hours. The reaction was quenched with saturated sodium sulfite solution. The mixture was acidified to pH 2-3 with 2 M HC1. The mixture was extracted with dichloromethane. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure to provide the title product (1.4 g, 92%) as a yellow oil.LRMS (ESI) calcd for molecular formula [C40H42O9P2+H]+ 729.23; found 729.20.Example 82Synthesis of 3-(6-((bis(benzyloxy)phosphoryl)methyl)-2-((bis(benzyloxy)phosphoryl)oxy)-3- methylphenyl)-3-methylbutanoic acid (82)

[1039] LRMS (ESI) calcd for molecular formula [C41H44O7P2+H]+ 743.246; found 743.3.rH NMR (400 MHz, DMSO) δ 11.89 (s, 1H), 7.47-7.13 (m, 21H), 6.99 (d, J = 7.9 Hz, 1H), 5.08-4.83 (m, 8H), 3.64 (d, J = 22.6 Hz, 2H), 2.93 (s, 2H), 2.22 (d, J = 1.9 Hz, 3H), 1.54 (s, 6H).31P NMR (162 MHz, DMSO) δ 27.82, -6.27.Example 83Synthesis of 3-(6-((bis(benzyloxy)phosphoryl)methyl)-2-((bis(benzyloxy)phosphoryl)oxy)-3- fluorophenyl)-3-methylbutanoic acid (83)Example 84Synthesis of 3-(3.6-bis((bis(benzyloxy)phosphoryl)methyl)-2-((bis(benzyloxy)phosphoryl)oxy)phenyl)-3- methylbutanoic acid (84)General Procedures for Sol-paclitaxel, Sol-docetaxel and Sol-carbazitaxel conjugate synthesis Procedure A: Sol-moietv chloroformate.

[1040] Diisopropylethylamine (0.14 mL, 0.78 mmol, 1.1 mol. equiv.) was added dropwise to a solution of sol-moiety alcohol (1 mol. equiv.) and bis(trichloromethyl) carbonate (1 mol. equiv.) in THF (10 vol equiv.) at 0 °C under an atmosphere of argon. After stirring for 45 minutes the reaction was diluted withwater, extracted with ethyl acetate, washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure to provide the desired sol-moiety chloroformate which was used without further purification.

[1041] Sol-moiety chloroformate (1 mol. equiv.) in anhydrous MeTHF (1 vol equiv.) was added dropwise to a cooled (0 °C) solution of taxane (1 mol. equiv.), A, A-dimethylpyridin-4-amine (0.1 mol. equiv.), and 2,2,6,6-tetramethylpiperidine (2.1 mol. equiv.) anhydrous MeTHF (4 vol equiv.). The mixture was stirred for 1 hour and then diluted with ethyl acetate and washed with water. The organic extract was washed with brine, dried (Na2SO4), and purified by reverse phase C-18 silica gel chromatography (50-85% acetonitrile in water) to afford the benzyl -protected sol -paclitaxel conjugate. The benzyl protected sol-taxane conjugate (1 mol. equiv.) was dissolved in ethanol (10 vol equiv.) and Pd / C (10% wt) (0.05 mol. equiv.) was added. The flask was purged with nitrogen and then stirred under an atmosphere of hydrogen for 1 h. The mixture was filtered and then evaporated to dryness under reduced pressure to afford the desired sol-moiety taxane conjugate.Procedure B: Sol-moiety Acid

[1042] Sol-moiety acid (1 mol. equiv.) in anhydrous acetonitrile (1 mL) was added dropwise to a cooled (0 °C) solution of taxane (1 mol equiv.), A, A, A’, A’-tetramethylchloroformamidinium hexafluorophosphate (TCFH) (1.0 mol. equiv.), and 1 -methylimidazole (2.1 mol. equiv.) in acetonitrile (0.15 M). The mixture was stirred for 1 hour at 23 °C. The mixture was evaporated to dryness under reduced pressure and purified by reverse phase C-18 silica gel chromatography (5-100% acetonitrile in water) to afford the benzyl-protected sol-taxane conjugate. The benzyl protected sol-paclitaxel conjugate (1 mol. equiv.) was dissolved in ethanol (10 vol equiv.) and Pd / C (10% wt) (0.05 mol. equiv.) was added. The flask was purged with nitrogen and then stirred under an atmosphere of hydrogen for 1 h. The mixture was filtered and then evaporated to dryness under reduced pressure to afford the desired sol-moiety taxane conjugate.General Synthetic Procedure for Sodium Salt Formation

[1043] To a solution of a deprotected sol-moiety drug conjugate (1 mol. equiv.) in THF (0.2 M) was added sodium bicarbonate (2-4 mol. equiv.). The mixture was stirred for 4 hours and then evaporated to dryness under reduced pressure. If needed, the product can be purified by reverse phase chromatography (30-70% MeCN in water).Example 85Synthesis of Sol-moiety Paclitaxel Conjugate (85)(3-((((((15',27?)-l-benzamido-3-(((2a7?,4S,4aS,67?,9S, IIS', 125, 12a7?,12bS)-6,12b-diacetoxy-12- (benzoyloxy)-4,ll-dihvdroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,ll,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-9-yl)oxy)-3-oxo-1-phenylpropan-2- yl)oxy)carbonyl)oxy)methyl)-4-(phosphonooxy)benzyl)phosphonic acid

[1044] Synthesized according to Procedure A and isolated as a bis sodium salt. LRMS (ESI) calcd for molecular formula [C56H61NO23P2-H]- 1176.3; found 1176.2. 1H NMR (500 MHz, D2O) δ8.04 (d, J = 6.8 Hz, 1H), 7.73-7.68 (m, 3H), 7.61 (t, J = 7.7 Hz, 2H), 7.56 (tt, J= 7.4, 1.4 Hz, 1H), 7.47-7.41 (m, 6H), 7.28 (d, 7 = 9.1 Hz, 1H), 7.23-7.19 (m, 3H), 6.39 (s, 1H), 6.01 (t, 7 = 9.0 Hz, 1H), 5.62 (d, 7= 7.0 Hz, 1H), 5.56 (d, 7 = 7.1 Hz, 1H), 5.53 (d, 7 = 7.3 Hz, 1H), 5.35 (d, 7= 11.8 Hz, 1H), 5.29 (d, 7= 11.8 Hz, 1H), 5.09 (dd, 7 = 9.8, 2.5 Hz, 1H), 4.27 (dd, 7 = 11.1, 7.4 Hz, 2H), 4.16 (d, 7 = 8.6 Hz, 1H), 3.71 (d, 7 = 7.1 Hz, 1H), 2.77 (d, 7= 19.7 Hz, 2H), 2.57-2.50 (m, 1H), 2.37 (s, 3H), 2.21 (s, 3H), 2.19 (s, 3H), 1.96 (dd, 7 = 15.4, 9.2 Hz, 1H), 1.83-1.77 (m, 4H), 1.65 (dd, 7= 15.5, 8.9 Hz, 1H), 1.59 (s, 3H), 1.10 (s, 3H), 1.08 (s, 3H).13C NMR (126 MHz, D2O) 5215.35, 206.67, 172.34, 172.12, 170.99, 170.21, 167.51, 160.36, 154.43, 150.06, 141.00, 135.56, 134.42, 133.08, 132.87, 132.35, 131.33, 129.89, 129.27, 128.91, 128.72, 128.64, 127.24, 127.14, 124.63, 119.69, 84.48, 80.64, 78.27, 77.04, 75.73, 74.82, 72.44. 70.65, 67.37, 59.96, 57.67, 54.67, 46.51, 42.74, 36.45, 35.46. 34.56, 30.17. 25.47, 22.31. 21.02, 20.15, 13.85, 9.54.31P NMR (202 MHz, D2O) δ 18.52, 0.14.Example 86Synthesis of Sol-moiety Paclitaxel Conjugate (86)(3-((((( -l-benzamido-3-(((2aR,4S,4aS.67?,9S,llS.12S,12aR,12bS)-6,12b-diacetoxy-12- (benzoyloxy)-4,ll-diliydroxy-4a.8.13,13-tetramethyl-5-oxo-2a.3.4,4a,5,6,9.10.11,12,12a,12b- dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-9-yl)oxy)-3-oxo-1-phenylpropan-2- yl)oxy)carbonyl)oxy)methyl)-4-(phosphonooxy)phenyl)phosphonic acid

[1045] Synthesized according to Procedure A and isolated as a tetra sodium salt. LRMS (ESI) calcd for molecular formula [C55H59NO23P2+H]+ 1164.30; found 1164.4. II NMR (500 MHz, D2O) 58.11 (d, J = 7.8 Hz, 2H), 7.81-7.74 (m, 5H), 7.70-7.67 (m, 2H), 7.63 (t, J = 7.5 Hz, 1H), 7.53-7.48 (m, 6H), 7.41 (dd, J = 8.3, 2.9 Hz, 1H), 7.28 (t, J = 7.1 Hz, 1H), 6.43 (s, 1H), 6.07 (t, 7 = 9.1 Hz, 1H), 5.69 (d, J = 7.0 Hz, 1H), 5.63 (d, 7= 7.0 Hz, 1H), 5.59 (d, 7 = 7.3 Hz, 1H), 5.41 (d, 7= 12.1 Hz, 1H), 5.36 (d, 7= 12.2 Hz, 1H), 5.17 (d, 7 = 9.6 Hz, 1H), 4.39 (d, 7 = 8.7 Hz, 1H), 4.31 (dd, 7 = 11.1, 6.7 Hz, 1H), 4.25 (d, 7 = 8.6 Hz, 1H), 3.77 (d, 7 = 7.3 Hz, 1H), 2.64-2.54 (m, 1H), 2.43 (s, 3H), 2.26 (s, 3H), 2.03 (dd, 7= 15.6, 9.2 Hz, 1H), 1.89-1.84 (m, 4H), 1.73 (dd, J = 15.6, 9.0 Hz, 1H), 1.65 (s, 3H), 1.16 (s, 3H), 1.13 (s, 3H).13C NMR (125 MHz, CD3OD) 5203.79, 170.28, 169.93, 169.22, 168.83, 166.29, 154.28, 140.92, 136.75, 134.01, 133.52, 133.24, 132.52, 132.43, 132.26, 132.16, 131.51, 129.99, 129.82, 128.75, 128.34, 128.33, 128.19, 127.25, 127.20, 84.51, 80.89, 77.64, 77.22, 76.08, 75.44, 74.86, 71.85, 70.94, 64.90, 57.85, 53.94, 43.20, 36.11, 35.05, 25.57, 21.88, 21.02, 19.42, 13.58, 9.08.31P NMR (202 MHz, CD3OD) 8 14.78, -5.76.Example 87Synthesis of Sol-moiety Paclitaxel Conjugate (87)(4-(((((( 15,27?)- 1 -benzamido-3-(((2a7?,45,4a5,67?,95, 115, 125, 12a?, 12b5)-6, 12b-diacetoxy- 12- (benzoyloxy)-4,ll-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,ll,12,12a,12b- dodecahydro- 177-7, ll-methanocvclodeca[3,41benzo[l,2- / ?1oxet-9-yl)oxy)-3-oxo-l-phenylpropan-2- yl)oxy)carbonyl)oxy)methyl)-3-(phosphonooxy)phenyl)phosphonic acid

[1046] Synthesized according to Procedure A and isolated as a bis sodium salt. LRMS (ESI) calcd for [C55H59NO23P2-H]- 1162.30; found 1162.4. II NMR (500 MHz, D2O) 58.11-8.05 (m, 2H), 7.79-7.69 (m, 3H), 7.68-7.62 (m, 3H), 7.62-7.56 (m, 1H), 7.54-7.43 (m, 6H), 7.40-7.22 (m, 3H), 6.41 (s, 1H), 6.11-6.02 (m, 1H), 5.70 (d, J = 6.7 Hz, 1H), 5.62 (d, J = 6.7 Hz, 1H), 5.57 (d, J = 7.3 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 5.36 (d, J= 12.8 Hz, 1H), 5.15 (dd, J = 10.1, 2.3 Hz, 1H), 4.36 (d, J = 8.6 Hz, 1H), 4.30 (dd, J = 11.1, 6.7 Hz, 1H), 4.22 (d, J = 8.7 Hz. 1H), 3.75 (d, 7 = 7.2 Hz, 1H), 2.56 (ddd, J = 14.6, 9.9, 6.6 Hz, 1H), 2.42 (s, 3H), 2.22 (s, 3H), 2.04 (dd, J = 15.6, 9.2 Hz, 1H), 1.87 (d, J = 1.4 Hz, 3H), 1.85-1.77 (m, 1H), 1.73 (dd, 7 = 15.6, 9.0 Hz, 1H), 1.62 (s, 3H), 1.13 (s, 3H), 1.10 (s, 3H).Example 88Synthesis of Sol-moiety Paclitaxel Conjugate (88)(3-((((((2a7?,4S,4aS,67?,9S,llS,12S,12aR,12bS)-6,12b-diacetoxy-9-(((2R,3S)-3-benzamido-2-hydroxy-3- phenylpropanoyl)oxy)-12-(benzoyloxy)-114iydroxy-4a,8,13,13-tetramethyl-5-oxo- 2a, 3, 4, 4a, 5, 6, 9, 10,11,12,12a, 12b-dodecahydro- 177-7,1 l-methanocyclodeca[3,4]benzo[ 1,2- / ? |oxcl-4- yl)oxy)carbonyl)oxy)methyl)-4-(phosphonooxy)phenyl)phosphonic acid

[1047] To a solution of paclitaxel (2.0 g, 2.34 mmol) in AfA imclhyl formamide (20.0 mL), tert-butyl(chloro)di(methyl)silane (1.4 g, 9.38 mmol) and imidazole (0.96 g. 14.071 mmol) were added. The mixture was stirred for 16 hours at 23 °C. The reaction was quenched with ice-water and then extracted with ethyl acetate, washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCh; 50% ethyl acetate in petroleum ether) provided the 2-silyl protected paclitaxel (2.2 g, 97%) as a white solid. LRMS (ESI) calcd for molecular formula [CssHesNOuSi+H]-!- 968.42; found 968.30.

[1048] To a solution of (2aR,4S,4aS,6R,9S, HS,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-((tert-butyldimethylsilyl)oxy)-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,ll-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,ll,12,12a-decahydro-lH-7,ll-methanocyclodeca[3,4] benzo[l,2-b]oxete-6,12b(2all)-diyl diacetate (685.0 mg, 0.708 mmol) in tetrahydrofuran (10.0 mL) was added lithium hexamethyldisilazide (1.0 M in THF, 1.4 ml, 1.417 mmol) at -78 °C under nitrogen atmosphere. The resulting mixture was stirred for 30 min at -78 °C under nitrogen atmosphere. Then, 5-(bis(benzyloxy) phosphoryl)-2-((bis(benzyloxy)phosphoryl)oxy)benzyl carbonochloridate (1.0 g, 1.417 mmol) was added to the flask. The mixture was stirred for additional 30 min at -78 °C. The reaction was warmed to 23 °C, quenched with saturated ammonium chloride solution, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), and evaporated to dryness under reduced pressure. Chromatography (SiCh: 75% ethyl acetate in petroleum ether) provided (2aR,4S,4aS,6R,9S,llS',12S',12aR,12bS')-9-(((2R,3>S')-3-benzamido-2-((ten-butyldimethylsilyl)oxy)-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4-((((5-(bis(benzyloxy)phosphoryl)-2-((bis(benzyloxy)phosphoryl)oxy)benzyl)oxy)carbonyl)oxy)-ll-hydroxy-4a,8,13,13-tetramethyl-5-oxo-3, 4, 4a, 5, 6, 9, 10, 11,12, 12a-decahydro-l H-7, 1 l-methanocyclodeca[3,4]benzo[ l,2- / ?]oxete-6,12b(2aH)-diyldiacetate (750 mg, 32%) as a white solid. LRMS (ESI) calcd for molecular formula [C89H97NO23P2Si+H]+ 1638.57; found 1639.20.

[1049] To a solution of (2aR,4S,4aS,6R,9S,llS,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-((tert-butyldimethylsiIyI)oxy)-3-phenylpropanoyI)oxy)-12-(benzoy!oxy)-4-((((5-(bis(benzyloxy)phosphoryl)-2-((bis(benzyloxy)phosphoryl)oxy)benzyl)oxy)carbonyl)oxy)- 11 -hydroxy-4a,8, 13, 13-tetramethyl-5 -oxo-3,4,4a,5,6,9,10,ll,12,12a-decahydro-lH-7,ll-methanocyclodeca[3,4] benzo[l,2-b]oxete-6,12b(2aH)-diyl diacetate (780.0 mg, 0.476 mmol) in ethanol (23.4 mL), HC1 (4 M in EtOH, 0.7 mL, 2.856 mmol) was added. The resulting mixture was slirred for 1 hour at 23 °C. The mixture was evaporated to dryness under reduced pressure. Chromatography (SiO2; 33% ethyl acetate in petroleum ether) provided (2aR,4S,4aS,6R,9S,llS,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4-((((5-(bis(benzyloxy)phosphoryl)-2-((bis(benzyloxy)phosphoryl)oxy)benzyl)oxy)carbonyl)oxy)- 11 -hydroxy-4a,8, 13, 13-tetramethyl-5 -oxo-3,4,4a,5,6,9,10,ll,12,12a-decahydro-lff-7,ll-methanocyclodeca[3,4]benzo[l,2- / 9]oxete-6,12b(2a7r)-diyl diacetate (170 mg, 23%) as a white solid. LRMS (ESI) calcd for molecular formula [C83H83NO23P2+H]+ 1524.48; found 1524.45.

[1050] The final deprotection step was performed according to the hydrogenation conditions in Procedure A and to give Sol-moiety paclitaxel-conjugate (88) as a bis sodium salt. LRMS (ESI) calcd for molecular formula [C55H5NO23P2+H]+ 1164.30; found 1164.30. ’ll NMR (400 MHz, CD3OD) 58.16-8.05 (m, 2H), 7.94-7.82 (m, 3H), 7.78-7.63 (m, 2H), 7.62-7.37 (m, 10H), 7.29 (t, J = 7.3 Hz, 1H), 6.41 (s, 1H), 6.16 (t, 7- 9.0 Hz, 1H), 5.73-5.59 (m, 2H), 5.56-5.40 (m, 2H), 5.23 (d, J = 12.7 Hz, 1H), 5.01 (d, J = 9.3 Hz, 1H), 4.75 (d, J = 5.5 Hz, 1H), 4.26^1.10 (m, 2H), 3.91 (d, J = 7.0 Hz, 1H), 2.60 (ddd, J = 14.2, 9.5, 7.0 Hz, 1H), 2.36 (s, 3H), 2.19 (s, 4H), 2.05-1.82 (m, 5H), 1.76 (s, 3H), 1.16 (s, 3H), 1.12 (s, 3H).Example 89Synthesis of Sol-moiety Paclitaxel Conjugate (89)(3-((((((lS,2R)-l-benzamido-3-(((2aR,4S,4aS,6R,9S,llS,12S,12aR,12bS)-6,12b-diacetoxy-12- (benzoyloxy)-4,ll-dihvdroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,ll,12,12a,12b- dodecahydro- 1 H-7.1 l-methanocyclodeca[3,4]benzo[ l,2-Z?]oxet-9-yl)oxy)-3-oxo-l-phenylpropan-2- yI)oxy)carbonyl)oxy)methyl)-5-methyl-4-(phosphonooxy)phenyl)phosphonic acid

[1051] Synthesized according to Procedure A. LRMS (ESI) calcd for molecular formula [C56H6INO23P2+H]+ 1178.31; found 1178.3.Example 90Synthesis of Sol-moietv Paclitaxel Conjugate (90)(3-((((((15.2R)-l-benzamido-3-(((2aR.45.4a5.6R.95.115.12,12aR.12b5)-6.12b-diacetoxy-12- (benzoyloxy)-4.11-dihydroxy-4a.8.13,13-tetramethyl-5-oxo-2a.3.4.4a,5,6,9.10.11,12.12a.l2b- dodecahvdro- 1 / 7-7.11 -methanocvclodecal 3.41benzo [ 1.2- / ?1oxet-9-yl)oxy)-3-oxo- 1 -phenylpropan-2- yl)oxy)carbonyl)oxy)methyl)-5-methoxy-4-(phosphonooxy)phenyl)phosphonic acid

[1052] Synthesized according to Procedure A to give the bis sodium salt. LRMS (ESI) calcd for molecular formula [C56H6iNO24P2+H]+ 1194.3; found 1194.3.1H NMR (500 MHz, CD3OD) 58.06-8.01 (m, 2H), 7.74-7.69 (m, 2H), 7.61-7.55 (m, 1H), 7.49 (dd, J = 8.4, 7.1 Hz, 2H), 7.46-7.39 (m, 5H), 7.39-7.33 (m, 6H), 7.32 (s, 1H), 7.21-7.16 (m, 1H), 6.37 (s, 1H), 6.02 (t, J = 9.1 Hz, 1H), 5.76 (d, 7= 6.0 Hz, 1H), 5.56 (d, J = 7.2 Hz, 1H), 5.40 (d, J = 6.0 Hz, 1H), 5.38-5.24 (m, 2H), 4.96-4.88 (m, 1H), 4.26 (dd, J = 11.0, 6.6 Hz, 1H), 4.11 (s, 2H), 3.82 (s, 4H), 3.74 (d, J = 7.2 Hz, 1H), 2.39 (ddd, J = 14.4, 9.7, 6.6 Hz,1H), 2.32 (s, 3H), 2.20-2.10 (m, 2H), 2.09 (s, 3H), 1.85 (d, 7 = 1.4 Hz, 3H), 1.79 (dd, J = 15.5, 8.9 Hz, 1H), 1.76-1.69 (m, 1H), 1.57 (s, 3H), 1.06 (d, 7 = 2.1 Hz, 7H).Example 91Synthesis of Sol-moietv Paclitaxel Conjugate(4-((((((15.2R)-l-benzamido-3-(((2aR.4.4a5,6R.95.115.12.12aR.12b5)-6.12b-diacetoxy-12- (benzoyloxy)-4,ll-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9.10,ll,12,12a,12b- dodecahydro- 1 / 7-7,1 1 -methanocvclodecal 3,41benzo 11,2-Z?]oxet-9-yl)oxy)-3-oxo- 1 -phenylpropan-2- yl)oxy)carbonyl)oxy)methyl)-2-methoxy-5-(phosphonooxy)phenyl)phosphonic acid

[1053] Synthesized according to Procedure A to give the tetra sodium salt. LRMS (ESI) calcd for molecular formula [C56H61NO24P2-H]- 1192.3; found 1192.4. H NMR (400 MHz, D2O) 58.08 (d, J = 7.8 Hz, 2H), 7.79-7.71 (m, 3H), 7.68-7.62 (m, 2H), 7.62-7.55 (m, 2H), 7.54-7.44 (m, 6H), 7.24 (t, J = 7.2 Hz, 1H), 6.97 (d, J = 6.5 Hz, 1H), 6.41 (s, 1H), 6.06 (t, 7 = 9.1 Hz, 1H), 5.71 (d, 7 = 7.0 Hz, 1H), 5.63 (d, 7 = 7.0 Hz, 1H), 5.57 (d, 7= 7.3 Hz, 1H), 5.44-5.33 (m, 2H), 5.11 (d, 7= 9.5 Hz, 1H), 4.36^1.18 (m, 3H), 3.78-3.71 (m, 4H), 2.622.50 (m, 1H), 2.41 (s, 3H), 2.24 (s, 3H), 2.09-1.97 (m, 1H), 1.89-1.79 (m, 4H), 1.75-1.60 (m, 4H), 1.12 (d, 7 = 8.9 Hz, 6H).31P NMR (162 MHz, D2O) 59.02, -2.15.Example 92Synthesis of Sol-moiety Paclitaxel Conjugate (92)((5 -(((((( 1 S R- 1 -benzamido-3-(((2aR,4S,4aS,6R,9, 1 IS, 12S, 12aR, 12bS)-6, 12b-diacetoxy- 12- (benzoyloxy)-4,ll-dihydroxy-4a.8.13,13-tetramethyl-5-oxo-2a.3.4,4a,5,6,9.10.11,12,12a.l2b- dodecahydro- lg-7,ll-methanocyclodeca[3,41benzo[l,2- / ?1oxet-9-yl)oxy)-3-oxo-l-phenylpropan-2- yl)oxy)carbonyl)oxy)methyl)-4-(phosphonooxy)-l,3-phenylene)bis(methylene))bis(phosphonic acid)

[1054] Synthesized according to Procedure A. LRMS (ESI) calcd for molecular formula [C57H64NO26P3+H]+ 1272.29; found 1272.3. 'll NMR (400 MHz, MeOD) 58.14-8.09 (m, 2H), 7.86-7.79 (m, 2H), 7.72-7.65 (m, 1H), 7.59 (t, J = 7.5 Hz, 2H), 7.55-7.49 (m, 3H), 7.48-7.42 (m, 4H), 7.40-7.35 (m, 1H), 7.31-7.24 (m, 2H), 6.44 (s, 1H), 6.12-6.02 (m, 1H), 5.82 (d, J= 6.3 Hz, 1H), 5.64 (d, J = 7.2 Hz, 1H), 5.51-5.36 (m, 3H), 5.05^1.95 (m, 1H), 4.33 (dd, J= 10.9, 6.6 Hz, 1H), 4.19 (s, 2H), 3.81 (d, J = 7.2 Hz, 1H), 3.37 (s, 1H), 3.10-3.00 (m, 2H), 2.54-2.42 (m, 1H), 2.39 (s, 3H), 2.27-2.11 (m, 5H), 1.88 (s, 3H), 1.85-1.74 (m, 2H), 1.65 (s, 3H), 1.14 (s, 6H).31P NMR (162 MHz, MeOD) 524.34, 23.54, -4.59.Example 93Synthesis of Sol-moiety Paclitaxel Conjugate (93)((4-(((((( 15,2 / ?)- 1 -benzamido-3-(((2a / ?,45,4a5,6 / ?,95, 115, 125, 12a / ?, 12b5)-6, 12h-diacetoxy- 12- (benzoyloxy)-4,ll-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,ll,12,12a,12b- dodecahydro-l A / -7. I l- l.2- / ?|oxel-9-yl)oxy)-3-oxo-l-phenylpropan-2-yl)oxy)carbonyl)oxy)methyl)-5-(phosphonooxy)-l,3-phenylene)bis(methylene))bis(phosphonic acid)

[1055] Synthesized according to Procedure A. LRMS (ESI) calcd for molecular formula [C57H64NO26P3-H]- 1270.29; found 1270.4. 'll NMR (500 MHz, MeOD) 58.15-8.10 (m, 2H), 7.82-7.76 (m, 2H), 7.71-7.65 (m, 1H), 7.59 (dd, J = 8.4, 7.0 Hz, 2H), 7.54-7.49 (m, 1H), 7.49-7.46 (m, 2H), 7.46-7.39 (m, 4H), 7.31-7.22 (m, 2H), 7.09 (s, 1H), 6.45 (s, 1H), 6.08 (t, J = 9.1 Hz, 1H), 5.78 (d, J = 6.1 Hz, 1H), 5.64 (d, J = 7.2 Hz, 1H), 5.53 (d, J = 12.0 Hz, 1H), 5.48-5.43 (m, 2H), 5.01 (dd, J= 9.8, 2.2 Hz, 1H), 4.35 (dd, 7 = 11.0, 6.6 Hz, lH), 4.19 (s, 2H), 3.81 (d, 7 = 7.2 Hz, 1H), 3.41-3.34 (m, 1H), 3.29-3.20 (m, 1H), 3.11 (d, 7 = 21.7 Hz, 2H), 2.54-2.44 (m, 1H), 2.39 (s, 3H), 2.24-2.13 (m, 4H), 1.91 (d, 7= 1.5 Hz, 3H), 1.88-1.77 (m, 2H), 1.66 (s, 3H), 1.18-1.11 (m, 6H).31P NMR (202 MHz, MeOD) 523.02, 22.73, -5.24.31P NMR (162 MHz, D2O) 522.13, 21.68, -4.44.Example 94Synthesis of Sol-moiety Paclitaxel Conjugate (94)((4-(((((( 1,2R)- 1 -benzamido-3-(((2aR,45,4aS,6R,9S, 125, 12aR, 12b5)-6, 12b-diacetoxy- 12-(benzoyloxy)-4,ll-dihvdroxy-4a.8.13,13-tetramethyl-5-oxo-2a.3.4,4a,5,6.9.10.11,12,12a,12b- dodecahydro-lH-7,ll-methanocyclodeca[3.41benzo[l,2-Moxet-9-yl)oxy)-3-oxo-l-phenylpropan-2- yl)oxy)carbonyl)oxy)methyl)-5-(phosphonooxy)-l,2-phenylene)bis(methylene))bis(phosphonic acid)

[1056] Synthesized according to Procedure A. LRMS (ESI) calcd for molecular formula [C57H64NO26P3+H]+ 1272.29; found 1272.5. ’H NMR (500 MHz, MeOD) 58.14-8.09 (m, 2H), 7.86 -7.80 (m, 2H), 7.71-7.65 (m, 1H), 7.62-7.57 (m, 2H), 7.56-7.49 (m, 3H), 7.48-7.42 (m, 4H), 7.38 (d, J = 2.7 Hz, 1H), 7.32 (d, J = 2.6 Hz, 1H), 7.27 (tt, 7 = 7.5, 1.3 Hz, 1H), 6.45 (s, 1H), 6.12-6.04 (m, 1H), 5.81 (d, J = 6.4 Hz, 1H), 5.64 (d, 7= 7.2 Hz, 1H), 5.48 (d, J = 6.5 Hz, 1H), 5.37 (d, 7 = 12.5 Hz, 1H), 5.26 (d, J = 12.4 Hz, 1H), 5.00 (dd, 7 = 9.8, 2.2 Hz, 1H), 4.34 (dd, 7= 11.0, 6.6 Hz, lH), 4.19 (s, 2H), 3.81 (d, 7 = 7.2 Hz, 1H), 3.35-3.33 (m, 1H), 3.30-3.28 (m, 2H), 3.26 (d, 7 = 5.3 Hz, 1H), 2.53-2.43 (m, 1H), 2.39 (s, 3H), 2.21-2.13 (m, 4H), 1.94-1.88 (m, 3H), 1.86-1.75 (m, 2H), 1.65 (s, 3H), 1.18-1.08 (m, 6H).31P NMR (202 MHz, MeOD) 523.63, 23.11, -4.97.31P NMR (162 MHz, D2O) 523.02, 22.16, -4.37.Example 95Synthesis of Sol-moiety Paclitaxel Conjugate (95)(2-(((((( 1 S2R- 1 -benzamido-3-(((2aR,4S,4aS,67?,9S, 11, 125, 12aR, 12bS)-6, 12b-diacetoxy- 12- (benzoyloxy)-4,ll-dihydroxy-4a.8.13,13-tetramethyl-5-oxo-2a.3.4,4a,5,6,9.10.11,12,12a,12b- dodecahydro- 177-7, ll-methano...

Claims

CLAIMSWhat is claimed is:

1. A sol-moiety drug conjugate having the structure of Formula (1):or a pharmaceutically acceptable salt thereof, whereinat least one of R1, R3, and R5is -O-P(O)(OH)2;at least one of the other of R1, R2, R3, R4, and R5is independently selected from - P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; each of the other of R1, R2, R3, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy;R6is a cleavable linker; andD’ is derived from a taxane,wherein R6is bonded to the taxane.

2. The conjugate of claim 1, wherein R1is -O-P(O)(OH)2.

3. The conjugate of claim 1, wherein R3is -O-P(O)(OH)2.

4. The conjugate of claim 1, wherein R5is -O-P(O)(OH)2.

5. The conjugate of claim 1, wherein each of R1and R3is -O-P(O)(OH)2.

6. The conjugate of claim 1, wherein each of R1and R5is -O-P(O)(OH)2.

7. The conjugate of claim 1, wherein each of R3and R3is -O-P(O)(OH)2.

8. The conjugate of claim 1, wherein each of R1, R3,and R3is -O-P(O)(OH)2.

9. The conjugate of any one of claims 1 to 8, wherein one of the other of R1, R2, R3, R4, and Rsis independently selected from -P(0)(0H)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

10. The conjugate of any one of claims 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and - CH(CO2H)2.

11. The conjugate of any one of claims 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

12. The conjugate of any one of claims 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

13. The conjugate of any one of claims 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is -P(O)(OH)2.

14. The conjugate of any one of claims 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is -CH2-P(O)(OH)2.

15. The conjugate of any one of claims 1 to 8, wherein one of the other of R1, R2, R3, R4, and R5is -CH2CO2H.

16. The conjugate of any one of claims 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

17. The conjugate of any one of claims 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

18. The conjugate of any one of claims 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

19. The conjugate of any one of claims 1 to 8, wherein two of the other of R1, R2, R3, R4, and Rsare independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

20. The conjugate of any one of claims 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are -P(O)(OH)2.

21. The conjugate of any one of claims 1 to 8, wherein two of the other of R1. R2, R3, R4, and Rsare -CH2-P(O)(OH)2.

22. The conjugate of any one of claims 1 to 8, wherein two of the other of R1, R2, R3, R4, and R5are -CH2CO2H.

23. The conjugate of any one of claims 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

24. The conjugate of any one of claims 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

25. The conjugate of any one of claims 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH(-P(O)(OH)2)2, and -CH2CO2H.

26. The conjugate of any one of claims 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

27. The conjugate of any one of claims 1 to 8, wherein three of the other of R1. R2, R3, R4, and R5are -P(O)(OH)2.

28. The conjugate of any one of claims 1 to 8, wherein three of the other of R1, R2, R1, R4, and R5are -CH2-P(O)(OH)2.

29. The conjugate of any one of claims 1 to 8, wherein three of the other of R1, R2, R3, R4, and R5are -CH2CO2H.

30. The conjugate of any one of claims 1 to 22, wherein one of the other of R1, R2, R3, R4, and R' is selected from halo, methyl, and methoxy; and each of the other of R1, R2, R3, R4, and Rsis hydrogen.

31. The conjugate of any one of claims 1 to 22, wherein one of the other of R1, R2, R3, R4, and R5is halo; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

32. The conjugate of any one of claims 1 to 22, wherein one of the other of R1, R2, R3, R4, and R' is methyl; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

33. The conjugate of any one of claims 1 to 22, wherein one of the other of R1, R2, R3, R4, and R5is methoxy; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

34. The conjugate of any one of claims 1 to 22, wherein two of the other of R1, R2, R3, R4, and R5are independently selected from halo, methyl, and methoxy; and each of the other of R1, R2, R3, R4, and R5is hydrogen.

35. The conjugate of any one of claims 1 to 22, wherein each of the other of R1, R2, R3, R4, and R5is hydrogen.

36. The conjugate of any one of claims 1 to 22, wherein at least one of R1, R2, R3, R4, and R3is independently halo, wherein halo is fluoro.

37. The conjugate of claim 1, whereinR1is -O-P(O)(OH)2;one of R2, R3, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R3, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

38. The conjugate of claim 37, wherein one of R2, R3, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

39. The conjugate of claim 37, wherein one of R2, R3, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

40. The conjugate of any one of claims 37 to 40, wherein one of R2, R3, R4, and R5is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

41. The conjugate of any one of claims 37 to 41, wherein one of R2, R3, R4, and R5is selected from halo, methyl, and methoxy.

42. The conjugate of claim 37, wherein each of the other of R2, R3, R4, and R3is hydrogen.

43. The conjugate of claim 1, wherein,R3is -O-P(O)(OH)2;one of R1, R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

44. The conjugate of claim 43, wherein one of R1, R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

45. The conjugate of claim 43, wherein one of R1, R2, R4, and R3is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

46. The conjugate of claim 43, wherein one of R1, R2, R4, and R5is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

47. The conjugate of any one of claims 43 to 46, wherein one of R1, R2, R4, and R3is selected from halo, methyl, and methoxy.

48. The conjugate of any one of claims 43 to 47, wherein each of the other of R1, R2, R4, and R5is hydrogen.

49. The conjugate of claim 1, wherein,R5is -O-P(O)(OH)2;at least one of R1, R2, R3, and R4is selected from -P(0)(0H)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R3, and R4is independently selected from hydrogen, halo, methyl, and methoxy.

50. The conjugate of claim 49, wherein one of R1, R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

51. The conjugate of claim 49, wherein one of R1, R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

52. The conjugate of claim49, wherein one of R1, R2, R3, and R4is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

53. The conjugate of any one of claims 49 to 52, wherein one of R1, R2, R3, and R4is selected from halo, methyl, and methoxy.

54. The conjugate of any one of claims 49 to 54, wherein each of the other of R1, R2, R3, and R4is hydrogen.

55. The conjugate of claim 1, whereineach of R1and R3is -O-P(O)(OH)2;one of R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R4, and R3is independently selected from hydrogen, halo, methyl, and methoxy.

56. The conjugate of claim 55, wherein one of R2, R4, and R5is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

57. The conjugate of claim 55, wherein;one of R2, R4, and R5is selected from -P(0)(0H)2, -CH2-P(O)(OH)2, and -CH2CO2H.

58. The conjugate of claim 55, wherein one of R2, R4, and R5is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

59. The conjugate of any one of claims 55 to 58, wherein one of R2, R4, and R5is selected from halo, methyl, and methoxy.

60. The conjugate of any one of claims 55 to 59, wherein each of the other of R2, R4, and R5is hydrogen.

61. The conjugate of claim 1, whereineach of R1and R5is -O-P(O)(OH)2;one of R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R3, and R4is independently selected from hydrogen, halo, methyl, and methoxy.

62. The conjugate of claim 61, wherein one of R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

63. The conjugate of claim 61, wherein one of R2, R3, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

64. The conjugate of claim 61, wherein one of R2, R3, and R4is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

65. The conjugate of any one of claims 61 to 64, wherein one of R2, R3, and R4is selected from halo, methyl, and methoxy.

66. The conjugate of any one of claims 61 to 65, wherein each of the other of R2, R3, and R4is hydrogen.

67. The conjugate of claim 1, whereineach of R3and R5is -O-P(O)(OH)2;one of R1, R2, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

68. The conjugate of claim 67, wherein one of R1, R2, and R4is selected from -P(O)(OH)2, - CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

69. The conjugate of claim 67, wherein one of R1, R2, and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

70. The conjugate of claim 67, wherein one of R1, R2, and R4is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

71. The conjugate of any one of claims 67 to 70, wherein one of R1, R2, and R4is selected from halo, methyl, and methoxy.

72. The conjugate of any one of claims 67 to 71, wherein each of the other of R1, R2, and R4is hydrogen.

73. The conjugate of claim 67, whereineach of R1, R3, and R5is -O-P(O)(OH)2;one of R2and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2and R4is selected from hydrogen, halo, methyl, and methoxy.

74. The conjugate of claim 73, wherein one of R2and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

75. The conjugate of claim 73, wherein one of R2and R4is selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

76. The conjugate of any one of claims 73 to 75, wherein one of R2and R4is selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

77. The conjugate of any one of claims 73 to 76, wherein one of R2and R4is selected from halo, methyl, and methoxy.

78. The conjugate of claim 73, wherein the other of R2and R4is hydrogen.

79. In a conjugate of Formula (1),R1is -O-P(O)(OH)2;two of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R2, R3, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

80. The conjugate of claim 79, wherein two of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

81. The conjugate of claim 79, wherein two of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

82. The conjugate of claim 79, wherein two of R2, R3, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

83. The conjugate of any one of claims 79 to 82, wherein one of R2, R3, R4, and R5is selected from halo, methyl, and methoxy.

84. The conjugate of any one of claims 79 to 83, wherein each of the other of R2, R3, R4, and R5is hydrogen.

85. The conjugate of claim 1, whereinR3is -O-P(O)(OH)2;two of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R4, and R5is independently selected from hydrogen, halo, methyl, and methoxy.

86. The conjugate of claim 85, wherein two of R1, R2, R4, and Rsare independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

87. The conjugate of claim 85, wherein two of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

88. The conjugate of claim 85, wherein two of R1, R2, R4, and Rsare independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

89. The conjugate of any one of claims 85 to 88, wherein one of the other of R1, R2, R4, and R5is selected from halo, methyl, and methoxy.

90. The conjugate of any one of claims 85 to 89, wherein each of the other of R1, R2, R4, and R5is hydrogen.

91. The conjugate of claim 1, whereinR5is -O-P(O)(OH)2;two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andeach of the other of R1, R2, R3, and R4is independently selected from hydrogen, halo, methyl, and methoxy.

92. The conjugate of claim 91, wherein two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

93. The conjugate of claim 91, wherein two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

94. The conjugate of claim 91, wherein two of R1, R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

95. The conjugate of any one of claims 91 to 94, wherein one of the other of R1, R2, R3, and R4is selected from halo, methyl, and methoxy.

96. The conjugate of any one of claims 91 to 95, wherein each of the other of R1, R2, R3, and R4is hydrogen.

97. The conjugate of claim 1, whereineach of R1and R3is -O-P(O)(OH)2;two of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2, R4, and R5is selected from hydrogen, halo, methyl, and methoxy.

98. The conjugate of claim 97, wherein two of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

99. The conjugate of claim 97, wherein two of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

100. The conjugate of claim 97, wherein two of R2, R4, and R5are independently elected from -P(O)(OH)2and -CH2-P(O)(OH)2.

101. The conjugate of any one of claims 97 to 100, wherein one of the other of R2, R4, and R5is selected from halo, methyl, and methoxy.

102. The conjugate of any one of claims 97 to 101, wherein the other of R2, R4, and R5is hydrogen.

103. The conjugate of claim 1, whereineach of R1and R5is -O-P(O)(OH)2;two of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(- P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2, R3, and R4is selected from hydrogen, halo, methyl, and methoxy.

104. The conjugate of claim 103, wherein two of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

105. The conjugate of claim 103, wherein two of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

106. The conjugate of claim 103, wherein two of R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

107. The conjugate of any one of claims 103 to 106, wherein the other of R2, R3, and R4is selected from halo, methyl and methoxy.

108. The conjugate of any one of claims 103 to 107, wherein the other of R2, R3, and R4is hydrogen.

109. In a conjugate of Formula ( 1 ),each of R3and R5is -O-P(O)(OH)2;two of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R1, R2, and R4is selected from hydrogen, halo, methyl, and methoxy.

110. The conjugate of claim 109, wherein two of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

111. The conjugate of claim 109, wherein two of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

112. The conjugate of claim 109, wherein two of R1, R2, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

113. The conjugate of claim 109, wherein the other of R1, R2, and R4is selected from halo, methyl, and methoxy.

114. The conjugate of claim 109, wherein the other of R1, R2, and R4is hydrogen.

115. The conjugate of claim 1, whereineach of R1, R3, and Rsis -O-P(O)(OH)2; andtwo of R2and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

116. The conjugate of claim 115, wherein two of R2and R4are independently selected from - P(0)(0H)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

117. The conjugate of claim 115, wherein two of R2and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

118. The conjugate of claim 115, wherein two of R2and R4are independently selected from - P(O)(OH)2and -CH2-P(O)(OH)2.

119. The conjugate of claim 1, whereinR1is -O-P(O)(OH)2;three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R2, R3, R4, and R5is selected from hydrogen, halo, methyl, and methoxy.

120. The conjugate of claim 119, wherein three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

121. The conjugate of claim 119, wherein three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

122. The conjugate of claim 119, wherein three of R2, R3, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

123. The conjugate of any one of claims 119 to 122, wherein the other of R2, R3, R4, and R5is selected from halo, methyl, and methoxy.

124. The conjugate of any one of claims 119 to 123, wherein the other of R2, R3, R4, and R3is hydrogen.

125. The conjugate of claim 1, whereinR3is -O-P(O)(OH)2;three of R1, R2, R4, and R3are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R1, R2, R4, and R5is selected from hydrogen, halo, methyl, and methoxy.

126. The conjugate of claim 125, wherein three of R1, R2, R4, and Rsare independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

127. The conjugate of claim 125, wherein three of R1, R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

128. The conjugate of claim 125, wherein three of R1, R2, R4, and Rsare independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

129. The conjugate of any one of claims 125 to 128, wherein the other of R1, R2, R4, and R3is selected from halo, methyl, and methoxy.

130. The conjugate of any one of claims 125 to 129, wherein the other of R1, R2, R4, and R5is hydrogen.

131. The conjugate of claim 1, whereinR5is -O-P(O)(OH)2;three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2; andthe other of R1, R2, R3, and R4is selected from hydrogen, halo, methyl, and methoxy.

132. The conjugate of claim 131, wherein three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2133. The conjugate of claim 131, wherein three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

134. The conjugate of claim 131, wherein three of R1, R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

135. The conjugate of any one of claims 131 to 134, wherein the other of R1, R2, R3, and R4is selected from halo, methyl, and methoxy.

136. The conjugate of any one of claims 131 to 135, wherein R5is -O-P(O)(OH)2; the other of R1, R2, R3, and R4is hydrogen.

137. The conjugate of claim 1, whereinR1and R3is -O-P(O)(OH)2;andeach of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

138. The conjugate of claim 137, wherein each of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

139. The conjugate of claim 137 wherein each of R2, R4, and R5are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

140. The conjugate of claim 137 wherein each of R2, R4, and R5are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

141. The conjugate of claim 1, whereinR1and R5is -O-P(O)(OH)2;andeach of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

142. The conjugate of claim 141, wherein each of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2143. The conjugate of claim 141, wherein each of R2, R3, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.

144. The conjugate of claim 141, wherein each of R2, R3, and R4are independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

145. The conjugate of claim 1, whereinR3and R5is -O-P(O)(OH)2;andeach of R1, R2, and R4are independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CO2H, -CH2CO2H, and -CH(CO2H)2.

146. The conjugate of claim 145, wherein each of R1, R2, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, -CH(-P(O)(OH)2)2, -CH2CO2H, and -CH(CO2H)2.

147. The conjugate of claim 145, wherein each of R1, R2, and R4is independently selected from -P(O)(OH)2, -CH2-P(O)(OH)2, and -CH2CO2H.148 The conjugate of claim 145, wherein each of R1, R2, and R4is independently selected from -P(O)(OH)2and -CH2-P(O)(OH)2.

149. The conjugate of any one of claims 1 to 148, wherein the cleavable linker R6is selected from -(CR2)P-, -(CR2)P-O-(CR2)P-, -(CR2)P-C(O)-, and -(CR2)P-O-C(O)-, wherein each p is independently selected from 1 and 2, and each R is independently selected from hydrogen and methyl.

150. The conjugate of claim 149, wherein each p is 1.

151. The conjugate of claim 149, wherein each p is 2.

152. The conjugate of any one of claims 149 to 151, wherein each R is hydrogen.

153. The conjugate of any one of claims 14910 151, wherein the cleavable linker R6is selected from -CH2-O-C(O)- and -C(CH2)2-CH2-C(O)-.

154. The conjugate of any one of claims 149 to 151, wherein the cleavable linker R6is selected from -CH2-O- and -CH(-CH3)-O-155. The conjugate of any one of claims 1 to 154, wherein the taxane is selected from paclitaxel, docetaxel, and cabazitaxel.

156. The conjugate of claim 155, wherein D’ has the structure of any one of Formula (41), (80), (81), (168), (169), or (223).

157. The conjugate of claim 1, wherein the drug is paclitaxel and the sol-moiety drug conjugate has the structure of any one of Formula (168-3A) to Formula (168-3AAA).

158. The conjugate of claim 1, wherein the drug is paclitaxel and the sol-moiety drug conjugate has the structure of any one of Formula (169-3A) to Formula (169-3AAA).

159. The conjugate of claim 1, wherein the drug is docetaxel and the sol-moiety drug conjugate has the structure of any one of Formula (80-3 A) to Formula (80-3 AAA).

160. The conjugate of claim 1, wherein the drug is docetaxel and the sol-moiety drug conjugate has the structure of any one of Formula (81-3 A) to Formula (81-3 A A A).

161. The conjugate of claim 1, wherein the drug is cabazitaxel and the sol-moiety drug conjugate has the structure of any one of Formula (41-3A) to Formula (41-3AAA).

162. The conjugate of any one of claims 1 to 161, wherein the pharmaceutically acceptable salt is selected from a sodium salt, a calcium salt, a magnesium salt, a tromethamine salt, an N-methyl D-glutamine salt, and a lysine salt.

163. A pharmaceutical composition comprising the sol-moiety drug conjugate or a pharmaceutically acceptable salt thereof of any one of claims 1 to 162 and a pharmaceutically acceptable excipient.

164. The pharmaceutical composition of claim 163 wherein the pharmaceutical composition is an oral formulation.

165. A kit comprising the sol-moiety drug conjugate or a pharmaceutically acceptable salt thereof of any one of claims 1 to 162.

166. A kit comprising the pharmaceutical composition of any one of claims 163 to 164.167 A method of treating cancer in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the sol-moiety drug conjugate or a pharmaceutically acceptable salt thereof of any one of claims any one of claims 1 to 162 or a pharmaceulical composition of any one of claims 163 to 164.

168. The method of claim 167, wherein the drug is paclitaxel.

169. The method of claim 168, wherein the cancer is selected from bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, fallopian tube cancer, gastric cancer, gastroesophageal junction adenocarcinoma, head and neck cancer, kidney cancer, liver cancer, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, prostate cancer, small cell lung cancer, soft tissue sarcoma, leslicular cancer, and thyroid cancer.

170. The method of claim 167, wherein the drug is docetaxel.

171. The method of claim 170, wherein the cancer is selected from adrenocortical carcinoma, bladder cancer, breast cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma, kidney cancer, leukemia, liver cancer, melanoma, non-small cell lung cancer,, ovarian cancer, pancreatic cancer, prostate cancer, small cell lung cancer, soft tissue sarcoma, testicular cancer, and thyroid cancer.

172. The method of claim 167, wherein the drug is cabazitaxel.

173. The method of claim 172, wherein cancer is selected from adrenocortical carcinoma, bladder cancer, brain cancer, breast cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma, liposarcoma, liver cancer, lung cancer, ovarian cancer, penile neoplasm, prostate cancer, renal cell carcinoma, and testicular cancer.

174. The method of any one of claims 167 to 173, wherein administering comprises orally administering.

175. A protected sol-moiety intermediate having the structure of Formula (2):or a salt thereof, wherein,at least one of Rla, R3a, and R5ais -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R3ais independently selected from -O-P(O)(OR9)2, - P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2, -C(O)(-OR10), -CH2C(O)(-OR10), and - CH(C(O)(-OR10))2;each of the other of Rla, R2a, R3a, R4a, andis independently selected from hydrogen, halo, methyl, and methoxy;R7is selected from -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2-C(CH3)2)-, and -C(CH3)2- CH2-; andeach R9and R10is independently selected from C1-4 alkyl, benzyl, phenyl, 2- (trimcthylsilyl)cthyl, and -C(CH3)3.

176. The intermediate of claim 175, wherein R7is -CH2-.

177. The intermediate of claim 175, wherein R7is -CH(CH3)-.

178. The intermediate of claim 175, wherein R7is -C(CH3)2-.

179. The intermediate of claim 175, wherein R7is -CH2-C(CH3)2-.

180. The intermediate of claim 175, wherein R7is -C(CH3)2-CH2-.

181. The intermediate of any one of claims 175 to 180, wherein each R9and R10is C1-4 alkyl.

182. The intermediate of any one of claims 175 to 180, wherein each R9and R10is benzyl.

183. The intermediate of any one of claims 175 to 180, wherein each R9and R10is phenyl.

184. The intermediate of any one of claims 175 to 180, wherein each R9and R10is 2- (trimethyl sil yl )ethyl.

185. The intermediate of any one of claims 175 to 180, wherein each R9and R10is -C(CHs)3.

186. The intermediate of any one of claims 175 to 180, wherein each R9is independently selected from ethyl and benzyl.

187. The intermediate of any one of claims 175 to 180, wherein each R9is ethyl.

188. The intermediate of any one of claims 175 to 180, wherein each R9is benzyl.

189. The intermediate of any one of claims 175 to 180, wherein each R10is independently selected from tert-butyl and benzyl.

190. The intermediate of any one of claims 175 to 180, wherein each R10is tert-butyl.

191. The intermediate of any one of claims 175 to 180, wherein each R10is benzyl.

192. The intermediate of claim 175 to 191, wherein each of Rla, R2a, R3a, R4a, and R5ais defined as for R1, R2, R3, R4, and R5in Formula (1).

193. A reactive sol-moiety precursor having the structure of Formula (3):or a salt thereof, wherein,at least one of Rla, R3a, and R5ais -O-P(O)(OH)2;at least one of Rla, R2a, R3a, R4a, and R5ais independently selected from -O-P(O)(OR9)2, - P(O)(OR9)2, -CH2-P(O)(OR9)2, -CH(-P(O)(OR9)2)2, -C(O)(-OR10), -CH2C(O)(-OR10), and - CH(C(O)(-OR10))2;each of the other of Rla, R2a, R3a, R4a, and R’ais independently selected from hydrogen, halo, methyl, and methoxy;R7is selected from -(CR2)P- where p is selected from 1 and 2, and each R is independently selected from hydrogen and methyl;R8is selected from a moiety reactive with a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, an NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group; and each R9and R10is independently selected from CM alkyl, benzyl, phenyl, 2- (trimethylsilyl)ethyl, and -C(CH3)2.

194. The precursor of claim 193, wherein each of Rla, R2a, R3a, R4a, and R5ais defined as for R1, R2, R3, R4, and R5in Formula (1) consistent with the definitions for Rla, R2a, R3a, R4a, and R5a.

195. The precursor of claim 194, wherein R7is selected from -CH2-, -CH(CH3)-, -C(CH3)2-, -C(CH3)2-CH2- and -CH2-C(CH3)2-.

196. The precursor of claim 194, wherein R7is -CII2-.

197. The precursor of claim 194, wherein R7is -CH(CH3)-.

198. The precursor of claim 194, wherein R7is -C(CH3)2-199. The precursor of claim 194, wherein R7is -CH2-C(CHJ)2-.

200. The precursor of claim 194, wherein R7is -C(CIh)2-CIl2-.

201. The precursor of any one of claims 194 to 200, wherein each R9is CM alkyl.

202. The precursor of any one of claims 194 to 200, wherein each R9is benzyl.

203. The precursor of any one of claims 194 to 200, wherein each R9is phenyl.

204. The precursor of any one of claims 194 to 200, wherein each R9is 2-(trimethylsilyl)ethyl.

205. The precursor of any one of claims 194 to 200, wherein each R9and R10is -C CHs)?.

206. The precursor of any one of claims 194 to 200, wherein each R9and R10is independently selected from ethyl and benzyl.

207. The precursor of any one of claims 194 to 200, wherein each R9and R10is ethyl.

208. The precursor of any one of claims 194 to 200, wherein each R9and R10is benzyl.

209. The precursor of any one of claims 194 to 200, wherein each R10is independently selected from tert-butyl and benzyl.

210. The precursor of any one of claims 194 to 200, wherein each R10is tert-butyl.

211. The precursor of any one of claims 194 to 200, wherein each R10is benzyl.

212. The precursor of any one of claims 193 to 211, wherein R8is reactive with a hydroxyl group.

213. The precursor of any one of claims 194 to 211, wherein R8is selected from Br, Cl, I, -OC(=O)CH2C1, -OC(=O)CH(CH3)-C1, --OCH2OC(=O)Cl, -OC(=O)C1, -OC(=O)OPh, -OC(=O)OCeH4NO2, -OC(=O)OC6H3(NO2)2, -OC(=O)OCeF5, -OCH2OC(=O)O-lV-hydroxysuccinimide, -OCH2SCH3, -OCH2C1, -C(O)-C1, and -COOH.

214. The precursor of any one of claims 194 to 211, wherein R8is selected from Br, Cl, and I.

215. The precursor of any one of claims 194 to 211, wherein R8is -OC(=O)CH2C1.

216. The precursor of any one of claims 194 to 211, wherein R8is --OCH2OC(=O)Cl.

217. The precursor of any one of claims 194 to 211, wherein R8is -OC(=O)C1.

218. The precursor of any one of claims 194 to 211, wherein R8is -OC(=O)OPh.

219. The precursor of any one of claims 194 to 211, wherein R8is -OC(=O)OCeH4NO2.

220. The precursor of any one of claims 194 to 211, wherein R8is -OC(=O)OC6H3(NO2)2.

221. The precursor of any one of claims 194 to 211, wherein R8is -OC(=O)OCeF5.

222. The precursor of any one of claims 194 to 211, wherein R8is -OCH2OC(=O)O-1V-hydroxysuccinimide.

223. The precursor of any one of claims 194 to 211, wherein R8is -OCH2SCH3.

224. The precursor of any one of claims 194 to 211, wherein R8is -OCH2C1.

225. The precursor of any one of claims 194 to 211, wherein R8is -CH2-C(O)-R10, whereinR10is selected from OH, Cl, ()- / V-hydroxysuccinimidc, OMs, OTs, and OTf.

226. The precursor of any one of claims 194 to 211, wherein R8is -CH2-C(O)-OH.

227. The precursor of any one of claims 194 to 211, wherein R8is -CH2-C(O)-C1.

228. The precursor of any one of claims 194 to 211, wherein R8is -CH2-C(O)-O4V-hydroxysuccinimide.

229. The precursor of any one of claims 194 to 211, wherein R8is -CH2-C(O)-OMs.

230. The precursor of any one of claims 194 to 211, wherein R8is -CH2-C(O)-OTs.

231. The precursor of any one of claims 194 to 211, wherein R8is -CH2-C(O)-OTf.

232. The precursor of any one of claims 193 to 194, whereinR7is -CH2-; andR8is selected from Br, Cl, I, -OC(=O)CH2C1, --OCH2OC(=O)Cl, -OC(=O)C1, -OC(=O)OPh, -OC(=O)OC6H4NO2, -OC(=O)OC6H3(NO2)2, -OC(=O)OC6F5, -OCH2OC(=O)O-lV-hydroxysuccinimide, -OCH2SCH3, and -OCH2CI.

233. The precursor of any one of claims 193 to 194, whereinR7is -CH2-; andR8is -O-C(O)-C1.

234. The precursor of any one of claims 193 to 194, whereinR7is -C(CH3)2-CH2-; andR8is -C(O)-R10, wherein R10is selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf.

235. The precursor of claim 194, wherein the precursor has the structure of any one of Formula (4A)-4AAA) as listed in FIGS. 4A-4J, whereineach R’ is independently selected from C1.4 alkyl, phenyl, benzyl, tert-butyl, allyl, and 2-(trimethylsilyl)ethyl;R is selected from hydrogen, halo, methyl, and methoxy;W is selected from OH, Cl, O-N-hydroxysuccinimide, OMs, OTs, and OTf; andZ is selected from halo -OC(=O)CH2C1, -OCH2O(C=O)C1, -O(C=O)C1, -O(C=O)OPh, -O(C=O)OC6H4NO2, -O(C=O)OC6H3(NO2)2, -O(C=O)OC6F5, -OCH2O(C=O)O-N-hydroxysuccinimide, OCH2SCH3, and OCH2C1.

236. The precursor of claim 235, wherein the precursor has the structure of any one of Formula (4A)-(4AAA), for each -PO(OR’)2, -OPO(OR’)2, -CH2-PO(OR’)2, -CH2-OPO(OR’)2, and -CH(-P(O)(OR’)2)2; and each R’ is independently selected from ethyl and benzyl.

237. The precursor of claim 236, wherein the precursor has the structure of any one of Formula (4A)-(4AAA), for each -COOR’, -CH2-COOR’, and -CH(COOR’)2, R’ is selected from tertbutyl and benzyl.

238. The precursor of any one of claims 235 to 237, wherein R is hydrogen.

239. The precursor of any one of claims 235 to 237, wherein R is methyl.

240. The precursor of any one of claims 235 to 237, wherein R is methoxy.

241. The precursor of any one of claims 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is selected from Br, Cl, and I.

242. The precursor of any one of claims 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)CH2C1.

243. The precursor of any one of claims 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is --OCH2OC(=O)Cl.

244. The precursor of any one of claims 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)CL245. The precursor of any one of claims 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)OPh.

246. The precursor of any one of claims 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)OCeH4NO2.

247. The precursor of any one of claims 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)OC6H3(NO2)2.

248. The precursor of any one of claims 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OC(=O)OC6F5.

249. The precursor of any one of claims 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OCH2OC(=O)O-A iydroxysuccinimide.

250. The precursor of any one of claims 236 to 240, wherein the precursor has the structure of any one of Formula (4A)-(4PP) and Z is -OCH2SCH3.2 1. The precursor of any one of claims 236 to 240, wherein in a precursor of Formula (4A)-(4PP), Z is -OCH2CI.

252. The precursor ofany one of claims 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is -OH.

253. The precursor of any one of claims 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is -Cl.

254. The precursor of any one of claims 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is O-A^-hydroxysuccinimide.

255. The precursor of any one of claims 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is -OMs.

256. The precursor of any one of claims 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is -OTs.

257. The precursor of any one of claims 236 to 240 the precursor has the structure of any one of Formula (4QQ)-(4AAA) and W is -OTf.2 8. A method of synthesizing the sol-moiety drug conjugate of claim 1 comprising reacting a therapeutic agent comprising a hydroxyl group, a primary amine group, a secondary amine group, a tertiary amine group, a NH-heterocycle, a sulfonamide group, a sulfamide group, a sulfonimine group, an amide group, an imide group, or a urea group with a reactive sol-moiety compound, in the presence of a base to provide a protected intermediate; and treating the protected intermediate (a) with TMSBr in CH2CI2 or (b) with hydrogen gas in the presence of Pd / C in ethanol; to provide the compound of Formula (1).